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Epigenetic regulation of the genome
The human diploid genome consists of roughly 6.5 billion base pairs (bp), divided over 
23 different chromosome pairs. This huge linear genome, and that of eukaryotes in 
general, is packed into the cell nucleus in a non-random and organized fashion. In order 
to store, maintain and use the genetic information in our genome, DNA is folded into a 
nucleoprotein structure called chromatin. Historically, chromatin is classified into two 
states: the more accessible state called euchromatin and a more inaccessible state called 
heterochromatin1, 2. Euchromatin allows the DNA to be accessed by protein machineries 
in the nucleus and is mainly found at actively transcribed loci. In contrast, the more 
inaccessible heterochromatin is mainly found at repressed and non-transcribed regions 
of the genome. Although chromatin organization of the genome is not static, it is 
mitotically heritable and is central in studying epigenetics: “nuclear inheritance which 
is not based on differences in DNA sequence”3. More specifically, epigenetics can be 
defined as “the sum of alterations to the chromatin template that collectively establish 
and propagate different patterns of gene expression and silencing from the same 
genome”1. Thus, epigenetic regulation lies at the heart of establishing and maintaining 
cell identity, and is achieved by modifying and regulating the chromatin template at 
multiple levels.
Chromatin, histones and their post-translational modifications
The basic component of chromatin is the nucleosome: an octamer of 4 different histone 
proteins (H2A, H2B, H3 and H4) wrapped by ~146 bp of DNA (Fig. 1A). The globular 
domains of H2A, H2B, H3 and H4 fold into the histone octamer, whereas the more linear 
tails of the histone proteins are protruding out of the nucleosome (Fig. 1A)1. Histone 
tails, and the globular domains to a lesser extent, are subject to a wide variety of post-
translational modifications including, but not limited to, acetylation, methylation, 
phosphorylation, ubiquitylation and sumoylation, which all in some way can affect the 
organization and/or regulation of the chromatin template. Eu- and hetero- chromatin 
are characterized by the presence of specific patterns of histone modifications, which 
influence the chromatin through directly impacting chromatin structure or acting as a 
scaffold for regulatory proteins1.
In general, euchromatin is characterized by high levels of acetylation on lysine residues 
in histones (Fig. 1B). The chromatin structure is directly affected by histone acetylation 
as it neutralizes the positive charge of lysine residues on nucleosomes, thereby 
interfering with the interaction of the nucleosome with negatively charged DNA and 
increasing the binding possibility of transcription factors to DNA4. Both eu- and hetero-
chromatic regions are enriched for lysine methylation, which can have different degrees 
and functionalities depending on the number of methyl groups added to the substrate: 
mono, di or trimethylation (Fig. 1B-D). Both the degree of methylation and the 
specific histone tail residue used as substrate are associated with different chromatin 
contexts. For example, active promoters are typically marked by high levels of Histone 
3 lysine 4 di- and tri-methylation (H3K4me2/3) (Fig. 1B), whereas long distance 
enhancers are usually marked by H3K4me15. Methylation of H3K4 is thus considered 
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to mark euchromatin. In contrast, methylation of H3K9 and H3K27 is typically found 
at heterochromatin, which can be further subdivided in constitutive and facultative 
heterochromatin. Constitutive heterochromatin, marked by high levels of H3K9me3, 
is gene poor, often repetitive in nature and silenced in all somatic cell types (Fig. 1C)2. 
Facultative heterochromatin, enriched for H3K27me3, is often found at gene bodies 
which need to be transcriptionally silenced in specific cell types or during development 
and is considered to be more plastic of nature (Fig. 1D)2.
Histone marks are established, recognized and removed by so called “writer”, “reader” 
and “eraser” proteins, respectively. Acetylation of histone is catalysed by histone acetyl 
transferases (HATs) and can be subsequently removed by histone deacetylases (HDACs). 
Both HATs and HDACs are subdivided into different subclasses based on domain 
organization of the proteins and substrate specificity1. Histone acetylation is “read” by 
proteins containing a bromodomain (BrD), which is found in at least 41 human proteins. 
Among these 41 proteins are transcription factors, chromatin remodelers and HATs, 
of which the latter create a positive feedback loop where histone acetylation leads to 
more histone acetylation (Fig. 1B)6, 7.
Methylation and demethylation of histones is carried out by different lysine methyl 
transferases (KMTs) and lysine specific demethylases (KDMs), respectively, which are 
non-redundant in target residues and degrees of methylation. All except one member 
of the large group of KMTs contain a SET domain, which catalyses lysine methylation8. 
Different KMTs have different substrate specificity: methylation of H3K4, for example, 
can be carried out by mixed lineage leukaemia (MLL) proteins, whereas H3K36 
methylation is mainly catalysed by SET2 (Fig. 1B)8. H3K9 methylation can be catalysed 
by different KMTs, including suppressor of variegation 3-9 homologue 1 (SUV39H1) and 
SUV39H2 (Fig. 1C). Two major H3K27 KMTs are identified to date: enhancer of zeste 
homologue 1 (EZH1) and EZH2, both only active in the context of the multi subunit 
Polycomb repressive complex 2 (PRC2) (Fig. 1D)8.
Lysine methylation can be “read” by a versatile group of protein domains, including the 
PHD zinc finger and the chromodomain9. As for acetylation, “reading” methylation can 
create a positive feedback loop. H3K9me creates a binding site for the chromodomain 
of Heterochromatin protein 1 (HP1) which recruits the H3K9me “writer” SUV39H1 
(Fig. 1C)10, 11. Similarly, the WD40 domain of the PRC2 component embryonic ectoderm 
development (EED) binds H3K27me3 and thereby promotes more H3K27me3 (Fig. 1D)8, 
12.
Next to the establishment of positive feedback loops, “Reader” proteins are also central 
to the concept of crosstalk between different histone modifications. At euchromatin, for 
example, the chromodomain of HDAC1, which travels with the transcriptional machinery, 
binds SET2 mediated H3K36me3 and leads to histone deacetylation in transcribed gene 
bodies (Fig. 1B)13-15. In heterochromatin, PRC2 mediated H3K27me3 is “read” by the 
PRC1 complex, which further promotes chromatin compaction and silencing through 
H2AK119 mono-ubiquitylation (H2AK119Ub) (Fig. 1D)16. In both examples, ”reading” 
of methylation marks leads to the removal or deposition of different modifications, 
12
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creating another layer of regulatory complexity on the chromatin template. Altogether, 
the dynamic nature of histone modifications, their ability to act as a docking platform for 
effector proteins and their potential crosstalk creates a potent mechanism to organize, 
maintain and employ the large amount of genetic information in the context of the 
chromatin template.
Epigenetic regulation on the DNA backbone: CpG methylation
The regulation of chromatin structure is not limited to the modification of histone 
proteins. In fact, the DNA backbone can be subject to methylation, which affects 
gene expression and chromatin organization. In mammals, CpG dinucleotides form 
the main substrate for cytosine methylation17. CpGs are found dispersed throughout 
the genome as single CpGs, or as clustered CpG islands (CGIs) in gene promoters. In 
general, single CpGs throughout the genome are methylated, whereas the majority of 
CGIs are unmethylated (Fig 1B-D)17. As for histone modifications, the human genome 
also encodes “writers”, “readers” and “erasers” of DNA methylation to ensure proper 
regulation and interpretation of this mark. 
Methylation of CpGs is “written” by DNA methyltransferases (DNMTs). DNMT1 primarily 
acts on hemi-methylated DNA and thereby is pivotal for maintaining CpG methylation 
patterns during DNA replication17, 18. DNMT1 is targeted to DNA replication foci by its 
interaction with proliferating cell nuclear antigen (PCNA). Specific targeting of DNMT1 
to heterochromatic regions is dependent on the H3K9me machinery. DNMT1 interacts 
with ubiquitin-like, containing PHD and Ring finger domains 1 (UHRF1), which binds 
H3K9me3 through its PHD finger, and with H3K9 KMTs directly (Fig. 1C)17. Binding 
through UHRF1 is mediated by ubiquitylation of H3K23, another example of crosstalk 
between epigenetic marks.
Figure 1: Schematic representation of histone proteins, chromatin and chromatin modifications
A) The double stranded DNA helix (thin black line) wraps itself around an octamer of 4 histone proteins 
-H2A (cyan), H2B (dark blue), H3 (green) and H4 (red)- to form the nucleosome, the basic component 
of the chromatin template. The linear tails of the histone proteins, subject to a wide variety of post-
translational modifications, are protruding out of the nucleosome. B) schematic representation of 
euchromatin at actively transcribed regions. Euchromatin is generally characterized by high levels 
of histone acetylation (green triangles) and trimethylation of H3K4 and H3K36 (green hexagons). 
MLL proteins trimethylate H3K4, whereas H3K36 is mainly methylated by SET2. Histone acetylation 
is “written” and “erased” by HATs and HDACs respectively. Active gene expression, indicated by 
the arrow, associates with CpG island hypomethylation, as H3K4 methylation inhibits de novo CpG 
methylation by DNMT3. C) Regions of constitutive heterochromatin are generally characterized by high 
levels of H3K9me3 and CpG methylation. HP1 proteins can bind H3K9me3 and recruit the SUV39H1 
methyltransferase, creating a positive feedback loop. CpG methylation is “read” by i.a. MeCP2 which 
promotes heterochromatin formation by recruitment of HDACs. Upon DNA replication, DNMT1 
is localized to sites of heterochromatin through UHRF1 in order to maintain methylation levels. D) 
Polycomb repressive complexes 1 and 2 play a major role in silencing gene expression at facultative 
heterochromatin. PRC2 catalyses H3K27me3 (yellow hexagons) which is “read” by PRC1 to establish 
H2AK119Ub (red circles) which further compacts the chromatin. TET enzymes, not necessarily at 













































DNMT3A and DNMT3B encode de novo methyltransferases which, together with 
the non-catalytic DNMT3L co-factor, establish the genome wide pattern of DNA 
methylation during early development17, 19. Establishment of DNA methylation in 
mammals is at least in part dependent on crosstalk with histone modifications (or the 
lack thereof). DNMT3A/B enzymes contain an ATRX-DNMT3-DNMTL (ADD) domain 
which efficiently binds unmethylated H3K417. However, H3K4me3, highly enriched at 
promoters of actively transcribed genes, inhibits binding of DNMT enzymes and as a 
consequence promoter CGIs are protected from de novo methylation (Fig. 1B, D). In 
contrast, methylation of H3K9 has a strong positive correlation with CpG methylation. 
At a subset gene promoters, which are silenced during differentiation, H3K9me (in)
directly recruits DNMT3A and/or DNMT3B and thereby promotes CpG methylation. 
De novo methylation at sporadic, non-genic CpG sites can occur either dependent or 
independent of H3K9me machineries, reliant on the genetic context. CpG methylation 
at these sites is an important mechanism to maintain genomic integrity and preserve 
the heterochromatic conformation of non-transcribed loci17.
DNA methylation can be read primarily by proteins containing a methyl binding domain 
(MBD), which was first identified in methyl-CpG binding protein 2 (MeCP2)20. MeCP2, 
as well as other MBD containing proteins, interacts with HDACs and KMTs to maintain 
a heterochromatic structure and thereby bridges two layers of epigenetic regulation 
(Fig. 1C)20. A possible direct link between CpG methylation and repressive histone 
methylation exists through SET domain and bifurcated 1 (SETDB1) and SETDB2, two 
H3K9 KMTs that have a putative MBD20. 
More recently, a class of enzymes was discovered that can “erase”, or better “edit”, 
CpG methylation. Active removal of CpG methylation is carried out through stepwise 
oxidation of the methyl group to hydroxymethyl, formyl and carboxyl which finally 
can be removed and subsequently repaired. This oxidation, and removal of meCpG, 
is carried out by ten eleven translocation 1 (TET1), TET2 and TET3 proteins (Fig. 1D)21. 
Next to active removal of CpG methylation, TET enzymes create another layer of 
possible epigenetic regulation:  the intermediates formed by the TET enzymes may have 
biological roles themselves22. In support of this, for example, is the observed stable 
and persistent enrichment of hydroxymethylation at euchromatic regions in cells of the 
neuronal lineage, which positively correlates with gene expression22. In summary, CpG 
methylation is established and maintained by DNMTs, interpreted by MBD containing 
proteins and removed by TET enzymes. It correlates with histone modification patterns 
and together these epigenetic systems dictate the organization of the chromatin 
template and create a platform to maintain and use genetic information in order to 
establish heritable patterns of gene expression, which identify cell identity.
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Epigenetics and disease 
The establishment of stable and heritable patterns of gene expression ensures cell, 
tissue and organ homeostasis. Therefore, epigenetic dysregulation of the genome is 
an important risk factor for the development of disease. Indeed, the dysregulation 
of the epigenome is one of the hallmarks of cancer cells, which generally display 
hypomethylation of sporadic CpGs, hypermethylation of hundreds of promoter CpG 
islands and disturbed patterns of histone modifications23, 24. Changes in the epigenetic 
regulation of the genic part of genome in cancer cells can lead to the activation of 
oncogenes and/or the silencing of tumor suppressors. Moreover, the globally 
unbalanced epigenome is believed to result in higher genomic instability, another 
hallmark of cancer cells24.
Next to cancer, various classes of epigenetic diseases have been recognized, among 
which imprinting disorders are the classic example. Imprinting is an epigenetic process 
leading to mono-allelic expression depending on parental origin of a substantial group 
of human genes and is primarily mediated by epigenetic regulation in cis on several 
levels. Genetic or epigenetic disruption of these imprinted regions leads to aberrant 
expression of the imprinted genes (biallelic expression or absence of expression) and 
can lead to human disease25, 26. For example, Beckwith-Wiedemann syndrome (BWS), 
characterized by overgrowth, and Silver-Russell syndrome (SRS), characterized by 
undergrowth and asymmetry, both map to an imprinted region on chromosome 11p15. 
Opposite incorrect epigenetic regulation of the loci that control the imprinting of this 
imprinted region leads to either increased paternal or maternal expression of the 
imprinted genes, leading to BWS or SRS respectively25, 26.
Imprinting disorders belong to the group of in cis epigenetic disorders, where 
local changes in the chromatin organization lead to human disease. Several in cis 
epigenetic disorders are known in which non-imprinted loci are involved. For example, 
genetic mutations in the fragile X mental retardation 1 (FMR1) gene lead to the 
neurodegenerative FXTAS disorder or fragile X syndrome, depending on the type of 
mutation27. In both cases, a trinucleotide repeat in the 5’ untranslated region (UTR) 
of FMR1 is expanded to either a pre-mutation allele (55-200 copies, FXTAS) or a full 
mutation allele (>200 copies, fragile X syndrome)27. The pre-mutation allele leads to 
transcriptional activation, presumably because the expansion results in the formation of 
a larger promoter region. Full mutation alleles, on the contrary, result in transcriptional 
repression of the FMR1 gene by the recruitment of repressive complexes that silence 
the locus27. The expanded repeat thus acts in cis to control the levels of transcription 
through epigenetic mechanisms.
The example of fragile X syndrome shows that a gene mutations can have an epigenetic 
effect in cis which leads to disease. The list of disorders where genetic mutations lead 
to an epigenetic phenotype in trans is considerably larger. Mutations in numerous 
“writers”, “readers” and “erasers” have been identified to underlie syndromes, often 
characterized by developmental problems and intellectual disability26. An intriguing 
example of an in trans disorder is Kabuki syndrome, characterized by intellectual 
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disability, facial dysmorphisms and short stature. Kabuki syndrome is caused by 
mutations in MLL2 or KDM6A, an H3K4 KMT and H3K27 KDM respectively28, 29. By 
modulating lysine methylation on histones MLL2 promotes chromatin relaxation 
whereas KDM6A inhibits chromatin repression. This essentially results in the same: 
a shifted balance of gene expression at target genes of these machineries, which is 
supported by the indistinguishable phenotype of both patient groups26.
All the above shows that faithful epigenetic regulation of genome is pivotal for cell 
homeostasis and that disruptions in this system, globally and locally, can result in 
human disease. In general, studies focus on the effect of epigenetic dysregulation on 
the genic compartment of the genome. Since the great minority of the human genome 
is actually protein coding, the effect on non-coding genomic regions should not be 
underestimated.
 
The repetitive genome: expand and silence.
With the completion of the human genome project at the beginning of the century, 
early estimates of the total number of genes in the human genome (around 100.000) 
were proven wrong30. In fact, the latest numbers indicate that the human genome 
contains less than 25.000 genes. Compared to the number of genes identified in lower, 
less complex, eukaryotes like Saccharomyces cerevisiae and Drosophila melanogaster, 
it becomes clear that increased organismal complexity does not solely depend on 
the number of genes (Fig. 2A)31, 32. Besides, the number of identified genes in these 
organisms does not reflect the size of their genomes (Fig. 2A). In other words: the 
complexity of human life, compared to that of budding yeast or fruit fly, cannot be 
simply explained by an increase in the number of genes.
Rather than the coding part of the genome, the steep increase in non-coding DNA 
sequences underlies the dramatic expansion of the human genome compared to that of 
other eukaryotes. With increasing genome sizes in Saccheromyces cerevisiae, Drosophila 
melanogaster and Homo sapiens, there is a concomitant decrease in the percentage of 
protein coding basepairs (Fig. 2B-D)33. The vast majority of the human genome, more 
than 97%, is actually non-protein coding and was referred to as non-functional “junk 
DNA”34. The publication of the “Encyclopedia of DNA Elements” (ENCODE), however, 
revealed that many of these junk DNA regions are actually functional, e.g. by acting 
as distant gene expression enhancer sites, and contribute to the regulation of gene 
expression patterns35. The increase in non-coding regulatory elements thus creates an 
additional layer of transcriptional regulation and thereby contributes to organismal 
complexity.
Apart from the size of the genome, the fraction of repetitive DNA positively correlates 
to organismal complexity (Fig. 2B-D). Up to 45% of the non-coding part of the human 
genome is repetitive of nature and is typically packed into constitutive heterochromatin. 
Repeated sequences include large stretches (10-300 kb) of duplicated sequence blocks 
known as segmental duplications. However, the majority of repetitive DNA is comprised 
of two main classes of highly repetitive elements: interspersed and tandem repeats36. 
17
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Interspersed repeats, including long/short interspersed nuclear elements (LINE/SINE) 
and long terminal repeats (LTRs), are viral DNA elements which have covered the 
human genome by retrotransposition and account for 90% of all repetitive elements 
in the human genome36. Tandem repeats, organised in a head to tail fashion, are 
polymorphic in length and further classified according to the size of the repetitive 
unit. Microsatellite repeats, or short tandem repeats (STR), have a repetitive unit of 
1-7 bp long and can span up to several hundreds of basepairs36. Telomeric repeats, as 
well as some centromeric satellite repeats, fall into this category. Minisatellites have a 
repeat unit size between 8 and 100 bp and are typically found near centromeres and 
telomeres. Micro- and mini-satellites are often used for DNA fingerprinting in forensic 
DNA analyses. Macrosatellites are at least 100 bp, but usually several kb per unit and 
can span up to several megabases in total length36, 37. In total, the repetitive genome 





















Genome size (Mb) number of genes
S. cerevisiae 12,2 6000
D. melanogaster 180 14000
H. sapiens 3107 25000

















Figure 2: The size of the genome and the fraction of repetitive DNA correlate with organismal 
complexity.
A) The genome size, rather than the number of encoded genes, correlates with increasing organismal 
complexity in S. cerevisiae, D. melanogaster and H. sapiens. B-D) The relative amount of non-coding 
DNA (intronic and intergenic) and the relative distribution between non-repetitive and repetitive DNA 
in S. cerevisiae (B), D. melanogaster (C) and H. sapiens (D) shows a correlation between organismal 
complexity and the amount of repetitive DNA.
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a repressed chromatin conformation in order to maintain genome stability and silence 
transcription of repeats.
This thesis focuses on the genetic and epigenetic features of facioscapulohumeral 
muscular dystrophy (FSHD) and immunodeficiency, centromere instability and facial 
anomalies (ICF) syndrome: epigenetic disorders in cis and in trans, respectively. 
Common to both diseases is the epigenetic dysregulation of repetitive DNA. In FSHD 
this is most often confined to the D4Z4 macrosatellite repeat, whereas in ICF syndrome 
the epigenetic dysregulation of repeat sequences occurs genome wide, including D4Z4 
and centromeric satellites. Both disorders will be further introduced below.
FSHD: derepression of a macrosatellite repeat
FSHD (OMIM 158900/158901) is a progressive muscular dystrophy first described 
by Landouzy and Dejerine, with recent estimates to affect approximately 1 in 8000 
individuals38, 39. Patients suffer from progressive weakening of the facial, shoulder and 
proximal limb muscles and often show asymmetric involvement of muscles40. With 
disease progression, also other muscles may become affected. FSHD mostly shows an 
age at onset in the second decade of life, but is however characterized by a high inter- 
and intra-familial variability in onset, progression and severity40. Extreme cases show 
muscle weakness at birth, whereas some individuals remain asymptomatic throughout 
life. Eventually, 20% of FSHD patients above the age of 50 years become wheelchair 
bound. A minority of patients shows respiratory and cardiac involvement (atrial 
arrhythmia), of which the latter is rarely symptomatic. Extra muscular symptoms have 
been reported and mainly involve retinal vasculopathy and progressive hearing loss40.
FSHD is linked to the subtelomeric D4Z4 repeat on chromosome 4q35
In most cases, FSHD is inherited in an autosomal dominant manner, with a high 
frequency (10-30%) of de novo cases39, 41. In the early nineties, linkage analysis revealed 
that FSHD segregates with marker loci in the subtelomere of chromosome 4q35, which 
harbours the D4Z4 macrosatellite repeat (Fig. 3A)42-44. Each D4Z4 repeat unit is 3.3 kb in 
size and the number of repeats per allele is highly polymorphic. The D4Z4 array consists 
of 1 to over 100 units, leading to a possible size difference of more than three mega-
basepairs between individual alleles (Fig. 3A)37. The 4q subtelomere exists in two equally 
frequently occuring haplotypes (4qA and 4qB), and FSHD uniquely associates with the A 
variant45-48. Using restriction enzyme analysis, it was found that partial deletion of D4Z4 
on 4qA alleles, resulting in a repeat array of less than 11 but more than 1 units, leads to 
the development of FSHD type 1 (FSHD1)49-52.  The number of residual repeats shows a 
rough positive correlation with age at onset and wheelchair use53, 54. Only contraction 
of 4qA alleles is pathogenic since D4Z4 repeat arrays of less than 10 units in the control 
population can be observed on 4qB chromosomes46.
The contraction of the D4Z4 repeat is diagnostic for the vast majority of FSHD 
patients. However, a small remaining group of patients, classified as FSHD2, shows 
an indistinguishable phenotype, but carries a D4Z4 repeat in the lower size range of 
control individuals55, 56. As seen for FSHD1, the disease relies on the presence of the 4qA 
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haplotype, as all FSHD2 patients carry at least one such allele55.
The D4Z4 macrosatellite repeat is located in the subtelomere of chromosome 4q35, 
which is immediately adjacent to the intact telomeric [TTAGGG] repeats. Subtelomeres 
are characterized by the presence of repetitive DNA and segmental duplications and 
are packed in a constitutive heterochromatin structure like the adjacent telomeres57, 58. 
Subtelomeric segmental duplications have occurred both intra- and inter-chromosomally 
and the duplicons can also be identified in non-subtelomeric regions of the genome, 
such as pericentromeres57. Indeed, the subtelomere of chromosome 4q, including the 
D4Z4 repeat array, is duplicated to the subtelomere of chromosome 10q (Fig. 3A), but 
contractions of the 10q copy of D4Z4 are typically not pathogenic59, 60.  Additionally, 
single, often incomplete, D4Z4 copies can be found dispersed throughout the genome, 
but were never linked to pathogenicity61-63.
Together, genetic analyses put the partial deletion of the D4Z4 macrosatellite repeat 
at 4q35 at the centre of FSHD pathology. Each D4Z4 unit encodes a copy of the DUX4 
retrogene, a member of the double homeobox transcription factor gene family which 
has only been identified in placental mammals64. DUX4 is most likely a retrotransposed 
copy of the ancestral and intron containing DUXC gene which is lost in the primate 
lineage64, 65. DUX4 does not have a rodent orthologue, however a paralogue has been 
identified: the rodent specific Dux array identified in mouse and rat suggests divergent 
evolutionary events leading to conservation of a tandemly repeated Dux gene64-66. 
Remarkably, the organization of DUXC/DUX4/Dux like genes into a tandem repeat 
array is conserved in mammals66. By ectopic expression, DUX4 was found to be a pro-
apoptotic protein and an inhibitor of muscle cell differentiation, however its expression 
or dysregulation in FSHD muscle could for a long time not be established67-70. The non-
detectable dysregulation of DUX4, together with the fact that only partial deletion of 
the heterochromatic D4Z4 repeat causes FSHD, suggested an epigenetic component in 
FSHD disease aetiology56.
The complex interplay of chromatin regulators at D4Z4
The D4Z4 repeat, as most macrosatellites, is transcriptionally silenced and organized 
into heterochromatin in somatic cells. D4Z4, characterized by a high density of CpG 
dinucleotides, is highly but inhomogeneously methylated and it is marked by H3K9me3 
in somatic cells, consistent with its heterochromatic nature (Fig. 3B)55, 56, 71-75. Remarkably, 
histone markers for euchromatin (acetylation), as well as facultative heterochromatin 
(H3K27me3) were also found to be enriched at D4Z4 (Fig. 3B)75, 76.  In FSHD individuals, 
the chromatin organization is disrupted in somatic cells as CpG methylation levels are 
reduced at D4Z4 (Fig. 3B)55, 56, 72. Moreover, using primary myoblasts and fibroblasts, 
it was shown that H3K9me3, mediated by SUV39H1, is decreased at D4Z4 in FSHD 
patient derived cell lines compared to healthy controls or patients suffering from other 
muscular dystrophies (Fig. 3B)75. Furthermore, the downstream “readers” of H3K9me3, 
HP1γ and Cohesin, were shown to be reduced at D4Z475. Together this shows that 
the heterochromatin organization at D4Z4 is disrupted in patients, leading to partial 
relaxation of the locus.
20
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The epigenetic changes observed at D4Z4 are common to FSHD1 and FSHD2. In fact, 
in FSHD2 individuals the chromatin changes are observed on both D4Z4 repeat arrays 
on chromosome 4 as well as the 10q copies, whereas in FSHD1 individuals the effects 
are restricted to the contracted pathogenic repeat55, 56, 75. FSHD1 is an in cis epigenetic 
disorder: the contraction of the repeat leads to a change in local chromatin structure, 
similar to fragile-X syndrome. In contrast, FSHD2 is an in trans epigenetic disorder 
as >80% of the FSHD2 patients carry mutations in the structural maintenance of 
chromosomes flexible hinge domain containing 1 (SMCHD1) gene, which is underlying 
the changes in D4Z4 chromatin structure77. 
SMCHD1 is structurally related to the SMC protein superfamily, which constitutes core 
proteins of the Cohesin complex, and was first identified in a screen to identify epigenetic 
modifiers of variegated expression in a murine model78. Smchd1 has been shown 
to play a role in X-chromosome inactivation, an epigenetic process ensuring dosage 
compensation in females by silencing one of the two X chromosomes. A hallmark of 
X-chromosome inactivation is the expression of a long non-coding RNA (lncRNA) known 
as Xist. Xist covers the X-chromosome in cis and recruits the PRC2 complex to ensure 
gene silencing throughout the inactive X-chromosome, with the exception of some 
genes that escape this process79. In female Smchd1 knockout mice, X-chromosome 
inactivation is perturbed, with promoter hypomethylation of CpG islands and 
concomitant upregulation of clustered transcripts normally subject to X-chromosome 
inactivation, showing a role for Smchd1 in establishment and/or maintenance of CpG 
methylation78, 80-82. Furthermore, it has been shown that SMCHD1 is involved in the 
higher order compaction of the inactivated X-chromosome by interacting with Xist 
and H3K27me382. Next to its role in X-chromosome inactivation, Smchd1 is involved in 
the silencing of several mono-allelically expressed autosomal genes, among which the 
clustered protocadherin genes on mouse chromosome 1881, 83. 
In concordance with all these observations, reduced binding of SMCHD1 at D4Z4 
correlates with CpG hypomethylation and chromatin derepression in FSHD2 patients 
(Fig. 3B)77. Moreover, SMCHD1 was shown to act as a modifier of disease severity in 
FSHD1 patients, supporting a role for SMCHD1 in both genetic forms of the disease84, 
85. Expression of both long and small non-coding RNAs from D4Z4 have been reported 
and linked to chromatin repression and/or activation86, 87. A lncRNA starting proximal to 
the D4Z4 repeat was shown to recruit the chromatin modifier ASH1L, an H3K36 KMT 
normally associated with euchromatin, resulting in derepression of DUX486. Conversely, 
expression of several different small interfering RNAs (siRNAs) matching the D4Z4 repeat 
sequence led to repression of D4Z4 in a DICER/AGO dependent fashion87. Altogether, 
a complex interplay of different mechanisms regulating the compaction of chromatin 
has been shown to act at the D4Z4 macrosatellite repeat, highlighting the epigenetic 
component of FSHD.
D4Z4 chromatin changes in FSHD lead to the derepression of DUX4
In absence of evidence for DUX4 expression in FSHD muscle cells, early studies proposed 
that the changed local chromatin environment at D4Z4 had an effect in cis on proximal 
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genes. This hypothesis relied either on proximal spreading of the altered chromatin 
structure at D4Z4 and/or changes in higher order chromatin organization and long 
range interactions. 4q35, in contrast to 10q26, preferentially localizes to the nuclear 
periphery88. This is likely mediated through interactions with the nuclear matrix, which 
is disturbed upon D4Z4 contraction89. Next to disturbed interactions with the nuclear 
























Figure 3: schematic representation of the genetic and epigenetic features of the FSHD locus on chro-
mosome 4q35.
A) The D4Z4 macrosatellite (triangles) and its flanking sequences, including the proximal FRG1 and 
FRG2 genes, is contracted in FSHD1 patients. All patients (FSHD1 and FSHD2) carry the 4qA variant 
of the p-LAM sequence element distal to the D4Z4, encoding a non-canonical poly adenylation signal 
allowing the formation of stable DUX4 transcripts. The D4Z4 repeat and some flanking sequences are 
duplicated to chromosome 10q26. Arches depict the reported long range interactions and/or position 
effects of the chromatin affected in FSHD. Inset: overview of the DUX4 transcript produced from the 
most distal D4Z4 unit and the p-LAM sequence. The full DUX4 open reading frame is included in the 
first exon and is therefore present in each repeat unit. B) The D4Z4 chromatin structure is character-
ized by the presence of methylation markers for both eu- and hetero-chromatin (hexagons) and high 
levels of CpG methylation. D4Z4 compaction is further established by binding of HP1 and SMCHD1. 
In FSHD patients, D4Z4 is decompacted evidenced by a loss of CpG methylation and H3K9me3 with a 
concomitant loss of SMCHD1 and HP1 binding.
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4q3589, 90. Furthermore, D4Z4 was reported to physically interact with more proximal 
regions by which it may influence the local chromatin structure of more upstream genes 
on 4q3591, 92.
Two candidate genes were identified in the region flanking D4Z4 proximally: FSHD 
region gene 1 (FRG1) and FRG2, of which the latter is also present on chromosome 10 
(Fig. 3A)93, 94. Both FRG1 and FRG2 were reported to be upregulated in FSHD, suggesting 
a mechanism of long range interactions and/or spreading of chromatin derepression 
from the D4Z4 repeat (Fig. 3A)63, 93, 95-97. Overexpression of FRG1, an Actin bundling and 
mRNA processing protein, induces a muscular dystrophy phenotype in different animal 
models, however most follow up studies failed to confirm the upregulation of FRG1 in 
FSHD patient material96-112. In contrast, FRG2 activation is a robust and reproducible 
hallmark of FSHD cells, however its function is unknown and overexpression in mice did 
not lead to a muscle phenotype93, 97, 101.
More recently, few studies revealed a possible link between deregulation of FAT atypical 
cadherin 1 (FAT1), located 3.6 Mb upstream of D4Z4, and FSHD pathology113-115. Mice in 
which Fat1 was genetically ablated developed asymmetric muscle wasting reminiscent 
of FSHD, and genetic analysis of FAT1 in human patients may suggest a secondary or 
indirect involvement of FAT1 in FSHD pathology113-115. Altogether, these studies highlight 
that genes proximal to the D4Z4 repeat may be deregulated in FSHD. Their involvement 
in the disease mechanism and the mechanisms behind their deregulation remain 
unclear at this point.
With the identification of several transcripts produced from D4Z4, including an mRNA 
encoding the full length DUX4 protein, efforts to identify the FSHD disease mechanism 
focused on DUX4 again116. The key to the FSHD disease mechanism lies within the 
unique association of FSHD with the 4qA haplotype distal to the D4Z4 repeat45-47. This 
sequence element (pLAM) encodes 1) an additional DUX4 exon distal to the last repeat 
unit and 2) a non-canonical DUX4 polyadenylation signal (PAS). Both these elements 
are absent in 4qB alleles, while the PAS is absent from 10q alleles68, 117. It was shown 
that the presence of this PAS can lead to the formation of a stable full length DUX4 
transcript and genetically unifies all FSHD patients (Fig. 3B)117. Additionally, full length 
DUX4 was shown to be abundantly expressed in sporadic myonuclei of FSHD derived 
proliferating myoblasts and differentiated myotubes, but at low or even undetectable 
levels in control derived material118, 119. 
These combined efforts have led to a unifying disease mechanism in which developing 
FSHD relies on three interdependent prerequisites: 
1. the presence of at least one PAS containing 4qA allele (contracted to 1-10 units in 
FSHD1);
2. chromatin derepression at D4Z4 through an in cis (FSHD1) or in trans (FSHD2) 
mechanism;
3. sporadic DUX4 expression in a myogenic context.
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Upon expression, DUX4 acts as a potent transcriptional activator. In muscle cells, DUX4 
activates a specific set of genes, through direct binding to a double homeodomain DNA 
motif120. In response to DUX4 activation, genes involved in in germline biology, early 
stem cell development and innate immunity are deregulated120. Furthermore, DUX4 
binds and activates retroelements, mainly of the ERV/MaLR type, which can lead to 
the formation of alternative transcriptional start sites for flanking genes120, 121. Many 
of the DUX4 targets identified by overexpression are deregulated in patient derived 
material, including fetal muscles, and account for the majority of transcriptional 
changes between FSHD and control muscle cells and/or biopsies112, 120, 122. More recently, 
a reporter based approach, allowing transcriptome analysis of individual muscle cells 
expressing endogenous DUX4, confirmed many of these targets and highlighted a role 
for disrupted RNA metabolism in FSHD pathology123.
Apart from initiating aberrant transcriptional programs in muscle cells, DUX4 
expression has other detrimental effects in various model systems which may or may 
not depend on its function as a transcriptional activator. In rhabdomyosarcoma cells 
it was shown that DUX4 induces cell cycle arrest in a P21 dependent fashion, possibly 
impacting muscle regeneration124. Besides, DUX4 expression in murine ES cells leads to 
reduced pluripotency and an imbalance in the formation of the three germlayers upon 
differentiation125. Expression of DUX4 in mesenchymal stromal cells promotes their 
differentiation into osteoblasts by an unknown mechanism126. DUX4 was also shown to 
inhibit RNA degradation through nonsense mediated decay (NMD). Expression of DUX4 
leads to the degradation of the NMD factor UPF1, thereby creating a positive feedback 
loop as DUX4 itself is a substrate for NMD127. Altogether, this likely accounts for the 
observed toxicity of DUX4 expression in skeletal muscle cells. 
Although the consequences of DUX4 expression are extensively studied, the mechanisms 
underlying the sporadic activation of DUX4 are not so well understood. What is driving 
the sporadic bursts of expression? Why is DUX4 expression increased during myotube 
differentiation? Few studies have focused on these aspects and how the sporadic 
expression of DUX4 leads to the progressive and variable phenotype characteristic of 
FSHD. For example, DUX4 activation is repressed by active Wnt/β-catenin signalling128. 
Next to that, DUX4 activation was linked to the activity of two enhancers proximal to 
D4Z4, which show myogenic activity in controls and patients129. DUX4 was also shown 
to be controlled by a telomere position effect (TPE), a chromatin mediated regulation 
similar to what was proposed for proximal gene regulation by D4Z4 (Fig. 3A)130. It was 
shown that the expression levels of DUX4, as well as FRG2, inversely correlate with 
the length of the adjacent 4q telomere. As telomere length naturally declines with 
(cellular) age and was shown to influence the epigenetic regulation of the adjacent 
subtelomeres131, 132, this study possibly links the expression levels of DUX4 to the 
progressive nature of FSHD. 
Determining the mechanism of sporadic DUX4 activation in skeletal muscle will be 
key to find targets for therapeutic intervention. Of importance is the identification 
of the different epigenetic mechanisms regulating the D4Z4 repeat and their relative 
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contribution to silencing DUX4 in muscle cells as these are potential druggable targets. 
Furthermore, the epigenetic regulation of D4Z4 can be a determinant of disease severity 
and variability: both endogenous factors, like epigenetic modifiers of D4Z4 chromatin 
structure, and environmental factors influencing the epigenome may determine 
penetrance of FSHD. 
Next to new avenues for mechanistic and molecular studies, the firm establishment of 
the FSHD disease mechanism also paves the road for the generation of animal models 
to initiate more translational research. The generation of faithful animal models is 
however challenged by the fact that the D4Z4 macrosatellite and the DUX4 gene do 
not have a homologue in a similar genomic context in other, non-primate species65. 
Recapitulation of the FSHD phenotype therefore has to rely on the ectopic expression 
of DUX4 in animal models, with the potential pitfall that the transcriptional targets 
of DUX4, and thereby its molecular effects, may not be conserved between different 
species. 
 
ICF syndrome: an epigenetic disorder in trans
Immunodeficiency, centromere instability and facial anomalies syndrome (OMIM 
602900/614064) is a rare autosomal recessive primary immunodeficiency, first 
described in two independent reports in the late 1970’s133, 134. Patients suffer from a 
triad of phenotypes of which hypo- or a-gammaglobunemia (low or undetectable levels 
of serum immunoglobulin A (IgA) and IgG) is the most prominent135, 136. Although serum 
immunoglobulins are drastically decreased in ICF patients, they do have circulating 
B-cells, suggesting a defect in the final steps of B-cell maturation and immunoglobulin 
selection and production136. A- or hypo-gammaglobunemia in ICF patients results in 
recurrent infections of the gastro-intestinal and/or respiratory tract, which are often 
fatal at young age, although some patients show long term survival. These symptoms 
can be alleviated by  immunoglobulin replacement therapy or haematopoietic stem cell 
transplantation135-137. Nearly all patients present with a distinct but variable spectrum of 
facial anomalies, of which hypertelorism, flat nasal bridge and epicanthus are the most 
prevalent135, 136. Further developmental problems include, but are not limited to, a delay 
in motor and speech development and variable intellectual disability135, 136.
ICF syndrome was one of the first epigenetic disorders to be recognized as such, because 
of the cytogenetic hallmark of centromere instability on chromosomes 1, 9 and 16134, 
138. This instability leads to chromosomal aberrations in cultured patient cells, similar to 
those observed in cell lines treated with demethylating agents134, 138. The involvement of 
centromeric chromatin organization was further proven by early reports showing DNA 
hypomethylation in ICF patients of mainly, but not exclusively, satellite 2 centromeric 
repeats, highly abundant on chromosomes 1, 9 and 16138, 139. 
Three different groups of patients can be recognized based on the genetic defect 
underlying the syndrome. In the late ‘90s two papers described mutations in DNMT3B to 
underlie ICF syndrome in approximately half of the patients (ICF1; OMIM 602900)140, 141. 
The majority of identified mutations affect the catalytic domain of DNMT3B and are of 
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the missense type, resulting in reduced methyltransferase activity of DNMT3B136, 142, 143. 
ICF1 patients carry at least one partially functional DNMT3B copy, as nonsense alleles are 
only identified in combination with missense alleles in compound heterozygotes136. This 
is in line with the observed phenotypes of mouse models for ICF1. Whereas Dnmt3b-/- 
mice show embryonic lethality, hypomorphic mouse models carrying (patient derived) 
missense mutations in Dnmt3b present with CpG hypomethylation at centromeric 
satellite repeats, craniofacial abnormalities, runting and an impaired immune system 
characterized by increased levels of apoptosis in T-cells144-146. Although some features of 
ICF syndrome are clearly recapitulated in these models, the most prominent difference 
is that none of the available models displays impaired B-cell functionality.
In line with a defect in one of the two de novo methyltransferases, the genome of ICF1 
patients is characterized  by global hypomethylation at both coding and non-coding 
regions147-150. Moreover, higher order chromatin structure organization is altered in 
ICF1 patients, exemplified by a changed nuclear localization of genes on the inactived 
X-chromosome151. ICF patients show hypomethylation at various types of repetitive 
elements throughout the genome, including interspersed LINE repeat elements and 
tandem repeats like centromeric satellites and the subtelomeric D4Z4 macrosatellite139, 
147, 152, 153. CpG hypomethylation at subtelomeres in ICF patients correlates with extensive 
shortening of the adjacent telomeres154. Telomeres are transcriptionally active, as they 
have been shown to produce telomere repeat containing RNAs (TERRA)155, 156. In ICF1 
derived patient cell lines an increase in expression levels of TERRA lncRNAs has been 
observed, most likely in some way linked to the extensive telomere shortening in these 
cells154. How these observations contribute to the disease mechanism remains unclear 
at this point. In general, analyses of methylation at genic and non-genic regions and 
transcriptional changes in ICF1 patient derived cell lines only showed partial correlations 
and have not revealed a comprehensive disease mechanism yet147-150, 157, 158.
A second group of patients, negative for mutations in DNMT3B, shares all epigenetic and 
phenotypic characteristics with ICF1 patients, however with additional hypomethylation 
of alpha-satellite DNA, a centromeric macrosatellite135, 159. Additionally, specific germline 
genes display hypomethylation and concomitant transcriptional activation in ICF1 
derived patient material only150.  Genetic analyses of these DNMT3B mutation negative 
patients revealed that the majority has mutations in zinc finger and BTB domain 
containing protein 24 (ZBTB24; ICF2; OMIM 614064)160-163. In contrast to what has been 
observed for DNMT3B, mutations in ZBTB24 do not localize to a confined domain of 
the gene136. In fact, mutations in ZBTB24 are almost exclusively of the nonsense type, 
most likely leading to complete absence of the full length protein in patients136. Thus 
far, no molecular function has been described for ZBTB24, although by homology it is 
member of the ZBTB family of (hematopoietic) transcription factors164. The BTB domain, 
found in the N-terminus of ZBTB24, mediates homo- or hetero-dimerization and may 
facilitate additional protein-protein interactions164. The C-terminal zinc finger (ZNF) of 
ZBTB proteins is thought to mediate the localization to specific DNA sequences. Based 
hereon, ZBTB24 is functionally unrelated to DNMT3B and discovering its function is of 
great importance to understand ICF pathology.
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The majority of ICF patients is genetically explained by mutations in DNMT3B or ZBTB24. 
However, the small group of patients negative for mutations in both genes (ICFX) shows 
that at least one additional gene defect underlies ICF syndrome. Both the identification 
of DNMT3B and ZBTB24 have not resulted in a comprehensive pathomechanism for 
the triad of phenotypes in ICF syndrome yet. Both further characterizing the function 
of the known ICF genes and identification of the gene(s) underlying ICFX is essential to 
understand the disease mechanism. The overlapping clinical phenotype of all patients 
suggests that DNMT3B, ZBTB24, and any number of additional ICF genes functionally 
converge at some point.
Outline of the thesis
This thesis focuses on two epigenetic diseases: FSHD and ICF syndrome. Common 
to both diseases is the epigenetic dysregulation of repetitive DNA, specifically the 
D4Z4 macrosatellite repeat. We first aimed to better understand the chromatin 
dysregulation at D4Z4 and its possible correlation to disease severity. In Chapter 2 
we set out to analyse the correlation of the chromatin compaction at D4Z4 in patient 
derived primary cell lines and the clinical severity. Although trends exist, a significant 
correlation between clinical severity and chromatin compaction, measured by relative 
amounts of H3K4me2 and H3K9me3, could not be observed. This study did reveal a 
clear correlation between muscle pathology in the vastus lateralis muscle and clinical 
severity. With regard to the known influence of telomeres on the epigenetic regulation 
of the adjacent subtelomeres, chapter 3 describes the effect of telomere shortening 
and cellular aging (senescence) on the epigenetic regulation of subtelomeres. We 
observed that subtelomeres, including the D4Z4 macrosatellite, are characterized by a 
shifted balance between markers for constitutive and facultative heterochromatin upon 
telomere induced senescence. 
In chapter 4, crosstalk and relative contributions of different epigenetic machineries 
affecting D4Z4 chromatin structure and DUX4 activity during muscle differentiation 
are investigated. SMCHD1, the major FSHD2 gene, is found to be a master regulator of 
the chromatin organization of D4Z4 in both genetic forms of FSHD and forms a barrier 
between the constitutive heterochromatic nature of D4Z4 and the PRC2 machinery, 
characteristic of facultative heterochromatin. In chapter 5 we challenge the position 
effect hypothesis of telomeres and D4Z4 on the FSHD specific activation of FRG2, by 
showing that FRG2 is a direct target gene of DUX4 and follows the expression pattern 
of other well-established DUX4 targets. Overall, these chapters highlight the clear 
epigenetic component in FSHD and the central role of DUX4 in its pathology.
Chapter 6 describes the generation of two transgenic mouse models. Both models 
carry human D4Z4 repeats in the size range of either FSHD1 (2.5 copies) or controls 
(12.5 copies) and our study shows that key (epi)genetic features of D4Z4 are conserved 
between man and mouse. Where the D4Z4-2.5 mouse recapitulates key features of the 
disease, including chromatin relaxation of the D4Z4 repeat and sporadic activation of 
DUX4, the D4Z4-12.5 resembles the situation observed in healthy controls. Although 
this mouse does not show an overt muscular phenotype, it offers great potential in 
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deciphering the mechanisms underlying DUX4 activation and potential ways to identify 
drugable targets for FSHD. 
Finally, with regards to ICF syndrome, chapter 7 describes the identification of mutations 
in the cell division cycle associated 7 (CDCA7) and the helicase, lymphoid specific 
(HELLS) genes in previously unexplained cases. By doubling the number of ICF disease 
genes, this work highlights the genetic heterogeneity of the disorder and leaves only 
few cases unexplained. Molecular characterization of these genes will help to decipher 
the pathomechanism of ICF syndrome.
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The aim of our study was to identify relationships between epigenetic parameters 
correlating with a relaxed chromatin state of the DUX4 promoter region and clinical 
severity as measured by a clinical severity score or muscle pathologic changes in D4Z4 
contraction-dependent (FSHD1) and –independent (FSHD2) facioscapulohumeral 
muscular dystrophy patients. Twenty primary fibroblast (5 control, 10 FSHD1 and 5 
FSHD2) and 26 primary myoblast (9 control, 12 FSHD1 and 5 FSHD2) cultures originating 
from patients with FSHD and controls were analyzed. Histone modification levels were 
determined by chromatin immunoprecipitation. We examined correlations between 
the chromatin compaction score (ChCS) defined by the H3K9me3:H3K4me2 ratio and 
an age corrected clinical severity score (CSS) or muscle pathology score (MPS). Possible 
relationships were investigated using linear regression analysis and significance was 
tested by Pearson’s product-moment coefficient.
We found a significant difference of the ChCS between controls and patients with FSHD1 
and between controls and patients with FSHD2. Tissue specific differences in ChCS were 
also observed. We also found a near-significant relationship between ChCS and the 
age corrected CSS in fibroblasts but not in myoblasts. Surprisingly, we found a strong 
correlation between the MPS of the vastus lateralis and the CSS. Our results confirm 
the D4Z4 chromatin relaxation previously shown to be associated with FSHD in a small 
number of samples. A possible relationship between clinical and epigenetic parameters 
could be established in patient fibroblasts, but not in myoblasts. The strong correlation 
between the MPS of the vastus lateralis and the CSS suggests that this muscle can be 
used to study for surrogate markers of overall disease severity.
37
Correlation of clinical parameters with epigenetic modifications at D4Z4
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant myopathy 
characterized initially by progressive wasting of the facial, shoulder and upper arm 
muscles1. Two distinct groups of affected individuals can be defined: > 95% of patients 
have a contracted D4Z4 repeat array below 10 units in the subtelomeric region of 
chromosome 4 (FSHD1) while < 5% of patients do not have a contracted D4Z4 array 
(FSHD2)2. Both FSHD1 and FSHD2 patients show CpG hypomethylation and specific loss 
of the repressive histone modification histone 3 lysine 9 trimethylation (H3K9me3) at 
the D4Z4 array3, 4. While in patients with FSHD1 the hypomethylation is restricted to 
the contracted allele, both alleles on chromosome 4 and both homologous arrays on 
chromosome 10 are hypomethylated in FSHD25. These epigenetic changes result in a 
relative chromatin relaxation which may facilitate the expression of full length double 
homeobox gene  4 (flDUX4) (Fig. 1)4, 5. However, in cultured myotubes from patients with 
FSHD, it is found that flDUX4 expression occurs only on specific genetic backgrounds 
of chromosome 4 containing an additional DUX4 exon immediately distal to the D4Z4 
repeat which stabilizes the transcript and leads to the production of abundant amounts 
of DUX4 protein in sporadic myonuclei6-8.
The age at onset, severity and disease progression is highly variable between and within 
FSHD families1. Several studies addressed the possibility of a correlation between disease 
severity measured by age at onset or clinical severity score (CSS) and the residual repeat 
size of the disease-associated D4Z4 repeat in FSHD1 patients9-11. A rough and inverse 
correlation was reported between D4Z4 unit number and severity: individuals with 1–3 
units typically exhibited the most severe phenotype, while patients with 4–10 D4Z4 
units generally show a high variability in clinical presentation12.
-methylated CpG nucleotide
-D4Z4 unit with heterochromatic structure








nD4Z4= 10-40 units DUX4
AAA
-A161 specific haplotype
Figure 1: Schematic representation of the FSHD locus in control individuals, patients with contraction 
dependent (FSHD1) and patients with contraction independent (FSHD2) FSHD. D4Z4 repeat units are 
indicated with triangles, the additional DUX4 exon with stabilizing polyA signal distal to the repeat 
is indicated with a box. Common chromatin features of D4Z4 in FSHD1 and FSHD2 are decreased 
CpG methylation levels and a more relaxed chromatin structure facilitating the expression of DUX4 
from the telomeric repeat unit. Overall reduction in CpG methylation of D4Z4 in FSHD is schematically 
indicated with reduced number of lollipop symbols.
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The correlation between CpG methylation level at D4Z4 and age-corrected CSS was also 
studied in FSHD1 and FSHD2 patients. No linear relationship was found between the 
CpG methylation level of the first D4Z4 unit on the contracted allele in peripheral blood 
lymphocytes and the age-corrected CSS in a limited number of patients12.
A recent study emphasizes the role of histone modifications in the pathomechanism of 
FSHD4. A combined presence of the transcriptionally permissive modification histone 3 
lysine 4 dimethylation (H3K4me2) and repressive histone modification H3K9me3 was 
detected in the promoter region of DUX4. A specific loss of H3K9me3 was reported 
in immortalized peripheral lymphoblastoid cell lines, primary fibroblast and primary 
myoblast samples of FSHD patients, both FSHD1 and FSHD2. We hypothesized that the 
ratio of H3K9me3 and H3K4me2, herein referred to as the chromatin compaction score 
(ChCS), is significantly different between control and affected individuals and examined 
the relationship between ChCS and measures of overall disease severity as well as 
between ChCS and histopathological changes in muscle.
Results
Significant difference in chromatin compaction score between controls and FSHD 
patients
Since D4Z4 repeats in FSHD1 and FSHD2 patients show identical epigenetic changes, 
we tested whether the ChCS, the ratio of H3K9me3:H3K4me2, discriminates control 
samples from FSHD1 and FSHD2 samples. Our study includes 5 control, 10 FSHD1 and 
5 FSHD2 primary fibroblast cultures in addition to 9 control, 12 FSHD1 and 5 FSHD2 
myoblast cultures. Cross-linked ChIP was performed using H3K9me3 and H3K4me2 
antibodies and ChCS were calculated by dividing H3K9me3 relative enrichment values 
by H3K4me2 relative enrichment values. Statistical analysis of fibroblast data showed 
significant differences between control and FSHD1 (P < 0.01) and control and FSHD2 
samples (P < 0.01) (Fig. 2A, B). ChCS were decreased in patient samples indicating a 
D4Z4 chromatin relaxation in patient samples.
Figure 2. Scatterplot of ChCS in fibroblasts (A) or myoblasts (B) of controls, FSHD1 and FSHD2 pa-
tients. Individual samples are represented by individual data points. Mean values with 1xSD are indi-
cated.
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Analyzed samples Fibroblast Myoblast
Gender Condition n Pearson-r p-value n Pearson-r p-value
M FSHD1 7 -0.612 0.144 3 0.095 0.940
F FSHD1 3 -0.166 0.894 9 -0.12 0.758
M + F FSHD1 10 -0.437 0.206 12 -0.186 0.562
M FSHD2 3 -0.258 0.834 3 0.992 0.082
F FSHD2 2 NA NA 2 NA NA
M + F FSHD2 5 0.127 0.838 5 0.319 0.600
M FSHD1 + FSHD2 10 -0.686 0.028 6 0.743 0.090
F FSHD1 + FSHD2 5 0.014 0.982 11 -0.136 0.690
M + F FSHD1 + FSHD2 15 -0.492 0.062 17 -0.066 0.801
Table 1.  Summary of analyses of age corrected CSS and CRS
Since FSHD is a progressive muscle disease we hypothesized that a relationship between 
epigenetic marks and the clinical phenotype is more pronounced in primary myoblast 
cultures. To avoid possible differences caused by the replicative history of the culture, 
chromatin was isolated from all samples at passage 6 or 7. Similar to the fibroblast 
results we found that the ChCS was significantly lower in FSHD1 compared with control 
(P < 0.05) as well as in FSHD2 compared with control (P < 0.01) samples. We also 
observed that maximum ChCS values in fibroblast cultures (6 on y axis in Fig. 2A) are 
lower than maximum ChCS values in myoblast cultures (25 on y axis on Fig. 2B).
Correlation analysis of ChCS and age-corrected CSS in myoblast and fibroblast samples
Next we performed linear regression analysis to study the relationship between ChCS 
and age-correlated CSS. Analysis was done separately on fibroblast and myoblast using 
all samples and separating them by disease subtype (FSHD1 or FSHD2). Since gender 
differences have been reported for the penetrance and the severity of the disease, 
samples were also analyzed after separation based on gender. A summary of analyses 
with corresponding p values determined by Pearson product moment coefficient are 
shown in table 1.
We found significant negative correlation between ChCS and age-corrected CSS in male 
FSHD1 and FSHD2 fibroblast samples (P = 0.028) suggesting that the chromatin at D4Z4 
is more relaxed in samples originating from males with a more severe phenotype. When 
combining male and female fibroblast samples the negative correlation reached near-
significance (P = 0.062). There was no significant correlation found in myoblasts in any 
combination of samples studied. Our results of fibroblast (P = 0.062) and myoblast 
samples (P = 0.801) are presented in Figure 3.
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Correlation analysis of ChCS and MPS in myoblast samples
Muscle biopsies were scored for MPS as described in the methods section. Correlation 
analysis between ChCS and MPS was done on 6 FSHD1 and 5 FSHD2 patients for whom 
both scores were available (Fig. S1). Statistical analysis showed no relationship between 
MPS and ChCS.
Correlation analysis of MPS and CSS
Finally we tested whether we could find a relationship between vastus lateralis MPS 
and CSS. Since MPS and CSS are compared in the same patient, we refrained from using 
the age-correction in establishing the clinical severity. As shown in Figure 4, in the 11 
FSHD patients for which both scores were available we found a significant and positive 
relationship between the muscle pathology score and CSS (r = 0.85; P = 0.0009).
Discussion
FSHD presents with high and unpredictable inter- and intrafamilial clinical variability in 
disease onset and progression1. To provide patients with a better prognosis it would be 
beneficial to identify genetic or epigenetic markers that correlate with disease severity. 
Earlier studies failed to identify correlations between genetic markers (D4Z4 repeat 
size) or epigenetic markers (D4Z4 methylation) that can be used in the clinic9, 12.
The focus of the present study was to investigate possible relationships between the 
epigenetic changes occurring in primary fibroblasts and myoblasts of FSHD1 and FSHD2 
patients at the promoter region of DUX4 and the clinical severity defined by the CSS or 
MPS. As a measure of chromatin changes, first we introduced the chromatin compaction 
score, ChCS, in which the relative enrichment of H3K9me3 at D4Z4 is divided by the 
relative enrichment of H3K4me2. The advantage of such a score is that it circumvents 
the correlation calculation problem of ChIP experiments studying repetitive sequences. 
Different samples contain different numbers of D4Z4 units and our experimental 
procedure detects all repeat units on chromosomes 4 and 10. A comparison between 
Figure 3. Scatterplot of ChCS vs. age-corrected CSS in fibroblast (A) and in myoblast samples (B). 
Male samples are represented by closed triangles, female samples by open triangles.
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different samples is only reliable if the measured signal can be correlated with D4Z4 
unit numbers. Since both H3K9me3 and H3K4me2 are present in every unit, their ratio, 
as calculated in the ChCS, gives a value per unit.
Statistical analysis revealed a significant difference between the ChCS of control and 
FSHD1 and between control and FSHD2 in fibroblast and myoblast cultures. These 
results, showing a significant decrease in ChCS in FSHD cell lines, confirm the previously 
reported epigenetic alterations at D4Z4 suggesting that the D4Z4 array in FSHD patients 
is less compact than in controls4.
Comparison of ChCS values between the disease subtypes separately in fibroblast and 
myoblast samples showed that independent of cell type FSHD1 ChCS values show high 
variation while FSHD2 ChCS values are lower and less variable. This might be explained 
by a much more widespread chromatin relaxation over all four repeats in FSHD2, while 
in FSHD1 the changes may be more restricted to the pathogenic allele. This is also 
observed for the loss of DNA methylation at D4Z45.
We also detected tissue-specific differences in the chromatin landscape at D4Z4 arrays 
of fibroblast and myoblast cultures with control myoblast ChCS values being higher 
than control fibroblast ChCS values. Genome-wide ChIP-seq studies have shown that 
the chromatin landscape in a particular cell type reflects its transcriptional activity and 
is therefore cell type-specific13. Our results show that ChCS values are also cell-type 
specific with a more compact chromatin organization of D4Z4 in myoblasts to prevent 
expression of flDUX4. This may explain the specific tissue involvement in FSHD.
Correlation analysis of the ChCS and age-corrected CSS revealed a significant relationship 
in male fibroblast patient samples (P = 0.028). Correlation analysis of all fibroblast 
samples gave borderline significance (P = 0.062). Gender differences for disease 
penetrance and severity have been reported and showed that males are typically more 
severely affected than females14. The weak correlation may be caused by the small 
sample size or because of technical reasons. In our ChIP assays we measure collectively 
Figure 4. Relationship analysis between the CSS and MPS. There is a significant correlation between 
MPS and CSS (P = 0.0009). Note that the analysis was done without age correction.
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the chromatin status of each DUX4 promoter in the entire array, rather than specifically 
interrogating the most telomeric unit from which flDUX4 originates. Moreover, in FSHD1 
we are not only measuring the DUX4 promoters of the pathogenic allele, but instead 
all D4Z4 and D4Z4-like arrays on chromosomes 4 and 10. Considering that in FSHD2 the 
chromatin status of all four chromosomes seems to be affected, this limitation should 
not apply to FSHD2. Nevertheless, also in FSHD2 cases we could not detect relationship 
between ChCS and age corrected CSS possibly due to small sample size.
Statistical analysis of myoblast data could not detect significant relationship between 
ChCS and age corrected CSS in any combination of samples (Table 1). Myoblasts 
are more sensitive to culturing conditions, often less homogeneous and can quickly 
transform to a pre-differentiation state, factors that may all affect their epigenetic 
profile. An alternative explanation might be that myoblast cultures carry a ‘history of 
disease’ that may affect the chromatin status of D4Z4 while fibroblasts, being derived 
from a non-affected tissue are not expected to have such history.
Irrespective of the explanation, if a negative correlation between the ChCS and CSS 
in fibroblast samples can be confirmed in larger group of patients, it would provide 
the first prognostic marker that can be measured in a relatively accessible tissue. In 
addition, since we could observe significant ChCS changes in myoblasts and fibroblasts, 
it is tempting to speculate that this score can also be used for prenatal diagnosis of 
FSHD2, a condition for which currently no validated diagnostic test exists.
An interesting observation from our study is that there is strong correlation between 
the CSS and the MPS of the vastus lateralis muscle. These results indicate that the 
pathology observed in the vastus lateralis muscle, typically not clinically affected in the 
early stages of FSHD, provides a good reflection of overall disease severity. This result 
shows that the vastus lateralis muscle, easily and safely accessible by needle biopsy 
techniques, is an ideal muscle to study for surrogate markers of overall disease severity. 
A non-invasive modality such as MRI to score the involvement of the vastus lateralis 
would be even more preferable. A study of lower extremity MRI in FSHD using a simple 
scoring system based on T1-W sequences was recently completed15. This study showed 
that the combined MRI score of all lower extremity muscles was highly correlated with 
CSS. Whether this correlation holds true when the MRI score is based on the score of 
only the vastus lateralis remains to be determined.
In summary, our study of a large cohort of patient and control fibroblast and myoblast 
cultures confirms earlier reports of D4Z4 chromatin relaxation in FSHD and introduces 
a practical chromatin compaction score (ChCS). We found a near-significant correlation 
between the ChCS and severity in patient fibroblast samples and identified an 
unexpected correlation between the CSS and the MPS. We propose that factors in 
addition to locus intrinsic properties, influence disease severity in FSHD.
Materials and methods
Patients and control individuals
All samples from controls and FSHD patients were obtained after signing informed 
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consents. Samples from 22 FSHD1, 10 FSHD2 and 14 controls were studied. Samples 
were analyzed for array size, 4q haplotype and DNA methylation according to published 
methods before the study (Tables S1 and S2)3, 16. Fibroblasts were derived from 2 mm 
punch skin biopsies obtained from the medial aspect of the distal forearm. Myoblasts 
were derived from needle muscle biopsy samples taken from the vastus lateralis 
muscle. An adjacent sample of muscle was processed for histopathology. Muscle and 
skin biopsy procedures are described here: http://www.urmc.rochester.edu/fields-
center/protocols/index.cfm. The muscle pathologic score (MPS) is based on review of 
four sections stained with Hematoxylin and Eosin as well as modified Gomori Trichrome 
staining. The 12 point pathologic score (0: normal, 12: end stage muscle) is based on 
assessment of variability in fiber size, percent of central nuclei, presence of active 
muscle fiber necrosis and regeneration and amount of fibrofatty replacement (http://
dev.mc.rochester.edu/fields-center/protocols/index.cfm).
Cell lines and culturing
All primary myoblast and fibroblast cell cultures were obtained from the University 
of Rochester’s FSHD biorepository (www.FieldsCenter.org). A list of used primary cell 
cultures, the 4q35 genotype and methylation status of D4Z4 is shown in Table S1 for 
myoblast samples and in Table S2 for fibroblast samples. Myoblast cell lines were 
cultured in DMEM/F-10 (#31550 GIBCO, Grand Island, NY) supplemented with 20% 
heat inactivated fetal bovine serum (FBS #10270 GIBCO), 1% penicillin/streptomycin 
(#15140 GIBCO), 10ng/ml basic rhFGF (#G5071 Promega, Madison, Wisconsin) and 
1μM Dexamethasone (#D2915 SIGMA, St. Louis, Missouri). Fibroblast cell lines were 
cultured in DMEM/F-12 media supplemented with 20% heat inactivated fetal bovine 
serum (FBS #10270 GIBCO), 1% penicillin/streptomycin (#15140 GIBCO), 10mM HEPES 
(#15630 GIBCO), 1mM Sodium Pyruvate (#11360 GIBCO).
Chromatin immunoprecipitation
Chromatin was prepared from cells fixed with 1% formaldehyde according to a published 
protocol17. Every sample was independently studied twice. ChIP-grade antibodies 
against H3K4me2 (no. 39142) and against H3K9me3 (no. 39162) used in this study were 
purchased from Active Motif (Carlsbad, CA, USA). Normal rabbit serum was used to 
measure unspecific binding of proteins to beads. Immunopurified DNA was quantified 
with Q-PCR primer pair4 and quantitative PCR measurements were done with CFX96TM 
real time system using iQTM SYBRR Green Supermix. Relative enrichment values were 
calculated by subtracting the IgG ChIP values representing background from the ChIP 
values with the H3K9me3 or H3K4me2 antibodies.
Statistical analysis
Differences in ChCS between controls, FSHD1 and FSHD2 samples were statistically 
analyzed by one-way-ANOVA, followed by LSD multiple comparisons test between 
individual groups. Correlations were tested by calculating the Pearson R coefficient with 
corresponding p-values between the age corrected CSS and ChCS or between CSS and 
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Subtelomeres are patchworks of evolutionary conserved sequence blocks, and 
harbor the transcriptional start sites for telomere repeat containing RNAs (TERRA). 
Recent studies suggest that the interplay between telomeres and subtelomeric 
chromatin is required for maintaining telomere function. To further characterize 
chromatin remodeling of subtelomeres in relation to telomere shortening and cellular 
senescence, we systematically quantified histone modifications and DNA methylation 
at the subtelomeres of chromosomes 7q and 11q in primary human WI-38 fibroblasts. 
Upon senescence, both subtelomeres were characterized by a decrease in markers of 
constitutive heterochromatin, suggesting relative chromatin relaxation. However, we 
did not find increased levels of markers of euchromatin or derepression of the 7q VIPR2 
gene. The repressed state of the subtelomeres was maintained upon senescence, which 
could be attributed to a rise in levels of facultative heterochromatin markers at both 
subtelomeres. While senescence-induced subtelomeric chromatin remodeling was 
similar for both chromosomes, chromatin remodeling at TERRA promoters displayed 
chromosome-specific patterns. At the 7q TERRA promoter, chromatin structure was co-
regulated with the more proximal subtelomere. In contrast, the 11q TERRA promoter, 
which was previously shown to be bound by CCCTC-binding factor CTCF, displayed 
lower levels of markers of constitutive heterochromatin which did not change upon 
senescence, whereas levels of markers of facultative heterochromatin decreased upon 
senescence. In line with the chromatin state data, transcription of 11q TERRA but not 7q 
TERRA was detected. Our study provides a detailed description of human subtelomeric 
chromatin dynamics and shows distinct regulation of the TERRA promoters of 7q and 
11q  upon cellular senescence.
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Introduction
The last decade has provided deeper knowledge on the stability and maintenance 
of the repetitive telomeric repeat structures at the ends of human chromosomes in 
biological processes such as cellular senescence. Non-transformed cells derived from 
mitotic tissues have a limited proliferative capacity, known as the Hayflick limit1, and 
will eventually become senescent. Senescent cells exit the cell cycle, start secreting 
specific proteins that affect the microenvironment and display a number of senescence-
associated markers, e.g. induction of cell cycle inhibitory proteins, senescence 
associated β-galactosidase (SA β-gal) and senescence associated heterochromatic foci 
(SAHF) formation2. Cellular senescence is considered an anti-tumorigenic mechanism 
which in vivo may be relevant especially at higher ages, since senescent cells accumulate 
with age in tissues with high cell turnover. In vitro, it has been shown that progressive 
shortening of telomeres is a potent trigger to induce cellular senescence3-5. 
Telomeres constitute the terminal structures of eukaryotic chromosomes and form 
a protective barrier against the incomplete replication of linear DNA. In mammals, 
telomeres are comprised of simple (TTAGGG)n repeats folded into a heterochromatic 
loop structure, facilitated by the shelterin protein complex6. Numerous reports on 
the inverse correlation of telomere length in peripheral blood cells and donor age, 
age-related traits and the risk for various age-related diseases highlight the potential 
relevance of telomere regulation7-11. It is as yet not clear however, whether telomere 
shortening causally contributes to these traits or represents a marker of cell division 
and senescence. 
Although most studies on the relationship between telomere shortening and senescence 
focused on its potential direct consequences on chromosome stability, it may have 
downstream consequences, particularly on the subtelomere, that may in turn affect 
telomere function12, 13. Subtelomeres, the first non-TTAGGG sequences directly adjacent 
to the telomere repeat, are evolutionary conserved chromosome domains consisting 
of patchworks of sequence blocks with high inter- and intrachromosomal similarity14, 
15. Subtelomeres are packed into constitutive heterochromatin, characterized by high 
levels of histone 3 lysine 9 trimethylation (H3K9me3) and CpG methylation13. A steep 
decrease of both markers is seen at subtelomeres upon drastic telomere shortening 
in mouse embryonic fibroblasts (MEFs) isolated from telomerase deficient mice, 
concomitant with an increase of markers for euchromatin (histone acetylation). This 
indicates a relative opening of the chromatin template at subtelomeres upon telomere 
shortening12, 13. 
Several human studies focusing on aging, as well as age related disease like Parkinson 
and Alzheimer disease, showed that telomere length correlates with CpG methylation 
at subtelomeres and that the direction of this correlation is dependent on the disease 
conditions13, 16-18. A recent study in dyskeratosis congenita suggested an interaction 
between the proper maintenance of telomeres and the chromatin state of subtelomeres19. 
A more causal relation between dysregulation of subtelomeric chromatin and human 
disease is seen in the progressive muscular dystrophy facioscapulohumeral muscular 
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dystrophy (FSHD). In FSHD, decreased chromatin compaction by reduced levels of CpG 
methylation and H3K9me3 at the subtelomeric D4Z4 repeat, encoding the toxic DUX4 
protein, leads to its aberrant transcription in muscle20-22. 
Chromatin alterations at subtelomeres may have other direct transcriptional 
consequences, as they harbor transcriptional start sites (TSS) for telomeric repeat 
containing RNAs (TERRA)23. The transcription of these long non-coding RNAs is 
influenced by subtelomeric CpG methylation and myeloid/lymphoid or mixed lineage 
leukemia (MLL) mediated H3K4me324, 25. More recently, a role for CTCF and cohesin 
was established in controlling telomeric transcription26. Telomere elongation by ectopic 
expression of telomerase, represses TERRA transcript levels and leads to increased levels 
of telomeric H3K9me3 without a concomitant change in the subtelomeric chromatin 
state27. In yeast, recent data shows that inducing TERRA expression leads to accelerated 
telomere shortening, by facilitating exonuclease activity at transcribed chromosome 
ends28, 29. 
From the currently available data a feedback model is emerging in which telomere 
length regulates the epigenetic structure of subtelomeres, thereby possibly affecting 
TERRA expression levels, which in turn have an effect on telomere length, induction 
of senescence and chromatin state. The data supporting this model were obtained in 
diverse model systems, using ectopic telomere length modulation or TERRA regulation. 
However, chromosome-specific data on subtelomeric chromatin remodeling and TERRA 
promoter regulation upon cellular senescence by physiological telomere shortening in 
a human system is lacking. Therefore, we systematically interrogated the chromatin 
state of subtelomeres in senescing primary human WI-38 fibroblasts. The chromatin 
state was assessed by quantifying markers for euchromatin (histone acetylation) and 
constitutive (CpG methylation, H3K9me3) and facultative (H3K27me3, H3K36me3) 
heterochromatin along the subtelomere. Together with chromosome specific analysis of 
TERRA promoters and transcripts, a complex picture of both common and chromosome 
specific epigenetic changes at human subtelomeres upon cellular senescence emerges.
Results
Late passage WI-38 fibroblasts display a senescent phenotype.
To study subtelomere chromatin dynamics upon cellular senescence, we cultured WI-38 
fibroblasts until they reached a senescent phenotype. Upon senescence, we observed 
overall telomere shortening evidenced by a shift in the smear in a TRF analysis (Fig. 
1A). Subsequent qPCR analysis revealed a 65% reduction in telomere copy number 
comparing early passage cycling cells to late passage senescent cells (E vs L, Fig. 1B). 
Upon cellular senescence, expression of the cell cycle inhibitory protein p16 was 
induced approximately 2 fold (Fig. 1C, D). Moreover, we observed that late passage 
cells display high levels of SAβ-gal activity in more than 95% of the cells, whereas in 
early passage only sporadic cells show staining (Fig. S1). Taken together, late passage 
WI-38 fibroblasts underwent replication induced telomere shortening and showed a 
senescent phenotype, in contrast to early passage cells. 
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Fig. 1. Late passage WI-38 fibroblasts underwent telomere shortening and display a senescent 
phenotype.
A) TRF analysis on genomic DNA isolated from early (E) passage and late (L) passage cells. DNA 
was digested with RsaI and AluI and reduction of the average telomere length is seen by the shift 
in the smear of the undigested telomeric DNA. B) Normalized relative quantification of telomeric 
copy number in E and L passage cells. Telomeric copy number was quantified by qPCR, relative to 
the 36B4 single copy locus and normalized to E passage cells. Error bars indicate SEM of a triplicate 
measurement. C) Western blot analysis in of p16 and actin expression in E and L passage cells followed 
by D) relative quantification, showed increased expression of p16 in L passage cells. Error bars indicate 
stdev of two biological replicates, asterisks indicate a p-value < 0.05 based on a Student’s t-test.
Decrease in markers of constitutive heterochromatin at subtelomeres upon senescence
The subtelomeres of human chromosome arms 7q and 11q are consisting of a single 
copy sequence which facilitates a chromosome specific analysis of histone modification 
levels at multiple loci with increasing distance to the telomere (Fig. 2A). We assessed 
H3K9me3 levels  at 6 loci on both subtelomeres and observed a variable 2-3 fold decrease 
of this modification at all loci upon cellular senescence (Fig. 2B-C). The decrease of 
H3K9me3 was not detected at the repressed, non-subtelomeric CT47 macrosatellite 
repeat array30, arguing against a general loss at heterochromatic loci (Fig. S2A). At 
the promoter of the actively transcribed GAPDH gene, no change in the low level of 
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Fig. 2. Decreased levels of markers of constitutive heterochromatin at subtelomeres upon 
senescence.
A) Location of the generated primer pairs along the subtelomeres of chromosome 7q and 11q. B) 
Relative quantification using ChIP-qPCR of H3K9me3 along the subtelomeres of 7q  and C) 11q shows a 
decrease at all loci upon senescence. H3K9me3 levels are corrected for IgG background and normalized 
to the relative amount of H3: (CtIgG-CtH3K9me3)/(CtIgG – CtH3). Error bars indicate SEM of at least duplicate 
qPCR measurements, asterisks indicate a p-value <0.05 based on a Student’s t-test. D) EpiTYPER based 
quantification of CpG methylation along the subtelomere of 7q and E) 11q showed a decreased DNA 
methylation at all sites measured. The mean methylation of multiple CpGs within the indicated probes 
is displayed.  F) Combined mean methylation levels of all subtelomeric probes at 7q and 11q showed 
a decreased DNA methylation along both subtelomeres. DNA methylation was quantified in triplicate, 
p-values are indicated and  * indicates a p-value <0.05 based on UNIANOVA analysis.
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H3K9me3 was observed upon cellular senescence (Fig. S2B). 
Mean methylation levels of sporadic CpGs at the regions under study showed variable 
levels at different loci, but at 4 out of 5 tested loci a significant decrease of 8-17% upon 
senescence (P < 0.05) was observed (Fig. 2D, E). The 5th locus, at 10kb from the 11q 
telomere, showed a similar trend (P = 0.08). Analysis of individual CpGs supported this 
observation (Fig. S3). Analysis per chromosome, by calculating the mean methylation 
level over multiple amplicons, revealed a significant average decrease of ~10% at 7q 
and ~6% at 11q (p < 0.05, Fig. 2F). Overall, we observed a reduction in markers of 
constitutive heterochromatin at two human subtelomeres upon cellular senescence, 
indicating a relative opening of the chromatin template.
No increased levels of euchromatin markers at subtelomeres upon senescence
In Terc-/- mice MEFs, the decrease of markers of constitutive heterochromatin with 
drastic telomere shortening is accompanied by increased histone acetylation levels.12 In 
our human cell system, H3K9ac was virtually absent at subtelomeres both in the early 
passage and upon cellular senescence (Fig. S4).  In contrast, H4K16ac was detected, 
but a decrease of at least 2 fold (Fig. 3A-B) was observed upon senescence. The latter 
was however not restricted to subtelomeres, as we observed a comparable decrease of 
this modification at the heterochromatic CT47 macrosatellite repeat array (Fig. S2A). In 
the context of the promoter of the actively transcribed GAPDH locus a relatively small 
increase of H4K16ac was observed (Fig. S2B). Altogether, we did not find evidence that 
the decreased levels of constitutive heterochromatin markers at subtelomeres upon 
senescence are accompanied by increased levels of markers of euchromatin.
Increased levels of H3K27me3 and H3K36me3 may compensate for loss of markers of 
constitutive heterochromatin
We wondered why the decrease of markers of constitutive heterochromatin marks did 
not go together with an increased level of euchromatin marks. Therefore, we tested 
whether chromatin repression was actually maintained, by involvement of different 
repressive mechanisms instead. As the Polycomb mediated H3K27me3 is considered a 
marker for both facultative and constitutive heterochromatin, we assessed its levels at 
the subtelomeres upon senescence. H3K27me3 was indeed detected at subtelomeres 
in early passage cells and we observed an up to 2 fold increase of this modification upon 
cellular senescence at 7 out of 12 loci on 7q and 11q (Fig. 3C-D). This suggests that a 
Polycomb-enforced chromatin repression occurs at these loci upon cellular senescence. 
The increase of H3K27me3 was most pronounced at 250 kb from the telomere on 
chromosome 7q, which is located in the fourth intron of the VIPR2 gene. Transcripts 
emanating from this gene were not detected in both passages (data not shown), again 
indicating the repressed chromatin state is indeed preserved in senescing cells. At 
the heterochromatic CT47 macrosatellite repeat array and the euchromatic GAPDH 
promoter we did not see increased levels of H3K27me3 (Fig. S2).
Recently it was shown that H3K36me3, a marker associated with actively transcribed 
gene bodies, is associated with both facultative and constitutive heterochromatin 
regions in mouse31. At the subtelomeres of 7q and 11q, we detected H3K36me3 with 
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an increase of at least 2 fold upon senescence at both subtelomeres (Fig. 3E-F). All 
subtelomeric loci displayed higher levels of this marker, but the largest increase was 
again detected within VIPR2.  Increased H3K36me3 was not restricted to subtelomeres, 
as similar increases were detected at the GAPDH promoter and CT47 macrosattelite 
repeat array (Fig. S2). Taken together, these data suggest a relative opening by reduction 
of constitutive heterochromatin markers is accompanied by increased levels of two 
Fig. 3. Relative quantification of subtelomeric H4K16ac, H3K27me3 and H3K36me3 upon senescence
Relative quantification using ChIP-qPCR of H4K16ac (A, B), H3K27me3 (C, D) and H3K36me3 (E, F) at 
increasing distance from the telomere at the subtelomeres of 7q (A, C, E) and 11q (B, D, F). H4K16ac 
is decreased at all loci and H3K36me3 shows an increase at both subtelomeres. H3K27me3 shows 
a more varied pattern; an increase is observed at 7 out of 12 loci. All values are corrected for IgG 
background and normalized to the relative amount of H3 ((CtIgG-Ctmodification)/(CtIgG – CtH3)), error bars 
indicate SEM of duplicate qPCR measurements, asterisks indicate a p-value < 0.05 based on a Student’s 
t-test.
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heterochromatin markers associated with different repressive mechanisms, which may 
maintain the repressed subtelomeric chromatin state upon senescence.
Since both model subtelomeres under study are of single copy nature, we wondered to 
what extent the observed effects would apply to other, more repetitive subtelomeric 
loci. To that end, we measured relative abundance of histone modifications at D4Z4, 
a subtelomeric repeat structure present at chromosomes 4q and 10q, that has been 
Fig. 4. TERRA promoter analysis reflects transcriptional activity at 7q and 11q irrespective of 
senescence
A) RT-PCR analysis of 7q, 11q and Xq specific TERRA transcripts allowed detection of 11q, but not 7q 
specific transcripts. Xq serves as an internal control. –RT: cDNA synthesis in the absence of reverse 
transcriptase to control for DNA background. gDNA: positive control for the PCR on a WI-38 genomic 
DNA extract. B) Epityper based quantification of TERRA promoter CpG methylation at 7q and 11q 
showed higher levels of methylation at 7q pTERRA compared to 11q pTERRA. The mean methylation 
of multiple CpGs within the indicated probes is displayed.  Upon senescence TERRA promoter 
methylation at both 7q and 11q does not change. Indicated p-values (* < 0.05) were obtained using an 
UNIANOVA analysis of triplicate measurements. C) Relative quantification by ChIP-qPCR  of H3K4me3, 
marking active promoters, showed higher levels at 11q pTERRA compared to 7q pTERRA, irrespective 
of senescence. All values are corrected for IgG background and are normalized to the relative amount 
of H3 (CtIgG-CtH3K4me3)/(CtIgG – CtH3). Error bars indicate SEM of duplicate qPCR measurements, asterisks 
indicate a p-value < 0.05 based on a student’s t-test.
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extensively studied in the context of FSHD20, 22. This showed that the described chromatin 
remodeling occurs on other subtelomeres as well, as we observed similar changes upon 
senescence compared to the subtelomeres of 7q and 11q (Fig. S5).
Specific chromatin regulation of 7q and 11q TERRA promoters upon senescence
The distal ends of subtelomeres harbor the TSS of TERRA transcripts. Recent data 
showed the involvement of the insulator protein CTCF at the TERRA promoter of 11q, 
but not at 7q26. Indeed, querying the WI-38 CTCF ChIP-seq tracks available from the 
UCSC genome browser, revealed CTCF binding just proximal to the TERRA promoter 
site at 11q, but not at 7q. We sought evidence for transcriptional activity of 7q and 11q 
TERRA in our cell system. Both in early passage and senescent cells we detected 11q 
TERRA transcripts, however, we could not detect TERRA transcripts emanating from 7q 
in both cell passages (Fig. 4A). Previously identified Xq transcripts24 were detected in 
both early and late passage cells and served as a control (Fig. 4A).
Fig. 5. Distinct chromatin remodeling at TERRA promoters of 7q and 11q upon senescence
TERRA promoter analysis showed distinct regulation of A) H3K9me3, B) H4K16ac, C) H3K27me3 
and D) H3K36me3 between 7q and 11q. The changes at the 7q TERRA promoter reflect the more 
proximal subtelomere, whereas the 11q TERRA promoter regulation is distinct from the more proximal 
subtelomere. All values are corrected for IgG background and are normalized to the relative amount of 
H3 ((CtIgG-Ctmodification)/(CtIgG – CtH3)). Error bars indicate SEM of duplicate qPCR measurements, asterisks 
indicate a p-value < 0.05 based on a student’s t-test.
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In line with this, the mean DNA methylation in senescent cells at the CpG dense TERRA 
promoter of 7q showed a significantly (p < 0.05) higher  methylation level than its 11q 
counterpart (~81% at 7q vs ~75% at 11q). Although not significant, we observed a 
similar trend in early passage cells (Fig. 4B). Moreover, promoter-associated H3K4me3 
levels, previously shown to be involved in TERRA regulation25, were 40-60% lower 
at 7q compared to 11q (Fig. 4C). Global TERRA levels are reported to decrease upon 
senescence25, which is in line with lower abundance of H3K4me3 at both 7q and 11q 
(Fig. 4C). CpG methylation levels did not change upon senescence, although some 
individual CpGs changed in both directions (Fig. S6).
To further determine the chromatin regulation of the TERRA promoters upon senescence, 
we quantified histone modification levels at both 7q and 11q. 7q pTERRA displayed 
similar chromatin dynamics upon senescence as the more proximal 7q subtelomere: 
reduced H3K9me3 and H4K16ac levels with an increase of H3K36me3 upon senescence. 
H3K27me3 showed a small decrease, however the described increase of this mark was 
mostly seen at greater distance to the telomere (Fig. 5A-D). 
In contrast, at 11q, bound by CTCF, we observed differential regulation of pTERRA 
compared to the proximal subtelomere. In early passage cells, the relative amount 
of H3K9me3 at pTERRA (1.04) was lower compared to more proximal sites (~1.44 on 
average), but we did not observe a decrease upon senescence (Fig. 5A). Strikingly, 
H3K27me3 showed a 2 fold decrease upon senescence, contrary to the more proximal 
subtelomere, where a change in opposite direction was observed (Fig. 5C). H4K16ac 
and H3K36me3 levels at pTERRA are comparable to the more proximal sites, although 
the levels of both markers remained higher upon senescence (Fig. 5B, D). Altogether, we 
observed that upon senescence, the chromatin remodeling of the 7q TERRA promoter 
is similar to the proximal subtelomere. The TERRA promoter at 11q however, showed a 
distinct chromatin remodeling upon senescence when compared to the proximal 11q 
subtelomere. 
Discussion
In this study, we systematically interrogated the changes in chromatin structure of human 
subtelomeres upon cellular senescence. Previous studies, in which ectopic telomere 
length modulation resulted in a large contrast in telomere length, reported opposing 
data on the effect of telomere length, a known trigger for cellular senescence, and 
subtelomeric chromatin state12, 27. In our model, using primary human fibroblasts, we 
observed a senescence-associated reduction of constitutive heterochromatin markers, 
which is accompanied by a gain of facultative repressive marks. Our data indicate that 
the repressed state is preserved during senescence as we found no increased levels of 
markers of euchromatin or evidence for derepression of the only annotated gene in the 
studied region. Furthermore, we observed distinct regulation of two TERRA promoter 
sites at subtelomeres of 7q and 11q. These data complement with recent data showing 




Upon cellular senescence, we observed a decrease in two markers of constitutive 
heterochromatin, H3K9me3 and CpG methylation, suggesting a relative relaxation of the 
chromatin structure. Reduced levels of these markers at subtelomeres were previously 
reported upon drastic telomere shortening in MEFs of a telomerase deficient mouse 
model12.  In contrast, telomere elongation by ectopic telomerase expression in human 
cell lines did not result in subtelomeric epigenetic changes27. However, the contrast in 
telomere length by ectopic telomerase expression is small, which may better reflect 
human physiological conditions, compared to telomerase deficient mice. Although 
the exact nature of the mechanism by which telomere length controls subtelomeric 
heterochromatin formation remains enigmatic, our data show that physiological 
telomere shortening and senescence signaling result in decreased levels of constitutive 
heterochromatin marks at subtelomeres.
Upon reduced H3K9me3 and CpG methylation, a concomitant increase of markers of 
euchromatin (histone acetylation) is seen with drastic telomere shortening in Terc-/- 
MEFs12. In our model, we did not observe a similar effect upon senescence. H3K9ac levels 
were low in both passages and we observed decreased levels of H4K16ac upon cellular 
senescence. Subtelomeric H4K16ac was previously shown to be higher upon aging in 
yeast, as a consequence of reduced Sir2 expression32. Global H4K16 deacetylation, on 
the contrary, was shown to be involved in the DNA damage response and associates with 
cellular senescence of MEFs in a mouse model for the Hutchinson Gilford premature 
ageing syndrome33. Our data show that the reduced levels of H4K16ac are not restricted 
to subtelomeres and are likely to be a genome-wide phenomenon, in concordance with 
its role in the DNA damage response and senescence.
We hypothesized that further chromatin activation upon decreased levels of markers of 
constitutive heterochromatin may be prevented by increased levels of the Polycomb-
dependent repressive H3K27me3 modification. Both H3K9me3 and H3K27me3 were 
previously reported to change globally upon cellular senescence in human primary 
fibroblasts34. O’Sullivan et al. describe decreased H3K9me3 and increased H3K27me3 
levels, which is in accordance with our observations at subtelomeres. Recent data, 
showing that the genome wide distribution of these markers does not change with RAS 
induced cellular senescence in human fibroblasts, suggest a different effect of oncogene 
induced- compared with replicative senescence35. 
H3K36me3 is mostly studied in the context of actively transcribed genes, but was 
recently suggested to be enriched in constitutive and facultative heterochromatin in 
mouse cells31. Indeed, we find considerable levels of this marker at both subtelomeres 
and at the silenced CT47 locus. In yeast, H3K36me3 recruits histone deacetylase 
complexes (HDACs) and thereby ensures repression of intragenic cryptic promoters36-38. 
It may be speculated that a similar mechanism exists in which subtelomeric sites become 
transcriptionally derepressed upon decreased levels of constitutive heterochromatin, 
eventually leading to deposition of H3K36me3 and recruitment of HDACs. In this scenario, 
higher levels of H3K36me3 have a repressive effect on the chromatin, maintaining 
the silenced state upon a decrease in H3K9me3 and CpG methylation. However, the 
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increased H3K36me3 levels were not specific for subtelomeres and in our model we 
cannot disentangle the order of events to prove this concept. More understanding of 
the context dependent functionality of the H3K36me3 mark is therefore desired.
Subtelomere CpG methylation and histone modification levels have been subject of 
study in the context of several human diseases and aging. Throughout these studies, a 
positive correlation between telomere length and subtelomeric CpG methylation was 
observed, which was depended on different disease states and integrity of the telomere 
maintenance pathway16-19. Indeed, with reduced telomere length and induction 
of senescence we observed reduced levels of CpG methylation at subtelomere. 
In the progressive muscular dystrophy FSHD, the subtelomeric D4Z4 repeat array 
is characterized by reduced CpG methylation and H3K9me3 levels, compared to 
controls20-22. In FSHD cell cultures, telomere length or senescence markers have not 
been studied. Our data may have implications for studying the epigenetic regulation of 
D4Z4, as we show that the replicative history of cell cultures can affect the chromatin 
structure of subtelomeres, also of the subtelomeric D4Z4 repeat array.
Since subtelomeres predominantly consist of repetitive sequences and subtelomeres of 
different chromosomes share highly homologous sequence blocks14, 15, we selected the 
single copy subtelomeres of 7q and 11q as a model. This allowed us to systematically 
screen the subtelomere at increasing distance to the telomere to identify possible 
position effects. However, we did not find a clear relation between the distance to the 
telomere and the changes in subtelomeric chromatin structure. The observed chromatin 
changes at the subtelomeres of chromosomes 7q and 11q and the D4Z4 repeat array 
at 4q and 10q were highly similar and possibly reflect a general phenomenon of 
subtelomeric chromatin remodeling upon senescence. We cannot, however,  rule out 
specific chromatin regulation at other subtelomeres, or at different locations at the 
subtelomeres under study. Moreover, we have only studied the effect of senescence in 
a single model system for cellular senescence. To assess whether our observations are 
in general associated with senescence, additional models should be studied. 
A striking exception to the commonalities between the studied chromosomes was the 
distinct regulation of the TERRA promoter at the subtelomeres of 7q and 11q. TERRA 
expression is regulated by specific CpG island motifs which have been identified on at 
least 20 different chromosome arms24. This specific CpG island is absent at both 7q and 
11q, however CpG dense sequences are present just proximal to the telomere of both 
chromosomes. We demonstrated that DNA methylation at these CpG islands does not 
change upon senescence, in spite the fact that TERRA transcripts were shown to be 
downregulated upon senescence25. The H3K4 methyltransferase MLL has been shown to 
associate with telomeres and regulate TERRA transcription25. Low but detectable levels 
of H3K4me3 were detected at the TERRA promoters of 7q and 11q and we detected 
higher levels at 11q than at 7q, irrespective of senescence. Both CpG methylation 
and H3K4me3 levels are reflected in transcriptional activity, as we only could detect 
11q transcripts. As TERRA has been shown to regulate telomere length, chromosome 
specific differences in TERRA regulation could offer an explanation for the observed 
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allelic variation of telomere length in senescent human cells39. 
Our data again emphasize that a chromosome arm specific analysis is needed 
considering the regulation of TERRA26. We showed that the 11q TERRA promoter is 
differentially regulated compared to the more proximal subtelomere, in contrast to the 
TERRA promoter of 7q. This is in line with recently published data, where involvement 
of CTCF and cohesin in TERRA regulation was shown at 11q, but not at 7q26. Next to 
its described role in TERRA transcription, our data suggests that the binding of CTCF 
proximal to the TERRA promoter results in the insulation and specific chromatin 
regulation of the TERRA promoter upon senescence. It may be hypothesized that TERRA 
promoters bound by CTCF, are be protected from the effects of telomere shortening 
and senescence signaling on the chromatin structure of subtelomeres, which would 
ensure proper regulation of TERRA transcription.
In conclusion, we show that human subtelomeres undergo extensive chromatin 
remodeling upon cellular senescence. A decrease in markers of constitutive 
heterochromatin does not lead to subtelomeric derepression but is accompanied by 
increased levels of transcriptional repressive modifications. We observed a strong 
overlap between the two subtelomeres under study, however, with respect to TERRA 
promoters, we showed chromosome specific remodeling occurs. 
Materials and Methods
Cell culture & β-galactosidase assay
WI-38 human fetal lung fibroblasts at two different population doublings (15, early and 
34, late) were obtained from Corriell (Corriell Cell Repositories, Camden NJ, USA). Early 
passage cells were expanded for 3–4 passages in DMEM F12 (31331) supplemented 
with 20% heat inactivated Fetal Calf Serum, 1% pen-strep, 1% sodium pyruvate and 
1% HEPES (all Invitrogen Life Technologies, Bleiswijk, The Netherlands) at 370 C, 5% 
CO2. Senescent cells were obtained by expanding PDL 34 cells until a non-proliferative 
state was reached. Cells were then kept in culture for an additional period of 2-3 weeks 
and to confirm senescence, activation of β-galactosidase was assessed as described40. 
DNA, RNA, chromatin and protein were isolated in parallel. Both early passage and 
late passage cells were expanded, harvested, and examined  in three independent 
experiments of which one complete set is shown.
Protein isolation, Western blot & quantification of p16
Cells were washed twice in 1 x PBS and after removal cells were lysed in RIPA buffer: 
20 mM TEA, 0.14 M NaCl, 0.1% DOC, 0.1% SDS, 0.1% triton X-100. 1x Complete EDTA 
free protease inhibitor cocktail and 1x Phosstop phosphatase inhibitor cocktail (both 
Roche, Mannheim, Germany) and sheared by passing through a 29G needle. Soluable 
protein content was measured by standard Pierce BCA analysis (Thermo Scientific, 
Etten-Leur, The Netherlands) and 15 µg protein was loaded on a standard 15% SDS 
PAGE. After protein transfer, membranes were blocked and incubated o/n at 40 C with 
antibodies against p16 (1:500, sc-56330, Santa Cruz biotechnology, Santa Cruz CA, USA) 
and actin (1:1000, A2066, Sigma, Zwijndrecht, The Netherlands). Detection and relative 
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quantification were done using the Odyssey system (V3.0, LI-COR biosciences, Lincoln 
NE, USA).
Telomere length analysis by southern blot and qPCR
Genomic DNA was isolated using a standard salting out method. Southern blot based 
telomere length analysis was done as described before41. In brief, 3 μg genomic DNA 
was o/n digested with RsaI and AluI (Thermo scientific) at 370 C and size separated on 
a 0.9% TAE agarose gel. DNA was denatured by incubating the gel in 0.4 M NaOH, 0.6 
M NaCl for 30 min, nicked and crosslinked by UV light and subsequently transferred 
to a Hybond XL membrane (GE Healthcare, Diegem, Belgium). The membrane was 
hybridized, washed, scanned with a Storm 820 phosphorimager (GE Healthcare) and 
analyzed using imagequant software (v2003.03. GE Healthcare). qPCR analysis of 
telomeric copy number was done as described before42 on the CFX96TM thermal cycler 
using iQ SYBR Green Supermix (both Bio-rad, Veenendaal, The Netherlands). Relative 
telomere length was calculated using the single copy 36B4 locus as a reference and 
subsequently normalized using the CFX software (v2.0, Bio-rad).
Chromatin Immunoprecipitation
ChIP experiments were based on the protocol described by Nelson et al. with some 
modifications43. In brief, cells were crosslinked in 1% formaldehyde (Merck-Milllipore, 
Amsterdam, The Netherlands) for 10 minutes and the reaction was quenched for 5 
minutes in 125 mM glycine. Cross linked cells were lysed and chromatin was sheared 
in a sonicator bath (Bioruptor UCD-20, Diagenode, Liège, Belgium) for 4 consecutive 
rounds of 10 minutes at maximum output and 15 seconds on/off cycles. Shearing was 
analyzed by phenol-choloroform extraction of DNA and agarose gel electrophoresis. All 
chromatin samples had a DNA size range between 200 – 2000 bp.  3 μg (DNA amount) 
chromatin was precleared with blocked sepharose A beads (GE healthcare) and 
incubated overnight at 40 with antibodies: rαH3 (ab1791, 2μl/rxn, Abcam, Cambridge, 
UK),  rαH3K9me3 (39161, 5 μl/rxn, Active Motif, La Hulpe, Belgium) rαH3K27me3 (#17-
622. 5 μl/rxn, Merck-Millipore) rαH4K16ac (39167, 4μl/rxn, Active Motif), rαH3K36me3 
(2 μl/rxn, pAb-058-050, Diagenode), rαH3K4me3 (#17-614, 3 μl/rxn, Merck-Millipore) 
and total IgG (5 μl/rxn, Merck-Millipore). IP was done with 20 μl blocked sepharose 
A beads/rxn for 90-120 minutes at 40C. Beads were washed according to the online 
available Millipore ChIP protocol (http://www.millipore.com/techpublications/tech1/
mcproto407). DNA was isolated using Chelex 100 resin (Bio-rad) and diluted 1:1 for 
Q-PCR analysis.
(q)PCR analysis of human subtelomeres
To circumvent potential PCR problems posed by the duplicated and repetitive 
nature of subtelomeres, we exploited the single copy nature of the subtelomeres of 
chromosomes 7q and 11q. To quantify histone modifications, we generated primer 
pairs using Primer3Plus using qPCR settings44 on both chromosome arms ranging from 
as close as <1 kb from the telomere, up to 250 kb from the telomere (Fig. 2a). All primer 
pairs were tested for chromosome specificity using a monochromosomal DNA panel 
(Coriell). We succeeded to generate specific primers ranging from directly adjacent to 
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the telomere up to 250kb from the telomere on both the subtelomeres of 7q and 11q. 
Primer sequences are listed in table S1 and annealing temperatures are indicated. qPCR 
analysis was done in duplicate using iQ SYBR Green Supermix (Bio-Rad) on the MyIQ 
thermal cycler or the CFX96tm real time PCR detection system  (Bio-Rad) using 4 μl 
1:1 diluted ChIP DNA per reaction. Relative quantities of histone modifications were 
calculated by taking the fold enrichment relative to the IgG background, normalized 
to input or H3 enrichment: (CtIgG-Ctmodification)/(CtIgG – CtH3). Representative data of 1 of 
the three culture replicates is shown and error bars indicate SEM of the normalized 
duplicate q-PCR values.
CpG methylation analysis
CpG islands at TERRA promoters were identified using the CpGplot tool available at http://
www.ebi.ac.uk/Tools/emboss/cpgplot. CpG methylation levels were determined using 
mass spectrometry based Epityper assays (Sequenom, San Diego CA, USA) as described 
before45. In short, DNA is converted with bisulfite and PCR amplified, transcribed to 
RNA, cleaved by RNAseA and the resulting methylated and unmethylated fragments 
were quantified by mass spectrometry. All measurements were performed in triplicate. 
Subtelomeric probe sequences are listed in table S1. The DNA methylation was entered 
as the dependent to an UNIANOVA (SPSS 18.0), as it accounts for the correlated nature 
of adjacent CpG sites. Variables defining the cell passage (early and late), the CpG site, 
the individual triplicates and the genomic location were entered as fixed effects. Data 
is shown for a single culture experiment, all p-values reported are two-tailed. For Figs. 
2D-F and 4B, the mean methylation level of multiple CpGs within a probe and, for Fig. 
2F, multiple probes per chromosome is displayed.
RNA isolation, TERRA cDNA synthesis and PCR detection
Cells were lysed in QIAzol lysis reagent and subsequently RNA was isolated using the 
RNeasy mini kit according to manufacturer’s instructions (both Qiagen, Venlo, The 
Netherlands). RNA integrity was confirmed (RIN > 9) by RNA 6000 Nano lab on chip 
analysis (Agilent technologies, Waldbronn, Germany) and 2 µg of total RNA was used for 
TERRA specific cDNA synthesis as described23, using the the SuperScript® III First-Strand 
Synthesis System (Life Technologies). PCR analysis was carried out using Phusion® High 
Fidelity DNA polymerase according to manufacturers conditions. PCR conditions: initial 
denaturing: 950 C, 3’ followed by 40 cycles of 30” 950 C, 30”  600 C (11q, Xq) / 610 C (7q), 
30” 720C and a final extension step of 10’ 720 C. Primer sequences are indicated in table 
S1. PCR products where analyzed by standard 1.5-2% TBE agarose gel electrophoresis 
and visualized using the OptiGo 750 imaging system with Proxima AQ-4 software (both 
Isogen life science, De Meern, The Netherlands).
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Facioscapulohumeral muscular dystrophy is caused by incomplete epigenetic repression 
of the transcription factor DUX4 in skeletal muscle. A copy of DUX4 is located within 
each unit of the D4Z4 macrosatellite repeat array and its derepression in somatic 
cells is caused by either repeat array contraction (FSHD1) or by mutations in the 
chromatin repressor SMCHD1 (FSHD2). While DUX4 expression has thus far only been 
detected in FSHD muscle and muscle cell cultures, and increases with in vitro myogenic 
differentiation, the D4Z4 chromatin structure has only been studied in proliferating 
myoblasts or non-myogenic cells. We here show that SMCHD1 protein levels at D4Z4 
decline during muscle cell differentiation and correlate with DUX4 derepression. In 
FSHD2, but not FSHD1, the loss of SMCHD1 repressor activity is partially compensated 
by increased Polycomb Repressive Complex 2 (PRC2)–mediated H3K27 trimethylation 
at D4Z4, a situation that can be mimicked by SMCHD1 knockdown in control myotubes. 
In contrast, moderate overexpression of SMCHD1 results in DUX4 silencing in FSHD1 
and FSHD2 myotubes demonstrating that DUX4 derepression in FSHD is reversible. 
Together, we show that in FSHD1 and FSHD2 the decline in SMCHD1 protein levels 
during muscle cell differentiation renders skeletal muscle sensitive to DUX4.
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Introduction
Facioscapulohumeral dystrophy (FSHD, OMIM 158900/158901) is characterized by 
progressive and often asymmetrical weakness of facial and upper extremity muscles 
typically starting in the second decade of life1. FSHD is one of the most common 
myopathies with a recently reported prevalence of 12:100.000 in the Dutch population 
and is inherited in an autosomal dominant fashion in most families2. FSHD is genetically 
linked to the polymorphic D4Z4 macrosatellite repeat array at 4q35, which in healthy 
subjects consists of 11-100 units, each of them being 3.3 kb in size and containing a 
copy of the DUX4 retrogene3-5.
The prevailing FSHD disease model postulates that DUX4 is normally silenced in somatic 
cells by repeat mediated epigenetic repression and that failure of this mechanism leads 
to partial decompaction of the D4Z4 chromatin structure and the expression of DUX4 in 
skeletal muscle of FSHD individuals6. Stable DUX4 expression requires a specific genetic 
background of chromosome 4 that contains a polymorphic DUX4 poly-adenylation signal 
(PAS) immediately distal to the D4Z4 repeat array7. Partial D4Z4 chromatin decompaction 
on a DUX4-PAS containing chromosome leads to the FSHD-specific pattern of DUX4 
expression in myotube cultures with few myonuclei expressing relatively abundant 
amounts of DUX4 protein8. Expression of the germline double homeobox transcription 
factor DUX4 is harmful to skeletal muscle since it activates germline and early stem cell 
programs, and modulates inflammatory pathways eventually resulting in increased cell 
death9-11.
In >95% of FSHD individuals (FSHD1) incomplete repression of DUX4 can be attributed to 
a contraction of the D4Z4 repeat array to a size of 1-10 units, whereas in the remainder 
of individuals with FSHD (FSHD2) the D4Z4 repeat arrays are in the normal size range5, 
12, 13. The majority of FSHD2 individuals carry heterozygous mutations in the structural 
maintenance of chromosomes hinge domain 1 (SMCHD1) gene on chromosome 
1814. SMCHD1 is a chromatin repressor that binds to D4Z4 and germline mutations 
in SMCHD1 result in reduced D4Z4 chromatin compaction and DUX4 expression14. 
Moreover, SMCHD1 was shown to act as a modifier of disease severity in FSHD1 and 
the functional consequences of SMCHD1 mutations, in combination with D4Z4 repeat 
size, determines the disease penetrance15, 16. 
Several lines of evidence indicate that epigenetic derepression of the D4Z4 
macrosatellite repeat array in FSHD results in DUX4 expression in skeletal muscle 
cells. In somatic cells originating from healthy individuals, such as myoblasts, the D4Z4 
repeat array is characterized by high, but inhomogeneous levels of CpG methylation 
and histone 3 lysine 9 trimethylation (H3K9me3)17-21. In proliferating FSHD somatic cell 
cultures, a reduction of both CpG methylation and H3K9me3 at D4Z4 has been reported 
together with reduced cohesin and heterochromatin protein 1 gamma (HP1γ) levels, 
presumably facilitating sporadic activation of DUX421. In addition, members of the 
Polycomb Repressive Complex 2 (PRC2) and the histone modification deposited by the 
PRC2 complex, H3K27me3, were identified at D4Z4 in control and FSHD1 proliferating 
myoblasts21-23. The mechanism of PRC2 recruitment remains however to be determined. 
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D4Z4 non-coding RNAs may have a role, since the endogenous RNAi pathway was 
recently demonstrated to facilitate DICER/AGO-dependent epigenetic silencing of the 
D4Z4 repeat arrays in muscle cells23-25. 
Although DUX4 expression has repeatedly been shown to be increased in FSHD muscle 
cells upon in vitro differentiation8, 26-28, data on the epigenetic regulation of the D4Z4 
repeat array during this process is scarce. Nevertheless, extensive changes in the 
genome wide chromatin structure have been reported upon myogenic differentiation in 
mouse muscle cells. In particular, the Polycomb complexes were shown to be pivotal for 
the regulation of lineage commitment and differentiation specific genes29. Moreover, 
multi-nucleated myotubes more closely resemble the in vivo structural composition 
of muscle than proliferating myoblasts. Taken together, differentiated myotubes are 
likely a more relevant in vitro model to study the epigenetic requirements for DUX4 
expression than proliferating myoblasts.
This prompted us to examine whether we could identify changes in D4Z4 chromatin 
regulation specific to differentiated muscle cells that might account for the susceptibility 
of this tissue to express DUX4 at higher levels than in myoblasts or many other tissues. 
Our study highlights the importance of SMCHD1 in regulating D4Z4 chromatin structure 
and DUX4 expression in muscle cells of both FSHD1 and FSHD2. Whereas a decline in 
SMCHD1 protein levels, and specifically its reduction at D4Z4, during skeletal muscle 
differentiation leads to DUX4 expression, ectopic expression of SMCHD1 in either 
FSHD1 or FSHD2 muscle cell cultures efficiently suppresses DUX4 expression. Moreover, 
in FSHD2 but not in FSHD1, the loss of SMCHD1 is accompanied by a gain in PRC2-
mediated H3K27 trimethylation, likely as a compensatory but incomplete mechanism 
to silence DUX4 in skeletal muscle.
Figure 1: DUX4 activation during myogenic differentiation coincides with SMCHD1 reduction
A) Immunofluorescence microscopy analysis confirmed the typical DUX4 protein expression pattern in 
myosin positive, multinucleated myotubes derived from FSHD1 and FSHD2 individuals. Images were 
taken using a 200x magnification, scale bars are displayed. B) Quantitative mRNA analysis in control (C), 
FSHD1 (F1) and FSHD2 (F2) primary myoblasts (B) and myotubes (T) showing increased levels of DUX4 
expression upon differentiation. GAPDH and GUSB were used as reference genes, n indicates number 
of samples, error bars display SD and significance was calculated using a two tailed student’s t-test. C) 
Quantitative mRNA analysis showed robust ZSCAN4 activation upon myogenic differentiation in FSHD 
myotubes. GAPDH and GUSB were used as reference genes, n indicates number of samples, error bars 
display SD and significance was calculated using a two tailed student’s t-test. D) Western blot analysis 
showing reduced levels of SMCHD1 upon muscle cell differentiation in a primary muscle cell culture 
derived from a control individual. Myoblasts (B) were differentiated into myotubes (T) for 48 h. H3 
serves as a control for equal protein loading, α-ACTIN serves as a control for the induction of myogenic 
differentiation. E) Western blot analysis of a control derived primary fibroblast undergoing forced 
myogenesis by ectopic MyoD expression for 48, 72 or 94 h showed a decrease in SMCHD1 protein 
expression. TUBULIN serves as a loading control. F) Duplicate RT-PCR analysis of DUX4 expression 
upon ectopic MyoD expression in a Control 1, FSHD1 1 or FSHD2 1 fibroblast (table S2) revealed DUX4 
activation in patient cells exclusively. Ectopic GFP expression was used as a control and GUSB serves as 
an internal PCR control. G, H) Normalized ChIP qPCR analysis of SMCHD1 binding at D4Z4 in isogenic 
fibroblasts (F), myoblasts (B) and myotubes (T) derived from the same control individual (panel G) and 
three independent control derived myoblast – myotube pairs showed the highest SMCHD1 abundance 
in myoblasts with a further decrease during myogenesis. Error bars display SD in panel G and H and 
significance was calculated using a two tailed student’s t-test. NS = not significant; * = P < 0.05; ** = 
P < 0.005.
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Figure 2: SMCHD1, but not SUV39H1 and Cohesin, regulates DUX4 expression
Western blot confirmation of A) SMCHD1, B) SUV39H1, D) RAD21, and E) SMC3 knockdown in control 
myotubes expressing the indicated lentiviral transduced shRNAs. Tubulin was used as a loading control. 
Representative blots of at least duplicate experiments are shown. C, F) Standard gel electrophoresis 
analysis of DUX4 expression upon lentiviral knockdown of SMCHD1, SUV39H1, RAD21 and SMC3 in 
control myotubes. Only depletion of SMCHD1 resulted in reproducible activation of DUX4 transcription. 
Representative gel photos are shown of at least duplicate experiments. The PCR fragment visible in 
one RAD21 knockdown was sequenced and shown to be the product of an a-specific amplification. 
G) Western blot analysis confirms a two / threefold increase of SMCHD1 expression upon its lentiviral 
transduction in 2 FSHD1 and 1 FSHD2 myotube cultures. GFP transduced myotubes served as a 
negative control. Numbers indicate normalized relative expression levels of SMCHD1 using Tubulin 
as a loading control followed by setting normalized SMCHD1 levels of GFP transduced samples (only 
expressing endogenous SMCHD1) to 1. H) Expression levels of DUX4 were significantly reduced upon 
ectopic expression of SMCHD1 in 2 FSHD1 and 2 FSHD2 myotube cultures. Relative DUX4 expression 
was calculated for each sample by normalization to GUSB and GAPDH housekeeping genes. Bars show 
values of each samples adjusted to the expression value of GFP transduced sample as 1. I) Expression 
levels of the DUX4 target genes RFPL2, ZSCAN4, and TRIM43 showed a significant reduction upon 
ectopic expression of SMCHD1 in 2 FSHD1 and 2 FSHD2 myotubes, concordant with decreased DUX4 
protein expression. Expression levels were normalized as described for panel Figure 1A. For panel H, I: 
Error bars display SD and significance was calculated using a two-tailed Student’s t-test. All P < 0.0005 
indicated by ***.
Results
DUX4 expression is induced upon myogenic differentiation and coincides with reduced 
SMCHD1 levels.
Although DUX4 expression has been reported repeatedly in FSHD myotubes8, 26-28, 
comprehensive data on the regulation of DUX4 expression in FSHD1 and in particular on 
FSHD2 muscle cells is scarce. Therefore, our first aim was to firmly establish that DUX4 
expression increases with differentiation of FSHD1 and FSHD2 muscle cells. We cultured 
a large set of primary myoblasts derived from control, FSHD1 and FSHD2 individuals and 
harvested RNA from both proliferating myoblasts and differentiating myotubes (further 
referred to as myoblasts and myotubes). The differentiation status of the cultures was 
confirmed by myotube formation, as visualized by immunofluorescent labeling of 
myosin, and MYOG transcript levels (Fig. 1A, Fig S1-S2). Multinucleated myofibers were 
observed in all conditions and differentiation was confirmed by the increase in MYOG 
levels in control, FSHD1 and FSHD2 muscle cell cultures. 
mRNA quantification by qRT-PCR confirmed the activation of DUX4 in FSHD1 and FSHD2 
myotubes, whereas we could not reproducibly detect DUX4 transcripts in control 
samples (Fig. 1B). While the increase of DUX4 expression during myotube formation 
in FSHD1 cells was statistically significant, FSHD2 cells were more variable. In FSHD2 
cells an increase of DUX4 during myogenesis can be observed, however FSHD2 muscle 
cell cultures already show variable levels of DUX4 transcripts before differentiation, 
which may explain the non-significant effect (Fig. 1B). Immunofluorescence microscopy 
on a subset of myotube cultures established the variegated pattern of DUX4 protein 
expression in both forms of the disease (Fig. 1A, Fig. S2). We also quantified expression 
levels of the previously established DUX4 target gene ZSCAN4 and observed FSHD-
specific induction during myoblast differentiation (Fig. 1C)9.
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Since we previously demonstrated that SMCHD1 is a D4Z4 chromatin repressor14, we 
examined SMCHD1 protein levels. Western blot analysis showed a reduction in SMCHD1 
protein levels after control myoblast differentiation (Fig. 1D), a phenomenon that could 
be reproduced by forced myogenic differentiation of control fibroblasts transduced with 
the myogenic transcription factor MyoD (Fig. 1E). Upon forced myogenesis by MyoD 
transduction in 2 FSHD1 and 2 FSHD2 fibroblast cell lines we observed induction of 
DUX4, whereas DUX4 remained undetectable in 2 control samples treated with MyoD 
(Fig. 1F, Fig. S3). Employing ChIP-qPCR in control fibroblast, myoblast and myotube 
cultures from the same donor we observed higher density of SMCHD1 at qD4Z4, located 
around the transcriptional start site of DUX4 (Fig. S4)21, in fibroblasts as compared to 
myoblasts, with a further decrease in myotubes (Fig. 1G). Analysis of three additional 
independent pairs of control myoblast and myotube cultures confirmed the significant 
decrease in SMCHD1 levels at D4Z4 after myoblast differentiation (Fig. 1H). Together, we 
confirm the FSHD-specific induction of DUX4 expression upon myogenic differentiation 
in a large set of FSHD1 and FSHD2 primary myotube cultures and upon MyoD-induced 
differentiation in FSHD fibroblasts. Moreover, we demonstrate that DUX4 expression 
negatively correlates with SMCHD1 levels at D4Z4 in myogenic cell cultures, specifically 
in differentiated myotubes. 
SMCHD1 levels control DUX4 expression in somatic cells
To establish a causal relationship between SMCHD1 protein levels and DUX4 expression 
in myotubes and SMCHD1 protein levels, we conducted lentiviral shRNA-mediated 
depletion experiments in differentiating primary control myoblast cultures (Controls 2 
and 8; table S1) carrying an FSHD-permissive DUX4-PAS containing 4A161 allele with 
D4Z4 repeat sizes varying between 20 and 32 units. Depletion of SMCHD1 resulted in 
robust activation of DUX4 expression (Fig. 2A, C; Fig. S5A), which is in agreement with 
our earlier observations14. This phenomenon of DUX4 activation seems to be rather 
specific for SMCHD1 since knocking down other known chromatin repressors of D4Z4 
in parallel experiments, using the same control myoblast cultures, did not lead to DUX4 
expression. Upon knockdown of SUV39H1, a histone methyltransferase previously shown 
to be involved in establishing the H3K9me3 modification at D4Z421, we did not observe 
a reduction in relative abundance of H3K9me3 at D4Z4 (Fig. 2B, Fig. S5, Fig. S6B), nor 
the transcriptional activation of DUX4, in 2 independent control myotube cultures (Fig. 
2C). Independent depletion of cohesin proteins SMC3 or RAD21 by a similar strategy did 
not cause a consistent activation of DUX4 either under these conditions (Fig. 2D-F). In 
support, we did not see significant changes in H3K9me3 levels or RAD21 levels between 
control and FSHD muscle cell cultures, in myoblasts or myotubes (Fig. S7; Fig. S8).
Since SMCHD1 levels decline at D4Z4 during myoblast differentiation, we next tested 
whether ectopic expression of SMCHD1 in FSHD myotubes can rescue the repression of 
DUX4. To this end, we transduced FSHD1 and FSHD2 myoblast cultures with SMCHD1 
expressing lentiviruses and allowed the cells to form myotubes. In both FSHD1 and FSHD2 
myotubes 2-3 fold overexpression of SMCHD1, as determined by western blot analyses, 
resulted in a 70-90% reduction in DUX4 mRNA levels (Fig. 2G-H). To confirm the silencing 
of DUX4, we analyzed the mRNA expression levels of three known downstream target 
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Figure 3: SMCHD1 depletion at D4Z4 leads to increased H3K27me3 and PRC2 binding. 
A) ChIP-qPCR analysis showed a statistically significant reduction of SMCHD1 at qD4Z4 upon its lentivi-
ral knockdown in control myotubes with two independent shRNA constructs in 2 independent control 
myotube cultures. B) ChIP-qPCR analysis of H3K27me3 at qD4Z4 upon SMCHD1 depletion showed a 
significant increase at qD4Z4. Enrichment values were normalized to H3 enrichment values. C) Normal-
ized ChIP-qPCR analysis of SUZ12 upon SMCHD1 depletion showed a statistically significant increase 
at qD4Z4 in 2 independent experiments performed on 2 control myoblast cultures. n indicates sample 
size, error bars indicate SD and significance was tested with students t test. D) ChIP-qPCR analysis of 
H3K27me3 at qD4Z4 showed a significant increase in FSHD2 myotubes compared to controls. Enrich-
ment values were normalized to H3 enrichment values. E) ChIP-qPCR analysis of SUZ12abundance 
showed a significant increase in FSHD2 myotubes at qD4Z4.On panel A, B, D and E n indicates sample 
size, error bars display SD and significance was tested using a one way-ANOVA followed by Bonferroni 
multiple comparison test. *= P < 0.05 **= P < 0.005 ***= P < 0.0005.
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genes of DUX4 protein. ZSCAN4, RFPL2, and TRIM43 expression levels decreased 70-90% 
upon overexpression of SMCHD1 (Fig. 2I). To rule out that the lower DUX4 transcript 
levels were a consequence of reduced muscle cell differentiation, we measured MYOG 
transcript levels. MYOG increased similarly between the GFP expressing control and 
SMCHD1 expressing FSHD myotubes, with the exception of one FSHD2 myotube culture 
that showed substantially higher MYOG levels in the SMCHD1 expressing compared to 
control GFP expressing conditions (Fig. S9). This demonstrates that modest upregulation 
of SMCHD1 has no inhibiting effect on myogenic differentiation. In conclusion, DUX4 
expression levels are strongly decreased upon moderate overexpression of SMCHD1, 
emphasizing its role as D4Z4 repressor in both genetic forms of the disease.
Figure 4: Treatment of FSHD2 myotube cultures with EZH2 inhibitor GSK126 increases DUX4 levels
A) Western blot analysis of control, FSHD1 and FSHD2 myotube samples after treatment with 0, 1, 2 
and 4 µM GSK126. Blots were probed with H3K27me3 antibody and H3 antibody as loading control. 
Shown are the reduced ratios of H3K27me3:H3 signal intensities in samples treated with GSK126 com-
pared to the untreated sample as a result of  EZH2 inhibition. B) qRT-PCR analysis of DUX4 expression 
in FSHD1 and FSHD2 myotubes after GSK126 treatment shows that relative DUX4 transcript levels are 
significantly increased in FSHD2 samples treated with 2 µM GSK126 but not in FSHD1 myotubes. Graph 
shows the results of 4 FSHD1 and 4 FSHD2  cell lines. Results of control cell lines are not shown, DUX4 
transcript was not detectable.  Error bars show SD, n indicates number of independent cell lines and 
significance was tested by two-way ANOVA followed by Bonferroni’s multiple comparison test. *=P < 
0.05.
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SMCHD1 reduction leads to PRC2 enrichment at D4Z4 in FSHD2 but not FSHD1
Since SMCHD1 was recently shown to associate with the repressive H3K27me3 
modification at the inactive X chromosome30, we further determined the levels 
of H3K27me3 and the PRC2 complex at D4Z4 upon depletion of SMCHD1 in two 
independent control myotube cultures. SMCHD1 knockdown resulted in a 2-fold 
decrease in SMCHD1 levels at D4Z4 using two different SMCHD1 shRNA vectors (Fig. 3A) 
and increased H3K27me3 levels at D4Z4 (Fig. 3B). Because of the increase in H3K27me3 
at D4Z4 upon SMCHD1 depletion, we further analyzed the involvement of the PRC2 
complex and observed a significant increase of the PRC2 protein SUZ12 at D4Z4 (Fig. 
3C).
To validate these data derived from knock down experiments in control myotube 
cultures, we investigated the levels of the PRC2 complex in primary control and FSHD 
myotubes. Previously, H3K27me3 levels at D4Z4 were reported to be similar in control 
and FSHD1 proliferating myoblast cultures at the DBE locus just proximal to qD4Z4 (Fig. 
S4)23. We measured H3K27me3 levels at qD4Z4 and observed significantly higher levels 
of H3K27me3 in FSHD2 myotubes (Fig. 3D), consistent with the increase we observed 
following knockdown of SMCHD1 (Fig. 3B). Increased H3K27me3 levels were also 
observed in FSHD2 myoblasts (Fig. S10). Next, we quantified the levels of the PRC2 
protein SUZ12 at D4Z4 and detected higher levels of SUZ12 at D4Z4 in FSHD2 samples 
(Fig. 3E), all consistent with an increase in H3K27me3 through PRC2 recruitment at 
D4Z4.
The decreased SMCHD1 activity in FSHD2 myotubes correlates with increased PRC2 
levels at D4Z4. To test the repressive role of PRC2 at D4Z4, we inhibited PRC2 activity by 
treating control, FSHD1 and FSHD2 muscle cell cultures with increasing concentrations 
of the EZH2 inhibitor GSK12631. After differentiation, total H3K27me3 levels were 
decreased in all cell cultures as shown by western blot analysis (Fig. 4A). DUX4 transcript 
levels increased significantly in FSHD2 samples treated at 2 µM GSK126, (Fig. 4B) 
suggesting that PRC2 is involved in the repression of D4Z4 in FSHD2, but not in FSHD1.
Discussion
Despite the recent advances in our understanding of the common molecular disease 
mechanism in FSHD1 and FSHD2 and the consensus model of incomplete epigenetic 
repression of DUX4 in somatic cells, the key epigenetic changes at D4Z4 in FSHD1 
and FSHD2, and the selective tissue involvement is only partly understood. FSHD 
is mainly a disease of skeletal muscle, suggesting that differentiated skeletal muscle 
might have an epigenetic state more permissive for DUX4 expression. In vitro, it 
was observed that DUX4 expression in FSHD muscle cells specifically increases upon 
myogenic differentiation. To date, however, most D4Z4 chromatin studies have focused 
on myoblast and non-myogenic cell cultures. The dynamics of the different epigenetic 
mechanisms involved D4Z4 chromatin organization during muscle cell differentiation, 
and their causality to DUX4 expression, have not been studied in detail. Here we show 
that SMCHD1 protein levels decrease during muscle cell differentiation and correlate 
with DUX4 expression, possibly making differentiated muscle cells particularly prone 
78
Chapter 4
to incomplete D4Z4 repression. Moreover we have identified the involvement of PRC2-
mediated H3K27 trimethylation of D4Z4 selectively in FSHD2.
Thus far most studies have been performed in FSHD1 muscle cell cultures, but we here 
firmly establish that in FSHD1 and FSHD2 DUX4 expression is strongly upregulated 
during muscle cell differentiation, emphasizing the importance of studying D4Z4 
chromatin structure in differentiated muscle cells. Our observation of the decline in 
SMCHD1 levels during muscle cell differentiation may provide an explanation towards 
the susceptibility of muscle in expressing DUX4 and prompted us to further explore the 
role of SMCHD1 in somatic DUX4 repression. Depletion of SMCHD1 in control myotubes 
resulted in robust DUX4 expression. Conversely, 1.5-3 fold increases in SMCHD1 protein 
levels by ectopic expression in FSHD1 and FSHD2 myotubes led to a significant decrease 
in DUX4 levels and that of its target genes. This demonstrates that the derepression 
of DUX4 in FSHD muscle cells is a reversible process that can be rescued by increasing 
SMCHD1 levels. 
SMCHD1 was recently shown to associate with H3K27me3 at the inactive X 
chromosome and we observed that loss of SMCHD1 at D4Z4 leads to an increase in 
PRC2 and H3K27me3 levels at D4Z4 in FSHD2. This strongly suggests that there is 
aberrant PRC2 regulation in FSHD2, but not FSHD1, myoblasts and myotubes. Since 
SMCHD1 has a role in the establishment and/or maintenance of CpG methylation, this 
observation consistent with recent studies showing an inverse relationship between 
CpG methylation and PRC2-mediated H3K27 methylation32. While the overall levels of 
some PRC2 complex proteins decline during murine myogenic differentiation33, our data 
suggest a local enrichment of PRC2 at D4Z4 in FSHD2 cells during this process. 
Previous studies did not observe a difference in PRC2 and H3K27me3 at D4Z4 in FSHD. 
However, these studies were mostly restricted to FSHD1 myoblast cultures22, 23, used 
primers that were not specific to chromosome 422, or analyzed a single cell line34 which 
may explain this difference. Indeed a recent study by Zeng et al. showed that although 
D4Z4 units are dispersed throughout the genome, epigenetically the D4Z4 repeat arrays 
on chromosomes 4 and 10 are distinctly regulated from their homologs34. 
Our data also identifies a difference between FSHD1 and FSHD2 in the epigenetic 
regulation of D4Z4. Depletion of SMCHD1 in control cells, mimicking FSHD2, leads 
to increased abundance of PRC2. The involvement of PRC2 in FSHD2 is further 
substantiated by the observation that GSK126 specifically increases DUX4 transcript 
levels in FSHD2, but not in FSHD1. Despite this epigenetic difference, SMCHD1 
depletion and overexpression respectively leads to activation and repression of DUX4 
in both FSHD1 and FSHD2 derived cells. It is unlikely that a selective involvement of 
a single contracted D4Z4 repeat array in FSHD1 creates a technical limitation in our 
ChIP approach (interrogating all four D4Z4 repeat arrays simultaneously) and explains 
the FSHD2-specificty of the involvement of PRC2 at D4Z4. Therefore, we conclude that 
although in both conditions DUX4 is derepressed, there are some unique epigenetic 
responses to repeat contraction or SMCHD1 malfunctioning in FSHD1 and FSHD2, 
respectively.
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Increased PRC2 recruitment and H3K27me3 levels are generally associated with 
transcriptional repression35. However, in FSHD2 they are associated with the 
transcriptional derepression of the DUX4 locus. PRC2 recruitment to the derepressed 
D4Z4 region may reflect a rather effective failsafe mechanism to compensate for the 
loss of other repressive mechanisms. Indeed a compensatory repressive mechanism 
by PRC2 is supported by our observation of increased DUX4 transcript levels in FSHD2 
myotubes in the presence of the EZH2 inhibitor GSK126. The specific nature of the 
trigger leading to the sporadic escape of repression typical for DUX4 remains unclear 
at this point and requires experimental approaches, which can dissect differences 
between single nuclei. 
We could not confirm a role for SUV39H1 or the cohesin complex in DUX4 repression 
in a myogenic context: we did not observe different H3K9me3 or SMC3 levels in 
myotubes and knockdown of SUV39H1 and cohesin in myotubes also did not activate 
DUX4. Knockdown of SUV39H1 did not decrease H3K9me3 at D4Z4 in myotubes 
either. Previously, siRNA mediated knockdown of SUV39H1 led to reduced levels of 
H3K9me3 at D4Z4 in HeLa cells21. Similarly, reducing SUV39H1 activity in proliferating 
immortalized myoblasts by knock down or treatment of primary and immortalized 
myoblasts with Chaetocin decreased H3K9me3 levels and resulted in transcriptional 
derepression of DUX434. The specificity of Chaetocin was recently challenged, however, 
as it might also inhibit the activity of other histone lysine methyltransferases36. Our 
data thus suggest that the regulation of this modification at D4Z4 is different between 
primary and immortalized myoblasts, and between proliferating and differentiating 
myoblasts, perhaps by involvement of additional methyltransferases such as G9a34. A 
recent report suggested a role for the telomere in the epigenetic regulation of D4Z437. 
Since myoblasts are immortalized by telomerase expression, it will be important to 
comprehensively compare the epigenetic regulation of the D4Z4 repeat array between 
primary and immortalized myoblasts. 
Together with earlier observations that SMCHD1 is a modifier of disease severity in 
FSHD1, our study suggests that D4Z4 derepression in FSHD1 and FSHD2 converge at 
SMCHD1. Contraction of D4Z4 in FSHD1 may lead to specific loss of SMCHD1 at the 
contracted allele, analogous to its interaction with telomeric repeats, which shows a 
non-linear positive correlation to telomere length38. Altogether this emphasizes the 
crucial role of SMCHD1 in suppressing DUX4 activity in somatic cells and its decline 
during muscle cell differentiation provides a plausible explanation for the increased 




Culturing of human primary myoblast cell lines
Human primary myoblast cell lines were originating from the University of Rochester 
bio repository (http://www.urmc.rochester.edu/fields-center/). Muscle samples 
were obtained after subjects were consented under a protocol approved by the 
institutional review board at the University of Rochester. Myoblasts were cultured 
in DMEM/F-10 media (#31550 Gibco/Life Technologies, Bleiswijk, The Netherlands) 
supplemented with 20% heat inactivated fetal bovine serum (FBS #10270 Gibco/
Life Technologies, Bleiswijk, The Netherlands), 1% penicillin/streptomycin (#15140 
Gibco/Life Technologies, Bleiswijk, The Netherlands) and 10ng/ml rhFGF (#G5071 
Promega, Leiden, The Netherlands) and 1μM dexamethasone (#D2915 Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was added to the medium. Myoblasts were fused at 
80% confluency by culturing them in DMEM/F-12 Glutamax media (#31331, Gibco/
Life Technologies, Bleiswijk, The Netherlands) containing 1% penicillin and stretomycin 
and 2% KnockOut serum replacement formulation (#10828 Gibco/Life Technologies, 
Bleiswijk, The Netherlands) for 36 hours. Human control fibroblast cell lines were 
maintained in DMEM/F-12, supplemented with 20% FBS, 1% penicillin and stretomycin 
, 10 mM HEPES (#15630#,Gibco/Life Technologies, Bleiswijk, The Netherlands) and 
1mM sodium pyruvate (##11360, Gibco/Life Technologies, Bleiswijk, The Netherlands). 
Used cell lines, D4Z4 allele information and experimental use are listed in supplemental 
table S1.
RNA isolation, cDNA synthesis and qRT-PCR
Myoblast and myotube samples were harvested for RNA isolation by adding QIAzol lysis 
reagent (#79306 Qiagen N.V., Venlo, The Netherlands). RNA was isolated by miRNeasy 
Mini Kit (#217004 Qiagen) including DNase treatment according to the manufacturer’s 
instructions. cDNA was synthesized with RevertAid H Minus First strand cDNA Synthesis 
Kit (#K1632 Thermo Fischer Scientific Inc., Waltham, MA) using 2µg template RNA and 
poly-dT primers. Gene specific cDNA products were quantified by qPCR in duplicate 
using SYBR green master mix supplemented with gene specific primers (table S2) using 
the CFX96 system (Bio-Rad, Veenendaal, The Netherlands). qRT-PCR data were analyzed 
by Bio-Rad CFX manager version 3.0 (Bio-Rad) using GAPDH and GUSB as reference 
genes for every individual sample. 
Transduction of primary cell cultures 
Full length SMCHD1 was PCR amplified from cDNA and cloned into the pRRL-CMV 
lentiviral backbone containing a puromycin selection marker using standard cloning 
procedures and the obtained construct was verified by Sanger sequencing. shRNA 
constructs originating from the Mission shRNA library (MISSION shRNA library, TRC1 
or TRC2; Sigma Aldrich) and are listed in supplemental table S2. Constructs were 
used to generate lentiviral particles, and myoblast cell lines were transduced at 50% 
confluency and 24 hours after transduction they were grown in media containing 0.5 
μg/ml puromycin for selection. Differentiation to myotubes was induced by serum 
reduction at 80% confluency and cells were harvested after 36 hours of differentiation. 
Transduction of fibroblasts to ectopically express MyoD1 and induce myogenesis was 
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performed as described previously39.
Chromatin Immunoprecipitation
Histone ChIP studies were carried out as described before17 using antibodies against 
H3 (ab1791, 2μl/rxn, Abcam, Cambridge, UK), H3K9me3 (39161, 5 μl/rxn, Active Motif, 
Carlsbad, USA), H3K27me3 (#17-622, 5 μl/rxn, Merck-Millipore, Amsterdam Zuid-Oost, 
The Netherlands), and total IgG (5 μl/rxn, Merck-Millipore, Amsterdam Zuid-Oost, 
The Netherlands). Non-histone ChIPs were carried out as described before14 using 
antibodies against SMCHD1 (ab31865, 5 μg/rxn, Abcam, Cambridge, UK) RAD21 (ab992, 
5 μg/rxn, Abcam, Cambridge, UK), SMC3 (ab9263, 5 μg/rxn, Abcam, Cambridge, UK), 
SUZ12 (D39F6, 5 μg/rxn, Cell Signaling, Leiden, The Netherlands). All antibodies were 
qualified for ChIP application by the manufacturer. All ChIP-qPCR experiments were 
performed 2 independent times. 
GSK126 treatment of primary myoblast cultures
3 control 4 FSHD1 and 4 FSHD2 human primary myoblast cultures were grown to 50-
60% confluency and culturing was continued in the presence of 0 µM, 1 µM, 4 µM and 8 
µM GSK126 (#1346574-57-9 MedKoo Biosciences, North Carolina, USA) in proliferation 
media. GSK126 was dissolved in DMSO (#D2650 Sigma-Aldrich, St Louis, USA) and the 
different concentration of GSK126 were added in equal volumes of DMSO to the cells. 
Cultures shown as 0 µM GSK126 were treated only with DMSO. After 24 hours culturing 
was continued in fusion media in the presence of the same concentration of GSK126 for 
another 24 hours. RNA and protein samples were harvested as described above. 
Western blot
Cell were directly lysed in NuPAGE LDS Sample Buffer (#NP0008, ThermoFisher 
Scientific, Waltham, USA) and loaded on Novex 4-12% Bis-Tris Protein Gels  (#WT4121A, 
ThermoFisher Scientific, Waltham, USA) according to manufacturer’s instructions. 
Running of the gel and transfer to Hybond nitrocellulose membranes (#10600048, GE 
Healthcare, Diegem, Belgium) were carried out using the Nupage Novex SDS-page gel 
system (ThermoFisher Scientific, Waltham, USA). Blots were blocked in 4% milk in PBS 
and incubated with antibodies against SMCHD1 (1:250), SUV39H1 (0.1 µg/ml, #07-
958, Merck-Millipore, Amsterdam Zuid-Oost, The Netherlands), RAD21 (1:500), SMC3 
(1:1000) and Tubulin (1:2000, T6199, Sigma-Aldrich, St Louis, USA). Detection and 
relative quantification were done using the Odyssey system (V3.0, LI-COR Biosciences, 
Lincoln NE, USA), except for blots in Figure 1, which were visualized by enhanced 
chemiluminescence (ECL).
Statistical analysis
All statistical analysis was done using GraphPad Prism 6 software and the exact method 
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Fig. S1: MYOG induction upon myogenic differentiation.
Fig. S2: Immunofluorescence analysis of sporadic DUX4 expression in FSHD2 
myotubes.
Fig. S3: DUX4 transcripts are detected in FSHD1 and FSHD2 fibroblasts transduced 
with MyoD.
Fig. S4: Graphical overview of the D4Z4 repeat unit and the DUX4 open reading frame. 
Fig. S5: SMCHD1 and SUV39H1 transcript levels are significantly lower in human 
primary myoblast treated with specific shRNAs than in samples treated with control 
shRNA.
Fig. S6: H3K9me3 levels at qD4Z4 upon depletion of SUV39H1 in control myotubes.
Fig. S7: Abundance of the repressive histone mark H3K9me3 does not show disease 
specific differences.
Fig. S8: Cohesin abundance at D4Z4 in patient samples is similar to levels measured in 
controls.
Fig. S9: MYOG expression levels upon SMCHD1 overexpression.
Fig. S10: Higher levels of H3K27me3 in FSHD2 derived myoblasts.
All supplemental figures belonging to this chapter can be accessed through http://goo.
gl/oAeg57 or by using the QR-code below.
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5DUX4 promotes transcription of FRG2 by directly activating its promoter in Facioscapulohumeral muscular dystrophy.
Thijssen et al. (2014), Skeletal Muscle, 4:19
Peter E. Thijssen, Judit Balog, Zizhen Yao, Tan Phát Pham, Rabi Tawil, Stephen 





The most common form of facioscapulohumeral muscular dystrophy (FSHD) is caused 
by a genetic contraction of the polymorphic D4Z4 macrosatellite repeat array in the 
subtelomeric region of chromosome 4q. In some studies, genes centromeric to the D4Z4 
repeat array have been reported to be over-expressed in FSHD, including FRG1 and FRG2, 
presumably due to decreased long-distance repression by the shorter array through a 
mechanism similar to position-effect variegation. Differential regulation of FRG1 in FSHD 
has never been unequivocally proven, however, FRG2 has been reproducibly shown to 
be induced in primary FSHD-derived muscle cells when differentiated in vitro. While 
the molecular function of FRG2 remains unclear and its contribution to FSHD pathology 
remains uncertain, recent evidence has identified the mis-expression of DUX4, located 
within the D4Z4 repeat unit, in skeletal muscle as the cause of FSHD. DUX4 is a double 
homeobox transcription factor that has been shown to be toxic when expressed in 
muscle cells. 
Results
In this study, we show that DUX4 directly activates the expression of FRG2. Increased 
expression of FRG2 was observed following expression of DUX4 in myoblasts and 
fibroblasts derived from control individuals. Moreover, we identified DUX4 binding sites 
at the FRG2 promoter by chromatin immunoprecipitation followed by deep sequencing 
and confirmed the direct regulation of DUX4 on the FRG2 promoter by luciferase 
reporter assays. Activation of luciferase was dependent on both DUX4 expression and 
the presence of the DUX4 DNA binding motifs in the FRG2 promoter. 
Conclusion
We show that the FSHD-specific upregulation of FRG2 is a direct consequence of the 
activity of DUX4 protein rather than representing a regional de-repression secondary 
to fewer D4Z4 repeats.
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Background
Facioscapulohumeral muscular dystrophy (FSHD, OMIM 158900/158901) is one of the 
most common myopathies with a prevalence of 1 in 8.000 according to a recent report1. 
Individuals with FSHD typically suffer from progressive weakening and wasting of the 
facial, and upper extremity muscles with considerable inter- and intra-familial variability 
in disease onset and progression2. The pathogenic mechanism of FSHD has been linked 
to the polymorphic D4Z4 macrosatellite repeat array, located on chromosome 4q35, of 
which each unit contains a copy of a retrogene encoding for the germline transcription 
factor double homeobox protein 4 (DUX4)3-5. DUX4 has been shown to regulate a set 
of germline, early development and innate immune response related genes and leads 
to increased levels of apoptosis when expressed in muscle cells6-8. Over recent years, a 
combination of detailed genetic and functional analyses in FSHD families and muscle 
biopsies has established that sporadic expression of the DUX4 retrogene in skeletal 
muscle is a feature shared by all individuals suffering from FSHD9, 10. 
Genetically, at least two forms of FSHD can be recognized. The majority of affected 
individuals (FSHD1, > 95%) are characterized by a contraction of the D4Z4 repeat array. 
In healthy individuals, the D4Z4 macrosatellite repeat array consists of 11-100 copies, 
whereas individuals with FSHD1 have at least 1 contracted allele of 1-10 repeat units4, 
5, 11. A second group of FSHD individuals (FSHD2, < 5%) do not show a contraction of 
the D4Z4 repeat array, however most often have mutations in the chromatin modifier 
structural maintenance of chromosomes hinge domain containing protein 1 (SMCHD1) 
on chromosome 18p12. Both groups share two important (epi-)genetic features: they 
carry an allele permissive for stable DUX4 transcription because of the presence 
of a polymorphic DUX4 polyadenylation signal (PAS) and they display epigenetic 
derepression of the D4Z4 repeat array in somatic tissue9, 13. More specifically, in muscle 
biopsies and muscle cell cultures DUX4 expression has been correlated with decreased 
levels of CpG methylation and repressive histone modifications together with increased 
levels of transcriptional permissive chromatin markers at D4Z410, 14-17. The epigenetic 
changes at D4Z4 can be either attributed to repeat array contraction (FSHD1) or loss of 
SMCHD1 activity at D4Z4 (FSHD2)2. 
The time interval between the genetic association of FSHD to the D4Z4 macrosatellite 
repeat array and the identification of sporadic DUX4 activation as a unifying disease 
mechanism encompasses almost 20 years of research into different candidate genes for 
FSHD4, 9. In the absence of a conclusive disease mechanism, genes proximal to the D4Z4 
repeat have been investigated as possible FSHD disease genes, postulating that their 
regulation is affected in FSHD through a position effect emanating from the D4Z4 repeat 
array16-22. Amongst those candidate genes were FSHD Region Gene 1 (FRG1) and FSHD 
Region Gene 2 (FRG2) (Fig. 1A). FRG1 is located on chromosome 4 at 120kb proximal 
to the D4Z4 repeat and encodes a protein involved in actin bundle organization and 
mRNA biogenesis and transport23-26. Its overexpression leads to a dystrophic phenotype 
in different animal models, probably by affecting actin bundling and splicing of 
transcripts encoding muscle effector proteins27-30. However, most studies have failed 
to demonstrate FRG1 upregulation in FSHD muscle17, 19, 20, 31-40. FRG2 is a gene at 37kb 
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distance from the repeat encoding a nuclear protein of unknown function41. The distal 
end of chromosome 4 that contains the D4Z4 macrosatellite repeat array has been 
duplicated to chromosome 1042, 43. Consequently, due to its close proximity to the D4Z4 
repeat array, FRG2 is located on both chromosomes 4 and 10 (Fig. 1A). Additionally, a 
complete copy of FRG2 has been identified on the short arm of chromosome 3. We and 
others have previously reported on FSHD-specific transcriptional upregulation of FRG2 
from both the 4q and 10q copies upon in vitro myogenesis, however its overexpression 
did not lead to a dystrophic phenotype in a transgenic mouse model17, 27, 31, 41. 
Until the discovery that mis-expression of DUX4 is shared by all FSHD individuals, these 
observations led to a disease model in which the contraction of the D4Z4 repeat array 
would create a position effect on proximal genes, thereby leading to their transcriptional 
activation. Such a mechanism cannot explain the activation of the 10q copy of FRG2, 
as this would require a trans-effect of the contracted repeat array. Although the D4Z4 
copies on 4q and 10q have been shown to interact in interphase nuclei44, this seems 
unlikely as 3D FISH approaches have revealed that the 4q D4Z4 repeat localizes to the 
nuclear periphery, whereas the 10q subtelomere does not45. More recently, it was 
shown that the expression of FRG2 in FSHD cells was influenced by telomere length 
through telomere position effects46, leading to the conclusion that DUX4 and FRG2 were 
independently regulated by telomere-length. In the current study we provide evidence 
that the activation of FRG2 is a direct consequence of DUX4 protein activity, providing 
an experimentally supported cause for its specific expression in FSHD muscle and 
reconfirming DUX4 as the FSHD disease gene. 
Methods
Cell culture
Human primary myoblast cell lines were obtained from the University of Rochester 
biorepository (http://www.urmc.rochester.edu/fields-center/) and were expanded and 
maintained in DMEM/F-10 (#31550 Gibco/Life Technologies, Bleiswijk, The Netherlands) 
supplemented with 20% heat inactivated fetal bovine serum (FCS #10270 Gibco), 1% 
penicillin/streptomycin (#15140 Gibco), 10ng/ml rhFGF (#G5071 Promega, Leiden, 
The Netherlands) and 1μM dexamethasone (#D2915 Sigma-Aldrich, Zwijndrecht, The 
Netherlands). Differentiation into myotubes was started at 80% confluency by serum 
starvation in DMEM/F-12 Glutamax (#31331, Gibco) supplemented with 2% KnockOut 
serum replacement formulation (#10828 Gibco) for 36 hours. All samples and their 
characteristics used for our study are listed in additional table 1. Rhabdomyosarcoma 
TE-671 were maintained in DMEM (#31966) supplemented with 10% FCS and 1% P/S, 
(all Gibco).
RNA isolation, cDNA synthesis and qRT-PCR
Cells were harvested using Qiazol lysis reagent (#79306 Qiagen N.V., Venlo, The 
Netherlands) and RNA was subsequently isolated using the miRNeasy Mini Kit (#217004 
Qiagen) including an on column DNase treatment according to the manufacturer’s 
instructions. 2µg RNA was used to synthesize poly-dT primed cDNA using the RevertAid 
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H Minus First strand cDNA Synthesis Kit (#K1632 Thermo Fischer Scientific Inc., 
Waltham, MA). Relative FRG2 expression was quantified on the CFX96 system (Bio-Rad, 
Veenendaal, The Netherlands) using SYBR green master mix (Bio-Rad) with the following 
primers: FRG2_Fw: GGGAAAACTGCAGGAAAA, FRG2_Rv: CTGGACAGTTCCCTGCTGTGT. 
For relative quantification GUSB and GAPDH were used as reference genes and 
amplified with the following primers: GAPDH_Fw: GAGTCAACGGATTTGGTCGT, GAPDH_
Rv: TTGATTTTGGAGGGATCTCG, GUSB_Fw: CCGAGTGAAGATCCCCTTTTTA, GUSB_Rv: 
CTCATTTGGAATTTTGCCGATT. All PCR reactions were carried out in duplicate and the 
data were analyzed using the Bio-Rad CFX manager version 3.0 (Bio-Rad).  
Luciferase reporter assays
Genomic fragments containing the FRG2 promoter were amplified by regular PCR 
(primers pFRG2_Fw: AGGCCTTACCTTGCCTTTGT; pFRG2_Rv: TCTTGCTGGTGGATGTTGAG) 
using cosmids 23D11 (chromosome 10) and cY34 (chromosome 4)47, 48. The obtained 
PCR fragments containing the promoter sites were digested with BglII and BclI and 
subcloned into the BglII digested pGL3 basic vector. Genomic locations of the cloned 
promotersites (UCSC hg19): chr4:190,948,283-190,949,163 and chr10:135,440,170-
135,441,050. DUX4 binding sites were deleted by ligating PCR products obtained with 
internal primers (Fw_internal: ATCTGAGGGCCCTGATTCCTGAGGTAGC, Rv_internal: 
ATCTGAGGGCCCCATTTTTAAGGTAGGAAGG) combined with RV3 and GL2 primers 
annealing in the pGL3 backbone. Single binding sites were destroyed using site directed 
mutagenesis by PCR amplifying overlapping fragments with the following primers: 
together with RV3 and GL2 primers. Insert sequences and correct orientation in the 
pGL3 vector were confirmed by Sanger sequencing.  60.000 TE671 cells were seeded in 
standard 24 well tissue culture plates and co-transfected with 200 ng pCS2/pCS2-DUX4 
and 200 ng of the indicated pGL3 constructs, using lipofectamine 2000 according to 
manufacturer’s instructions. 24 hours after transfection cell lysates were harvested and 
luciferase activity was measured using the Promega luciferase assay kit, according to 
manufacturer’s instructions. Co-transfections with Renilla luciferase constructs for data 
normalization were omitted as we previously observed regulation of this construct by 
DUX449. Transfections were carried out in triplicate, error bars indicate the SEM of three 
independent experiments.
RNA sequencing and ChIP sequencing
RNA sequencing and ChIP sequencing data were obtained and analyzed as described 
before6, 36. All datasets have previously been made publicly available in the Gene 
Expression Omnibus (accession numbers GSE56787, GSE33838). FRG2 expression in 
response to DUX4 overexpression is displayed for MB135, a control derived primary 
Site 1Fw: CCTCAGGAATCAGGGGCTACATAGGGTAGCACTGACTCAACCT
Site 1Rv:  AGGTTGAGTCAGTGCTACCCTATGTAGCCCCTGATTCCTGAGG
Site 2Fw:  GGCTAATTAGGTTAGCACTGACTCACCCTATGCAATTCAATTTTATTGCATTTGATC
Site 2Rv:  GATCAAATGCAATAAAATTGAATTGCATAGGGTGAGTCAGTGCTAACCTAATTAGCC
Site 3Fw:  ACCTAATCAATTCAATTTTATTGCATTTGCACTAAGTATCTTCCCCATTTTTAAGGTAGGAAGG
Site 3Rv:  CCTTCCTACCTTAAAAATGGGGAAGATACTTAGTGCAAATGCAATAAAATTGAATTGATTAGGT 
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myoblast, and a control derived fibroblast. The genomic snapshots of the different 
datasets were generated using the IGV genome viewer version 2.3.3250, 51. 
Results
FRG2 expression is activated in differentiating FSHD derived muscle cells
We cultured a set of primary muscle cells derived from six controls, six FSHD1 and nine 
FSHD2 individuals and harvested RNA to analyze FRG2 transcript levels by quantitative 
realtime-PCR (qRT-PCR). We confirmed the significant FSHD-specific activation of FRG2 
in differentiating myotubes (Fig. 1B). In control samples, we observed a minor increase 
in FRG2 expression that was not statistically significant (Fig. 1B). Analysis of previously 
Figure 1. FRG2 activation in FSHD derived differentiating myoblasts
A) Schematic representation of the FSHD locus on chromosome 4q35. Rectangles indicate the different 
genes, arrows their transcriptional direction. Triangles represent D4Z4 repeat units and the single 
inverted repeat unit upstream of FRG2. Each unit contains the full DUX4 ORF, only the last repeat unit 
produces a stable transcript in FSHD patients. The dashed line indicates the duplicated region present 
on chromosome 10q26. B) qRT-PCR analysis of mean FRG2 expression levels in control (C), FSHD1 (F1) 
and FSHD2 (F2) derived proliferating myoblasts (MB) and differentiating myotubes (MT) shows the 
significant activation of FRG2 during differentiation only in F1 and F2 derived cells. Relative expression 
was determined using GAPDH and GUSB as reference genes. Sample numbers are indicated and error 
bars represent the standard error of the mean. Asterisks indicate significant differences based on a 
one-way ANOVA (P = 0.0014), followed by pairwise comparison using bonferroni correction, NS = non-
significant. C) Genomic snapshot (location indicated at the bottom) of RNA sequencing data of two 
control, two FSHD1 and two FSHD2 derived proliferating myoblasts (MB) and differentiating myotubes 





























































DUX4 activates FRG2 in FSHD
published RNA-seq data from two additional controls and a subset of FSHD samples 
confirmed FRG2 activation (Fig. 1C) and single base pair variations, known to differ 
between the three copies of FRG241, indicated transcripts were induced from FRG2 
genes at all three genomic locations (Fig. 2). Therefore, we conclude that increased 
transcription of FRG2 is not restricted to the copy on the 4q disease allele in FSHD1 
and likely not caused by a cis effect of D4Z4 chromatin relaxation. The increase of 
FRG2 transcript levels coincided with activation of DUX4 transcription upon in vitro 
myogenesis in FSHD derived samples (additional Fig. 1), as was reported before by us 
and others36, 52, 53. Altogether this confirms previously published data and highlights the 
robust transcriptional activation of all annotated copies of FRG2 in differentiating FSHD 
myotubes.
FRG2 activation is a direct consequence of DUX4 protein activity
As the activation of FRG2 in FSHD-derived myotubes follows the pattern of previously 
identified DUX4 target genes, we wondered if FRG2 is regulated by DUX4 directly. 
Indeed, we previously showed that FRG2 transcription was induced at least twofold 
by expression array analysis in DUX4 over-expressing control myoblasts6. This robust 
increase in FRG2 transcription was confirmed by RNA-seq in both myoblasts and 
fibroblasts (Fig. 3A) that were transduced with DUX4 expressing lentiviruses, ruling 
FRG2 (FLJ20518; chr3:75,713,479-75,716,365)
1 2 3 4
Location Chr3:75,714,702 Chr3:75,714,807 chr3:75,714,898 chr3:75,715,033
Variant (chr.) A(3)/G(4,10) G(3,10)/A(4) G(3)/A(4,10) T(3)/C(4,10)
Readcount 35/88 37/13 22/29 94/39
1 2 3 4#
#: T/C variant, reference sequences of FRG2 do not differ at this position
Based on UCSC genes uc003dpt.4 (FLJ20518; Chr3), uc003izv.3 (LOC100288255, Chr4) & uc010qvg.2 (FRG2B, Chr10)
chr3:75,714,687-75,715,066
Figure 2. sequence analysis of RNA sequencing reads reveals activation of FRG2 from all copies
Graphical representation of RNA-seq reads mapping to the FRG2C locus at chromosome 3p. Single 
nucleotide polymorphisms can be identified and are indicated by colored vertical lines (A = green, C 
= blue, G = orange, T = red). Different reads could thereby be assigned to the three different genomic 
copies of FRG2. Sequence analysis was based on the reference sequences obtained from the UCSC 
genome browser (build 19).
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out a muscle specific effect of DUX4 on FRG2 expression. Direct targets of DUX4 were 
previously identified by overlaying expression data with chromatin immuno-precipitation 
(ChIP) sequencing data6. Following the same approach, we observed DUX4 binding at 
the promoter of FRG2 (Fig. 3B). Sequence analysis of the 4q and 10q copies of the 
FRG2 promoter revealed that both chromosomes harbor three consensus binding sites 
Figure 3. FRG2 is activated as a consequence of DUX4 protein activity at its promoter
A) Genomic snapshot (location indicated at the bottom) of mapped RNA-seq reads at the chromosome 
4q FRG2 locus. Overexpression of DUX4 results in the activation of FRG2 in myoblasts (M) and 
fibroblasts (F), GFP overexpression was used as a control. B) Graphical representation of DUX4 binding 
at the 4q FRG2 promoter (genomic snapshot location indicated at the bottom) as revealed by ChIP-seq 
analysis. (data obtained in myoblasts). C) Genomic fragments obtained from chromosomes 4 and 10 
were cloned upstream of the luciferase gene. Polymorphisms distinguishing both copies are indicated 
(Variants 1-3) and the three identified DUX4 binding sites are displayed, with nucleotides matching the 
previously identified core DUX4 binding sequence underlined. All numbers show the relative distance 
to the TSS of FRG2, in the 10mut1-3 constructs the number indicates the first displayed nucleotide. The 
10Δ construct lacks all three DUX4 binding sites, whereas in 10mut1-3 the red nucleotides were mutated 
to the nucleotides indicated below them, thereby destroying the individual DUX4 binding sites.  D) 
DUX4 activates the FRG2 promoter in a luciferase reporter assay. Both the 4q and 10q copy of the 
FRG2 promoter are activated by DUX4. The 10q copy lacking the DUX4 binding sites (10Δ) was not 
activated by DUX4. Destruction of the three individual binding sites revealed that sites 1 and 2 are 
mediating the DUX4 dependent activation of FRG2. Counts per second (CPS) are a direct measure of 
luciferase activity, error bars indicate the SEM of three independent experiments. Asterisks indicate 
significant differences based on a one-way ANOVA (P < 0.0001), followed by pairwise comparison 
using bonferroni correction, NS = non-significant.
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for DUX4, which are not affected by minor sequence differences between the two loci 
(Fig. 3C). To test the functional significance of these DUX4 binding sites, we designed 
luciferase reporter constructs harboring the FRG2 promoters of chromosomes 4 and 
10. Co-transfection of these constructs with pCS2-DUX4 or the empty pCS2 backbone 
in TE-671 rhabdomyosarcoma cells confirmed that the activation of FRG2 is mediated 
by DUX4 protein expression (Fig. 3D). To confirm that the activation of the luciferase 
reporter gene was indeed mediated by DUX4 binding, we generated a reporter construct 
with a micro-deletion of all three DUX4 binding sites in the FRG2 promoter derived from 
chromosome 10 (10Δ, Fig. 3C). Upon co-transfection with the PCS2-DUX4 expression 
vector, the luciferase activation was completely ablated (Fig. 3D). We identified three 
consecutive DUX4 binding sites in the FRG2 promoter, of which sites one and three 
contain a single base pair variation in the core sequence identified previously6. To 
dissect which sites were responsible for DUX4 dependent FRG2 activation, we designed 
three additional constructs, in which one of the three sites was destroyed by site 
directed mutagenesis (Fig. 3C). Upon transfection of these constructs we observed that 
the activation of FRG2 by DUX4 is mediated primarily through the two binding sites 
furthest from the FRG2 transcriptional start site (TSS), as luciferase activity in response 
to DUX4 expression was no longer significantly induced. While destruction of the first 
binding site resulted in a complete absence of luciferase activation, the effect of DUX4 is 
still moderate, but non-significant, if site two is mutated (Fig. 3D). Destroying the third 
binding site did not affect the DUX4 mediated activation of the FRG2 promoter (Fig. 3D). 
Altogether, our data shows that DUX4 binding at the FRG2 promoter is underlying the 
transcriptional activation of FRG2 in FSHD derived myogenic cultures. 
Discussion
Ever since the D4Z4 macrosatellite repeat array was genetically associated with FSHD, 
great effort has been put into identifying the underlying disease mechanism. The 
initial lack of evidence for active transcription of DUX4, encoded in each D4Z4 repeat 
unit, shifted the focus to genes immediately centromeric to the array, like FRG1 and 
FRG2. Although FRG1 overexpression in mice leads to a dystrophic phenotype, its 
deregulation in muscles of FSHD patients has not been consistently demonstrated19, 27, 
28, 31-34, 36-40. In contrast, upregulation of FRG2 was consistently reported in FSHD-derived 
differentiating muscle cells; however the mechanism of FSHD-specific upregulation of 
FRG2 had not been conclusively established17, 31, 41.
Activation of FRG2 in FSHD cells was previously attributed to de-repression through a 
position effect mechanism secondary to the contraction of the D4Z4 repeat array17, 41. 
Moreover, it was shown that KLF15 regulates both FRG2 expression and the activity of 
a putative enhancer in within D4Z4, thereby possibly facilitating a cis effect of the D4Z4 
repeat array on the proximal FRG2 locus54. This model was challenged by showing that 
CpG methylation levels at a single CpG site centromeric to D4Z4 are unaffected in FSHD13, 
indicating that DNA methylation was not broadly altered in the region centromeric to 
the D4Z4 repeat array in FSHD cells. The recent establishment of a unifying disease 
mechanism for FSHD, that primarily centers around DUX4, further challenges a position 
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effect model that involves the deregulation of genes proximal to D4Z4 as a consequence 
of D4Z4 repeat array contraction. In line with this notion, we now show that FRG2 is a 
direct target gene of DUX4, providing a direct explanation for its upregulation in FSHD 
muscle.  
As sporadic DUX4 activation is induced during in vitro muscle cell differentiation, 
the expression profile of FRG2 fits that of previously reported DUX4 target genes. It 
is interesting to note that we observed increased, though not significantly, FRG2 
expression in control derived differentiating muscle cells, which might indicate a minimal 
activation of the locus during in vitro myogenesis in control cells. DUX4 expression has 
been reported to occur in control derived myogenic cultures, albeit at much lower 
frequencies, and thus FRG2 may be activated as a consequence of that55. Alternatively, 
FRG2 expression may be sporadically induced through other mechanisms, exemplified 
by the reported regulation by KLF1554.
DUX4 acts a potent transcriptional activator and induces expression of germline and 
early development genes through binding a specific homeobox sequence6. ChIP-seq 
analysis indeed identified DUX4 binding at the promoter of FRG2, which contains three 
consecutive DUX4 binding sites. Our experiments showed that the two sites furthest 
from the TSS of FRG2 are mediating the activation of FRG2 upon the expression of 
DUX4, confirming our earlier work showing that the probability of transcriptional 
activation by DUX4 increases with the number of consecutive DUX4 binding sites56. The 
FRG2 promoter sites at chromosomes 3, 4 and 10 are highly conserved, with identical 
sequences for the DUX4 sites on 4 and 10 and a limited number of single nucleotide 
differences between these and chromosome three that are predicted to preserve DUX4 
binding, explaining the activation of all copies by DUX441. In contrast to the complicated 
proposed mechanism of cis and trans effects of D4Z4 contraction at 4q17, 41, the protein 
activity of DUX4 offers a simple and experimentally supported explanation for the 
activation of FRG2. 
It was previously shown that FRG2 and DUX4 are regulated, at least in part, by telomere 
position effects46. Trans-activation of the FRG2 promoter was ruled out by transfecting 
promoter reporter constructs in immortalized FSHD derived myoblasts. However, the 
sporadic nature of DUX4 expression in these cells would seriously decrease the signal-
to-noise ratio in this assay and a direct effect of DUX4 on FRG2 expression would likely 
have been missed. Although we cannot rule out a direct telomere position effect on 
FRG2 in this study, we suggest that the observed increase of FRG2 can be attributed to 
the increased DUX4 levels rather than to telomere position effects on FRG2. DUX4 itself 
may indeed be partially under control of telomere length and as such its target genes 
would follow a similar regulation.
As of yet, the functional consequence of FRG2 activation in FSHD remains elusive. 
FRG2 localizes to the nucleus41, but its function has never been demonstrated and a 
possible role in FSHD disease progression is therefore unclear. The identification of 
FSHD individuals with proximally extended deletions, in which not only a large part 
of the D4Z4 repeat array, but also proximal sequences (including FRG2) were deleted, 
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again suggests that a cis-acting effect on FRG2 is not necessary for FSHD pathology57, 58. 
However, since DUX4 activates other genomic copies of FRG2, it remains possible that 
this protein contributes to some aspect of the disease. 
Conclusion
In this study we have firmly established that the long known activation of FRG2 in 
FSHD derived differentiating muscle cells is a direct consequence of DUX4 activity at 
its promoter. This provides further evidence for DUX4 as the central player in the FSHD 
disease mechanism and demonstrates that the higher expression of FRG2 in FSHD does 
not result from regional de-repression secondary to fewer D4Z4 repeats.
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Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused 
by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic 
expression of DUX4, a retrogene encoding a germline transcription factor encoded in 
each repeat.  Unaffected individuals generally have more than 10 repeats arrayed in 
the subtelomeric region of chromosome 4, whereas the most common form of FSHD 
(FSHD1) is caused by a contraction of the array to fewer than 10 repeats, associated 
with decreased epigenetic repression and variegated expression of DUX4 in skeletal 
muscle. We have generated transgenic mice carrying D4Z4 arrays from an FSHD1 allele 
and from a control allele. These mice recapitulate important epigenetic and DUX4 
expression attributes seen in patients and controls, respectively, including high DUX4 
expression levels in the germline, (incomplete) epigenetic repression in somatic tissue, 
and FSHD-specific variegated DUX4 expression in sporadic muscle nuclei associated 
with D4Z4 chromatin relaxation. In addition we show that DUX4 is able to activate 
similar functional gene groups in mouse muscle cells as it does in human muscle cells. 
These transgenic mice therefore represent a valuable animal model for FSHD and will 
be a useful resource to study the molecular mechanisms underlying FSHD and to test 
new therapeutic intervention strategies.
 
Author Summary 
Facioscapulohumeral dystrophy (FSHD) is a progressive muscle disorder which is 
associated with contraction and chromatin relaxation of the D4Z4 macrosatellite 
repeat on chromosome 4q. Each unit of the repeat contains a copy of the primate-
specific DUX4 retrogene, encoding a germline transcription factor which is repressed in 
somatic tissue. In FSHD, somatic repression of the DUX4 gene is compromised, leading 
to a variegated expression pattern of DUX4 in muscle cells. The complex (epi)genetic 
etiology of FSHD has long hampered the generation of a faithful animal model and 
thus far the role of FSHD candidate genes has only been studied in model organisms by 
overexpression approaches. Here we present two transgenic mouse models containing 
either patient- or control-sized D4Z4 repeats. In our mice, the regulation of the FSHD 
locus is preserved in both lines and only in the disease model somatic derepression 
and variegated expression of DUX4 is observed. These mice thus reflect many aspects 
of the complex regulation of DUX4 expression in humans. These models may therefore 
become valuable tools in understanding the in vivo regulation and function of DUX4, its 
role in FSHD and the evaluation of therapeutic strategies.
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Introduction
Each unit of the D4Z4 macrosatellite repeat contains a copy of the DUX4 retrogene 
that encodes a double homeobox transcription factor1-4. DUX4 is highly expressed in 
the germline and epigenetically repressed in most somatic tissues, including skeletal 
muscle5, 6. Recently, we and others showed that facioscapulohumeral dystrophy (FSHD), 
a muscular dystrophy predominantly affecting facial and upper extremity muscles7, 
is caused by D4Z4 repeat contraction-dependent (FSHD1) or –independent (FSHD2) 
chromatin relaxation in somatic tissues and low levels of DUX4 mRNA expression in 
skeletal muscle5, 8-10. On normal chromosomes 4, the D4Z4 repeat array varies between 
11-100 units, while in FSHD1 one of the chromosomes 4 has an array of 1-10 units 
associated with a less repressive D4Z4 chromatin structure11-13. In FSHD2, the D4Z4 
repeats are not contracted and D4Z4 chromatin relaxation can be observed on all 
arrays8. 
The low abundance of DUX4 mRNA in FSHD muscle tissue represents a variegated 
pattern of expression with abundant DUX4 protein expressed in a small number of 
nuclei6, 14, presumably due to an occasional escape from the inefficient epigenetic 
repression. The polyadenylation (pA) site for DUX4 mRNA is in the DNA sequence 
immediately telomeric to the last D4Z4 repeat unit and chromosome 4 haplotypes non-
permissive for FSHD contain inactivating polymorphisms at the pA site, explaining the 
haplotype-specificity of this disease2, 15, 16. 
When expressed in skeletal muscle, the DUX4 transcription factor activates genes 
normally expressed in the germline, essentially inducing a stem cell program in 
the postmitotic muscle cell. In addition, DUX4 binds and transcriptionally activates 
endogenous retrotransposons and simultaneously blocks the innate immune response, 
at least in part through the transcriptional activation of a beta-defensin5. 
The parental gene to primate DUX4 was necessarily expressed in the germline, since 
germline retro-transposition was necessary for it to enter the primate lineage. As a 
retrogene, however, DUX4 was dissociated from its evolved enhancers, promoters, 
and pA site, suggesting that the DUX4 retrogene adopted independently evolved 
mechanisms to regulate its developmental expression17. One hypothesis is that the 
repression of DUX4 transcription in most somatic tissues relies on an independently 
evolved mechanism of repeat-mediated silencing. If true, then it is to be expected 
that somatic DUX4 silencing is an evolutionary conserved mechanism that can be 
recapitulated in other species such as mouse.  
No studies have yet addressed whether the D4Z4 repeat array and its flanking sequence 
is sufficient to accurately reproduce the developmental pattern of DUX4 expression, nor 
whether the FSHD mutation can recapitulate the decreased epigenetic repression and 
variegated DUX4 expression in a mouse model. The latter question is particularly relevant 
as both primates and rodents have lost the parental copy of the DUX4 retrogene18, 
but only primates have DUX4 integrated in the context of a D4Z4 macrosatellite repeat 
array and it is not known whether integration of the human array in mice can – at least 
in part – recapitulate the molecular characteristics of FSHD.
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Here we report the generation and molecular characterization of two transgenic mouse 
lines: one carrying a D4Z4 genomic region from a contracted pathogenic FSHD1 allele 
and one carrying a normal sized, non-pathogenic allele. Our data suggest that somatic 
epigenetic silencing of DUX4 indeed is an evolutionary conserved mechanism and 
that contracted D4Z4 repeat arrays are silenced less efficiently, leading to a variegated 
expression pattern of DUX4 protein in skeletal muscle nuclei.
Results
Generation of transgenic mouse models
To determine whether the D4Z4 repeat with the DUX4 retrogene contains the regulatory 
elements necessary for germline expression and copy-number dependent somatic 
epigenetic repression, we generated two transgenic mouse lines. One line carries an 
EcoRI fragment derived from the lambda-42 (L42) clone of an FSHD1 allele (Fig. 1A). This 
allele is of the FSHD-permissive 4A161 background, containing the DUX4 pA signal, but 
lacking the more downstream exons 6 and 76, and contains two-and-a-half copies of the 
D4Z4 unit and flanking sequences (herein referred to as D4Z4-2.5 mice)11. Integration 
of the L42 clone at mouse chromosome 17 was confirmed by conventional and COBRA-
FISH analyses and in total 4 copies of the EcoRI fragment were integrated as evidenced 
by MLPA analysis (Fig. 1B-D). The second transgenic mouse line was generated using 
two overlapping PAC clones, containing the upstream FRG1 and FRG2 genes, an array 
of 12.5 D4Z4 repeat units and flanking sequences, also harboring the FSHD-permissive 
4A161 haplotype and lacking exons 6 and 7 (herein referred to as D4Z4-12.5 mice) (Fig. 
1E)6. Recombination and single integration of the two PAC clones at chromosome 2 was 
confirmed by fiber-FISH, COBRA-FISH and MLPA analyses (Fig. 1D, E, F). Thus, D4Z4-
2.5 mice have D4Z4 repeat lengths that cause FSHD in humans, whereas D4Z4-12.5 
mice have an array length sufficient to maintain epigenetic silencing of DUX4 in somatic 
tissue in humans.
DUX4 expression in transgenic mice 
We have previously reported that human DUX4 is expressed in stem cells of the male 
germline6. In both D4Z4-2.5 and D4Z4-12.5 mice abundant levels of DUX4 mRNA 
were observed in germ line tissues, most notably in testis (Fig. 2). In D4Z4-2.5 mice, 
Figure 1. Integration site and copy number of D4Z4-2.5 and D4Z4-12.5 constructs in the mouse 
genome. 
A) Schematic draw of the L42 EcoRI fragment used to generate the D4Z4-2.5 mouse line. B) Metaphase 
spread of D4Z4-2.5 fibroblasts co-stained with dapi and the CY3 labeled L42 probe shows integration 
at a single pair of chromosomes. C) COBRA-FISH analysis on D4Z4-2.5 fibroblast metaphase spreads 
probed with biotinylated-L42 fragments shows integration of L42 on chr17. D) Detection of copy 
number of the integrated fragments in both mouse models by MLPA analysis. The probe mix contained 
three probes specific for wild type alleles, one probe designed against the human p13E-11 region and 
one probe against D4Z4. E) Schematic draw of PAC clones used to generate the D4Z4-12.5 mouse. F) 
COBRA-FISH analysis on D4Z4-12.5 fibroblast metaphase spreads probed with a biotinylated PAC clone 
shows integration of the PAC clone on chr2. G) Fiber-FISH analysis of D4Z4-12.5 fibroblasts. Both PAC 
clones, labeled and hybridized to DNA fibers, were shown to be recombined during integration into 
the mouse genome.
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in situ hybridizations with specific 5’ and 3’ DUX4 probes revealed DUX4 transcripts 
in cells near the periphery of the seminiferous tubules (Fig. S1) consistent with 
spermatogonia and primary spermatocytes, as has been reported for normal human 
testis6. In D4Z4-2.5 mice, abundant DUX4 mRNA levels were also detected in ES cells 
and early developmental stages, which were chosen based on timing of key myogenic 
developmental waves, showing a gradual decline during development (Fig. 2)19-22. We 
also detected DUX4 mRNA in D4Z4-12.5 embryos, albeit at lower abundance, and in ES 
cells (Fig. 2; Fig. S3).
We selected a panel of somatic tissues, including several skeletal muscles which 
aretypically affected in FSHD7, 23. Reproducible levels of DUX4 mRNA were detected in 
all analyzed skeletal muscles of adult D4Z4-2.5 mice, including affected muscles of the 
limbs, trunk and head (Fig. 3A; Fig. S2). These levels were low and varied considerably 
between gender-matched littermates, as judged from semiquantitative analysis. 
Expression of DUX4 in non-muscle tissue could be expected as the candidate orthologue 
Dux is found to be expressed in cerebellum tissue1. Indeed, DUX4 transcripts were 
detected in non-muscle tissues, including cerebellum but with the exception of liver, 
where only in one mouse DUX4 could be detected once (Fig. 3B; Fig. S3). In D4Z4-12.5 
mice, DUX4 transcripts could only be reproducibly detected in the tibialis anterior and 
pectoralis muscles, whereas all other somatic tissues did not show reproducible DUX4 
expression (Fig. 2A-B; Fig S2; Fig. S3). This suggests that, as seen in humans5, 9, DUX4 is 
expressed variably in skeletal muscle of our transgenic mice and that decreased D4Z4 
copy number contributes to inefficient DUX4 repression in somatic tissue, leading to a 
higher probability of expression. 
Figure 2. Quantative expression analysis of DUX4 transcripts from the telomeric D4Z4 unit in D4Z4-
12.5 and D4Z4-2.5 mice.
Quantitative RT-PCR data of DUX4 in D4Z4-2.5 embryonic stem cells (ES), in complete embryos of day 
E8.5, 9.5, 13.5 and 16.5, representing key myogenic developmental stages, and in adult ton=tongue, 
testis and in complete embryo day 13.5 and testis tissue of D4Z4-12.5 mice . Expression is normalized 
to the mouse reference gene Hprt and plotted in log10 scale. Error bars indicate SEM of the mean 
(n=2-5).
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In human FSHD muscle cell cultures, inefficient DUX4 repression results in occasional 
nuclei expressing abundant amounts of DUX4. Therefore, we tested the expression 
of human DUX4 in D4Z4-2.5 and D4Z4-12.5 satellite-cell-derived myoblasts, both 
by (quantitative) RT-PCR (Fig. 3C-D) and by immunofluorescent labeling (Fig. 4). In 
satellite-cell-derived myoblasts and differentiated myotube cultures obtained from 
Figure 3: Analysis of transcriptional activity of DUX4 in a panel of tissues of D4Z4-2.5 and D4Z4-12.5 
mice
DUX4 transcripts measured in 7 weeks old D4Z4-2.5 and D4Z4-12.5 mice (n=3) in A) muscle tissue: Hea 
= Heart, Dia = Diaphragm, Pec = Pectoralis Mas = Masseter, Orb = Orbicularis oris, Qua = Quadriceps, 
TA = Tibialis anterior, Gas = Gastrocnemius, Ton = Tongue and B) somatic non-muscle and germline 
tissue: Tes = Testis, Ute = Uterus, Ova = Ovarium, Eye, Cer = Cerebellum, Spl = Spleen, Kid = Kidney, 
Liv = Liver. C) DUX4 transcripts measured in satellite-cell-derived myoblasts, myotubes and interstitial 
fibroblast extracted from EDL muscle of D4Z4-12.5 and D4Z4-2.5 transgenic mice. D) Quantitative RT-
PCR data of DUX4 expression in D4Z4-2.5 myoblasts (n=2) and myotubes (n=2) 48 hours after induction 
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D4Z4-12.5 mice, DUX4 transcripts and DUX4 protein could not be detected (Fig. 3C 
and data not shown). In contrast, in satellite-cell-derived myoblasts of D4Z4-2.5 mice, 
DUX4 transcripts and sporadic DUX4-positive nuclei could be observed. Remarkably, 
all sporadic DUX4 positive nuclei were Myog negative and did not fuse into myotubes, 
as evidenced by co-staining with Myosin heavy chain (Fig. 4A-B). These data suggest 
DUX4-mediated inhibition of myoblast differentiation, as has been shown previously 
in zebrafish24. Total expression levels and frequency of DUX4-positive nuclei increased 
by 2-4 fold upon differentiation into myotubes (Fig. 3D and 4D). Satellite-cell-derived 
myoblasts obtained from fast-twitch (EDL) and slow-twitch (soleus) fibers from D4Z4-
2.5 mice showed the same DUX4 protein expression pattern (data not shown). Of 
interest, interstitial fibroblasts obtained from collagenase digested D4Z4-2.5 EDL and 
soleus muscle did not express DUX4 transcripts (Fig. 3C), indicating that the expression 
of DUX4 in the D4Z4-2.5 EDL and soleus is muscle cell specific. 
Altogether, these data show that both the RNA and protein expression pattern of 
DUX4 in our D4Z4-2.5 mouse model recapitulates several features of FSHD. DUX4 is 
more efficiently silenced with increasing D4Z4 copy number in our two mouse models, 
thereby forming a paradigm for the difference between human FSHD1 patients and 
healthy controls.
Chromatin structure of D4Z4 in transgenic mice
Next, we studied the chromatin structure of the integrated D4Z4 repeats in order to 
determine whether the observed DUX4 expression patterns correlate with epigenetic 
differences in the FSHD and control transgenic loci. At control alleles in humans, D4Z4 is 
characterized by high CpG methylation levels and the co-occurrence of histone 3 lysine 
9 trimethylation (H3K9me3) and histone 3 lysine 4 dimethylation (H3K4me2). FSHD 
alleles are epigenetically characterized by reduced D4Z4 CpG methylation and a reduced 
H3K9me3:H3K4me2 ratio, referred to as the chromatin compaction score (ChCS)12, 25-
28. We assessed DNA methylation and the ChCS in the two mouse lines at indicated 
sites within the transgenic loci (Fig. 5A). DNA methylation analysis using methylation-
sensitive restriction enzymes followed by Southern blotting (representative blot shown 
in Fig. 5B) showed that both the proximal and internal D4Z4 units of the array were highly 
methylated (60-90%) in gastrocnemius muscle of D4Z4-12.5 mice (Fig. 5C), similar to 
unaffected individuals. In gastrocnemius muscle of D4Z4-2.5 mice, the D4Z4 units were 
Figure 4. Bursts of DUX4 protein expression in differentiating D4Z4-2.5 muscle cells. 
Satellite-cell-derived myoblasts extracted from single EDL fibers of D4Z4-2.5 mice were differentiated 
for 12, 24 and 48 hrs and co-stained for DUX4 and Myog or for DUX4 and Myosin heavy chain. A) 
Representative DUX4 and Myog IF staining images of D4Z4-2.5 myotubes, 24hrs after induction of 
differentiation, indicate absence of Myog in DUX4 expressing cells. B) Representative DUX4 and Myosin 
HC IF staining images of D4Z4-2.5 myotubes, 24hrs after induction of differentiation, indicate exclusion 
of DUX4 positive cells from newly formed myotubes. Both DUX4 (panel C) and Myog (panel D) positive 
nuclei in relation to total amount of nuclei (DAPI staining) were counted during the differentiation 
process. C) Approximately 2:1000 nuclei showed nuclear DUX4 staining. D) The percentage of Myog 
positive nuclei revealed an increase in differentiation committed cells with time. After 48 hours of 
differentiation almost all myoblasts are committed to differentiation. Error bars indicate stdev of the 
plotted mean (n=7); *P < 0.05 compared to t=12 hrs; #P < 0.05 compared to t=24 hrs.
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relatively hypomethylated (10-20%; P < 3.10-5) (Fig. 5C), similar to FSHD patients and in 
concordance with the observed difference in DUX4 expression between the two mouse 
lines (Fig. 3A). Similar results were obtained for quadriceps, heart, brain and liver of 
both transgenic lines (data not shown). Bisulphite DNA methylation analysis of different 
regions within D4Z4 in embryonic and adult tissues showed that D4Z4 hypomethylation 
in D4Z4-2.5 mice is indeed stable and uniform between tissues (Fig. S4). Similar analysis 
in 10 month old mice showed that this epigenetic signature is stable with age (data 
not shown). Chromatin immunoprecipitation (ChIP) analyses in mouse fibroblasts and 
Figure 5. Epigenetic structure of D4Z4 in D4Z4-2.5 and D4Z4-12.5 mice.
A) Schematic draw of the regions within D4Z4 where CpG and histone methylation were interrogated. B) 
Representative figure of a methylation sensitive Southern blot assay to quantify DNA methylation levels. 
Upon BsaAI digestion, gel separation and blotting, two distinct bands representing the unmethylated 
and methylated fragment are visualized and quantified. C) Southern Blot analysis was done using two 
different methylation sensitive restriction enzymes, BsaAI and FspI, in adult gastrocnemius muscle 
tissue of D4Z4-12.5 and D4Z4-2.5 mice. Both probes p13E-11 and D4Z4 were used to measure CpG 
methylation levels in the most proximal unit and all units, respectively. The methylation percentages 
of the two different CpG sites are plotted. Error bars indicate stdev of the plotted mean (n=4 D4Z4-12.5 
vs n=5 D4Z4-2.5, *P < 0.001). D) Histone methylation levels of D4Z4 in transgenic D4Z4-12.5 and D4Z4-
2.5 embryonic (MEFs) and adult fibroblasts. Chromatin was precipitated with H3K4me2, H3K9me3 and 
control IgG antibodies. Precipitated DNA was amplified with qPCR primers amplifying the transcription 
start site of DUX4. Levels of H3K9me3 in relation to H3K4me2 have been plotted as the chromatin 
compaction score (ChCS).
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myoblasts showed a relative decrease in ChCS in D4Z4-2.5 compared to D4Z4-12.5 mice 
(Fig. 5D and data not shown), similar to what was seen in patient derived human skin 
fibroblasts and primary myoblasts when compared to control subjects28. Taken together, 
ChIP and DNA methylation analyses indicate a relative chromatin relaxation of the D4Z4 
repeats in D4Z4-2.5 mice compared to D4Z4-12.5 mice, concordant with the observed 
DUX4 expression pattern, thereby accurately modeling the difference between FSHD 
patients and control individuals. 
Genic consequence of DUX4 expression in mouse muscle cells
In human muscle cells, DUX4 activates germline and early stem cell programs while 
suppressing several genes involved in the innate immune response5. To assess the 
Germline & early development logFc FDR
















PRAMEF orthologues logFc FDR
Gm13040 * 2.33 1.54E-14
Gm13043 * 2.31 3.55E-13
BC080695 * 2.03 5.87E-13
Gm16367 1.12 3.06E-09
Gm13119 2.21 7.84E-17
Table 1: deregulated genes in response to DUX4 expression in C2C12, linked to functional groups 
shown to be deregulated in human myoblasts upon DUX4 expression. 
* Genes in cluster, possible duplications: >97% sequence homology.
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consequence of ectopic DUX4 expression on global gene expression in mouse muscle 
cells, proliferating C2C12 cells were transiently transfected with a DUX4 expression 
vector (pCS2-DUX4) or, as a control, the empty pCS2 control vector5. After 24 hours, 
DUX4 expressing cells were enriched by FACS sorting and global gene expression changes 
were mapped by performing array analysis. We identified 183 significantly deregulated 
genes (2-fold change and FDR<0.05), of which 142 genes showed up-regulation and 41 
genes showed down-regulation (table S1). GO pathway analysis was hampered by the 
small number of deregulated genes, but manual inspection of the gene list revealed 
a considerable overlap with the deregulated genes in human myoblasts expressing 
DUX45. Out of the 183 genes regulated by DUX4 in mouse C2C12 cells, 43 (23%) were 
previously determined to be regulated by DUX4 in human muscle cells, of which 39 
changed in the same direction (table S2). 
As in human cells, DUX4 regulated a number of germline-specific, early stem cell and 
innate immune response genes in the mouse C2C12 cells (table 1). Mouse orthologs 
of human genes regulated by DUX4, such as Zscan4c and at least three orthologs of 
the PRAMEF gene family (although poorly annotated in mice) showed transcriptional 
activation in the presence of DUX4 (table 1; table S1; Fig. S5). Immune modulation by 
DUX4 in human muscle involves a number of innate immunity related genes. Also in 
C2C12 cells, DUX4 regulates at least eight genes related to the innate immune response, 
for example Wfdc3, encoding a secreted peptide proposed to have antimicrobial 
activity5, 29. Using quantitative RT-PCR, we validated expression levels of DUX4 and a 
selection DUX4 regulated genes in DUX4 transfected C2C12 muscle cells (Fig. 6A-D). 
We confirmed deregulation of genes which were switched on by DUX4 (panel A), genes 
which are deregulated in both human and mouse (panel B) and genes implicated in 
germ cell biology and early development (panel C). Deregulated genes linked to innate 
immunity (panel D) showed activation upon transfection, which was dampened in 
the presence of DUX4, as was shown in similar experiments with human myoblasts5. 
Altogether, ectopic expression of DUX4 in C2C12 cells results in deregulation of a gene 
set which shows overlap with DUX4 responsive genes and gene sets in human myoblasts.
DUX4 can act as a transcriptional activator in C2C12
To identify genes in the mouse genome that are directly regulated by DUX4, C2C12 
myoblasts were transiently transfected with pCS2-DUX4 and subjected to ChIP-seq 
analysis. We identified a total of 2784 peaks (p-value < 10-5, FDR 0.02) and identified a 
DUX4 consensus binding sequence, highly similar to what was found in human muscle 
cells (Fig. S6A and previously described5), with a strong conservation of the core 
TAAYYYAATCA double homeobox binding motif (Fig. S6A). The genomic distribution 
of the identified peaks showed a slight bias for promoter sequences, as is seen for 
transcription factors, but not for DUX4 in human myoblasts (Fig. S7)5. Next we identified 
DUX4 regulated genes (log2FC > [.58], FDR < 0.05) that have a DUX4 binding site within 
a CTCF insulator domain surrounding their transcriptional start site (TSS). In this way, 
91 potential direct DUX4 target genes were identified, of which 10 genes showed 
DUX4 enrichment within a -2 to +2 kb window from their TSS (table S3). To validate 
the direct effect of DUX4, we selected 4 of these 10 direct target genes and validated 
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Figure 7. Expression of the DUX4 induced Wfdc3 gene in myoblasts and tongue muscle of D4Z4-2.5 
mice. 
Relative expression of Wfdc3 in satellite-cell-derived myoblast cultures from single EDL fibers (D4Z4-
2.5: n=6 and D4Z4-12.5: n=5) and tongue tissue isolated from 7-8 weeks old mice (D4Z4-2.5: n=6 and 
D4Z4-12.5: n=6). Expression levels are relative to Cyclophilin-B and Hprt and normalized to levels in 
D4Z4-12.5 mice, plotted as the mean ± SEM. Asterisks indicate P < 0.05 according to a independent 
two-tailed student’s t-test.
their expression levels by qRT-PCR (Fig. 6E). Nhlrc3 and 2810046L04Rik are adjacent 
and transcribed in opposite direction, indicating DUX4 might enhance expression from 
both promoters. To confirm that DUX4 indeed functions as a transcriptional activator at 
these sites, the DUX4 consensus binding site found at 2810046L04Rik and Nhlrc3 was 
cloned in both orientations upstream of a luciferase reporter gene and it significantly 
induced expression of the reporter construct when co-transfected with DUX4 (Fig. S8). 
Taken together, we find evidence that DUX4 can act as a transcriptional activator in 
mouse muscle cells as it does in human muscle cells. In addition, we identify direct 
DUX4 targets that might serve as suitable biomarkers in our D4Z4-2.5 mouse model of 
FSHD.
Non-genic consequence of DUX4 expression in mouse muscle cells 
In human cells, DUX4 has been shown to bind and activate retrotransposons, mainly 
of the MaLR type5. Our ChIP-seq analysis showed that DUX4 binds to several different 
types of retrotransposons also in the mouse genome. Both uniquely mappable (table 
S4) and non-unique sequence reads (table S5) show enrichment for DUX4 binding at 
LTR, LINE and, to a lesser extent, SINE retroelements. Quantitative RT-PCR analysis 
supports an upregulation of transcripts emanating from LINE-L1 and MalR (Mte2b) 
retrotransposons in the presence of DUX4 (Fig. 6F). Like in humans, the DUX4 core 
TAAYYYAATCA binding motif is present in each repetitive element, although flanking 
nucleotides show repeat specific differences (Fig. S6B-C)5. We conclude that under 
these experimental conditions DUX4 binds and transcriptionally activates repetitive 
elements in the murine genome, similar to its activity in the human genome. 
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DUX4 responsive genes in D4Z4-2.5 derived muscle cell cultures, adult skeletal muscle 
and embryos
Since DUX4 expression levels in adult D4Z4-2.5 skeletal muscle are low and only a 
subset of myonuclei show DUX4 protein immunoreactivity in the D4Z4-2.5 satellite-
cell-derived myoblast cultures, we examined whether we could observe changes in the 
expression levels of DUX4 responsive genes identified by ectopic expression of DUX4 in 
C2C12 cells. In a set of five D4Z4-12.5 and six D4Z4-2.5 muscle cell cultures we found 
significant deregulation of Wfdc3 (Fig. 7). In tongue muscle of D4Z4-2.5 mice, where 
we observed relative robust DUX4 transcript levels, again Wfdc3 levels were found to 
be significantly increased in D4Z4-2.5 adult mice as compared to D4Z4-12.5 adult mice 
(Fig. 7). Since we observed relatively robust levels of DUX4 during embryogenesis, we 
also investigated whether we could observe the activation of Wfdc3 during this stage. 
In D4Z4-2.5 embryos at day E9.5 we observed robust expression of DUX4 (Fig. 3) and 
concordantly, Wfdc3 mRNA levels increased by 2-fold compared to wildtype (WT) 
controls (P = 0.002) (Fig. S9). Together these data showed that despite the low and 
variable levels of DUX4 itself, Wfdc3 showed reproducible upregulation in D4Z4-2.5 
cells and tissues, which makes it a suitable candidate for serving as a biomarker of DUX4 
activity.
Phenotype of D4Z4-2.5 mice
The phenotype of FSHD patients shows high inter- and intrafamilial variation. Next to the 
progressive muscle weakening, hearing loss and retinopathy are frequently observed 
extramuscular features30.  The most obvious phenotype in our D4Z4-2.5 mice is the 
development of eye abnormalities in approximately 54% of the D4Z4-2.5 mice with an 
onset of around 8-12 weeks of age (Fig. S10). Although variable, the mice develop a 
progressive keratitis of unknown etiology, possibly reflecting incomplete eyelid closure 
or another yet to be determined cause. 
The overall morphology and histology of the limb and some head muscles appeared 
normal. Inducing mild muscle damage by down-hill running (eccentric activation) did 
not induce measurable muscle weakness and damage in D4Z4-2.5 mice. Grip strength, 
creatine kinase levels, Evan’s blue dye uptake and proportion of central nuclei were all 
similar between WT and D4Z4-2.5 mice (table S6). In addition, expression of myogenic 
and immunogenic markers shown to be deregulated in many mouse models for 
muscular dystrophies31, were not changed in muscle of the D4Z4-2.5 mice (table S6). 
Inducing muscle regeneration by cardiotoxin injection, also did not cause significant 
differences with respect to regeneration capacity between WT and D4Z4-2.5 mice. At 10 
and 28 days after treatment, we examined the percentage of central nuclei, distribution 
of fiber sizes and fibrotic tissue formation. Only in the formation of fibrotic tissue, a 
trend towards delayed regeneration was observed, as in D4Z4-2.5 a slight increase was 




DUX4 has been implicated in FSHD pathology based on its inappropriate expression 
in skeletal muscle of patients with FSHD6, 16, 17. DUX4 encodes a double homeobox 
transcription factor which activates germline, early stem cell and other programs in FSHD 
muscle, eventually leading to cell death5, 32, 33. FSHD has a complex etiology: insufficient 
epigenetic silencing caused by D4Z4 contraction in FSHD1 or heterozygous mutations 
in the chromatin modifier SMCHD1 in FSHD2 patients results in the inappropriate 
expression of the retrotransposed DUX4 gene in skeletal muscle8, 9, 14, 25, 27, 34.  
In this study, we have established mouse models that recapitulate several important 
aspects of FSHD and control individuals with respect to the aforementioned genetic 
and epigenetic features of the D4Z4 macrosatellite repeat array, encoding the DUX4 
gene. Like in FSHD and control individuals, DUX4 is expressed in the germline of D4Z4-
2.5 and D4Z4-12.5 mice and, like in FSHD, D4Z4-2.5 mice show low and variable DUX4 
expression levels in somatic tissue. In FSHD patients, there is little information about 
somatic expression of DUX4 in non-muscle tissue, but our studies in mice suggest that 
derepression of DUX4 is not limited to skeletal muscle, consistent with the observed 
body-wide hypomethylation of D4Z4. In our D4Z4-12.5 mouse model we observe more 
efficient somatic repression of the DUX4 locus, where DUX4 can only be reproducibly 
detected in pectoralis and tibialis anterior muscle, typically affected in FSHD. Excitingly, 
the D4Z4-2.5 mouse model also reproduces the characteristic variegated expression 
pattern of DUX4 protein in FSHD muscle cell cultures: only a small sub-population of 
myonuclei express abundant levels of the DUX4 protein. 
Thus far, several animal models over-expressing FSHD candidate genes have been 
produced. Some of them focused on the proximally located FSHD candidate gene FRG135. 
Transgenic mice and Xenopus laevis, over-expressing FRG1 either muscle-specifically 
or systemically, both demonstrated an abnormal musculature36-38. Nevertheless high 
over-expression of FRG1 does not reflect the human FSHD expression profile and 
FRG1 upregulation in FSHD muscle remains controversial39-42. DUX4 over-expressing 
models have revealed the robust toxicity of DUX4 in somatic tissue, as demonstrated 
by massive cellular loss and abnormal development32, 33, 37, 43-45. In muscle cells, DUX4 
has been shown to cause cell death and renders myoblasts hypersensitive to oxidative 
stress32, 33, 43. While these models provide insight into the potential harmful effect of 
DUX4 in muscle or organismal development, none of them take into account the specific 
endogenous expression pattern of DUX4 and its related effect. 
The mouse models presented here, both carry human genomic constructs with the 
FSHD permissive subtelomeric region necessary for somatic DUX4 expression. Our data 
strongly suggests that the transcriptional profile of the DUX4 retrogene seems to be 
maintained and follows the pattern observed in patients and controls. While we can 
find reproducible evidence of somatic derepression of DUX4 in adult D4Z4-2.5 mice, 
including the variegated pattern of DUX4 positive myonuclei in cell culture, D4Z4-12.5 
mice show more efficient repression of DUX4 in their somatic tissues. This pattern of 
DUX4 expression suggests a locus-intrinsic property of the D4Z4 repeat array, of which 
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the regulation is conserved between mouse and human muscle. However, we cannot rule 
out that some differences between the two transgenic mouse lines in the expression of 
DUX4 are the consequence of different chromatin regulation at the sites of integration. 
We should exert some extra caution, since we only were able to generate one founder 
line for D4Z4-2.5 after over 450 attempts. Nonetheless, the D4Z4-2.5 mouse model is 
the first organismal model that can provide more insights in DUX4 regulation in vivo 
during development; e.g., why, how and when are sudden bursts of DUX4 expression 
in skeletal muscle regulated. This is particularly relevant since primates have lost the 
parental gene that retrotransposed to create the DUX4 retrogene18. As it was recently 
demonstrated that the detrimental effects of DUX4 expression in mouse muscle can be 
reversed by RNA interference46, our model may also serve well therapeutic intervention 
studies targeting DUX4 expression in skeletal muscle.
The FSHD specific somatic derepression of DUX4 has been associated with changes in 
D4Z4 chromatin structure, characterized by decreased DNA methylation and a lower 
ChCS12, 27, 28. D4Z4-12.5 mice, containing a normal sized D4Z4 repeat array of 12.5 units, 
show a heterochromatic D4Z4 repeat structure comparable to human control subjects. 
D4Z4-2.5 mice, containing an FSHD1 sized D4Z4 array of two-and-a-half units, show a 
more open D4Z4 chromatin structure similar to FSHD patients. Although we cannot 
rule out integration-site specific effects, the CpG methylation and histone marker data 
of the D4Z4 arrays in both mouse lines support the model that the chromatin status of 
this locus is determined by a repeat length-dependent mechanism and that somatic 
DUX4 repression is enforced through an evolutionary conserved mechanism of repeat-
mediated silencing. The most proximal D4Z4 unit displayed lower CpG methylated than 
the internal units (Figs. 2B, D, E vs. 2F, G), a phenomenon also observed for the D4Z4 
array in humans25, 47. In addition, we clearly demonstrated differences in DNA methylation 
between different CpG dinucleotides within D4Z4. Thus, even though D4Z4 is integrated 
at different sites within a mouse genomic background, its “human” epigenetic profile 
seems to be preserved. It will be of interest to study the conservation of the recently 
described involvement of the Polycomb/Trithorax complex in the regulation of D4Z4 
and the transcripts emanating from it48. Our mouse model could serve as a suitable 
model to further study the specific epigenetic regulation as analyses are not hampered 
by the presence of other homologous repeat arrays or degenerate copies as is the case 
in human samples.
DUX4 can act as a transcription factor causing the deregulation of specific gene 
programs when ectopically expressed in human cells2, 5, 14. To better understand if the 
DUX4 protein can exert similar functions in the context of the mouse genome, we 
analyzed its effects in C2C12 cells by combining ChIP-seq with trancriptome data sets. 
Our ChIP-seq data showed that the core motif bound by DUX4 in human was highly 
conserved in the mouse, although the relative abundance of binding sites was relatively 
enriched for promoters in the mouse dataset5. In addition to regulating specific gene 
sets, DUX4 also binds and activates several classes of retrotransposons in the mouse 
genome, including Line-1 and Mte-2b, the latter one closely related to human MaLR 
LTRs which are specific DUX4 targets in the human genome5. This indicates that the 
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primate specific retrogene DUX4 can – at least in part – elicit a similar transcriptional 
response at retrotransposons in mice and raises the question whether DUX-related 
transcription factors in the germline are involved in retrogene biology.
Our data also showed that ectopic DUX4 expression has some similar genic 
consequences in mouse cells as it has in human cells. However, in contrast to humans, 
where DUX4 alters the expression of a large number of genes, in mice DUX4 only affects 
the expression levels of 183 genes, possibly reflecting the primate specificity of DUX4. 
This limited number of genes precluded pathway analysis, but we observed that ~25% 
of genes deregulated in the mouse genome are also deregulated by DUX4 in humans, 
including genes involved in early development, germline biology and innate immunity. 
In addition, we identified a number of genes which are not shared between the mouse 
and human dataset, but fall in one of the aforementioned categories. Over 40% of the 
genes we identified to be regulated by DUX4 were also identified in the inducible DUX4 
overexpression study done by Bosnakovski et al.32. Combining our ChIP-seq analysis 
with the transcriptome analysis allowed direct DUX4 target identification and revealed 
that DUX4 can act as a transcriptional activator in mouse as it does in human cells.
We observed that some genes, including the early development and germline genes, 
become activated in mouse C2C12 muscle cells where normally these genes are not 
expressed. These genes may serve as good biomarkers in our mouse models for future 
studies tailored towards therapeutic effects of DUX4 downregulation. When studied in 
tissues and cell cultures isolated from our mouse models, indeed Wfdc3 was shown to 
be significantly increased in D4Z4-2.5 mice compared to the D4Z4-12.5 mice. Although 
only a limited number of nuclei show expression of DUX4, we see robust upregulation 
of Wfdc3 transcription, which is also seen for the activation of target genes in human 
FSHD samples. The nature of this observation remains elusive, however the structure of 
the DUX4 transcript makes it a likely target for nonsense mediated decay, whereas its 
target genes are generally not.
Although we were not able to document an obvious skeletal muscle phenotype in D4Z4-
2.5 mice expressing low and variable levels of DUX4 in their muscles, we did notice a 
trend towards muscle weakness. The EDL muscle consists of somewhat smaller fibers 
and after induction of severe muscle damage by cardiotoxin injection, D4Z4-2.5 mice 
show a small delay in muscle regeneration. To improve therapeutic readout in our D4Z4-
2.5 mouse, it will be interesting to assess DUX4 expression and muscle regeneration 
after multiple rounds of muscle damage, for example by crossbreeding D4Z4-2.5 with 
mdx mice. 
Interestingly, over time more than half of the D4Z4-2.5 mice develop an abnormal eye 
phenotype eventually leading to blindness. Weakness of the eyelid muscles (orbicularis 
oculis) and thereby the difficulty in closing eyes is characteristic for FSHD. Moreover, 
60% of FSHD patients also develop retinal telangiectasis, which can even lead to retinal 
detachment, known as Coat’s syndrome49. Therefore it will be imperative to assess the 
eye pathology in our D4Z4-2.5 mouse in more detail.
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In conclusion, we here report on the first transgenic mouse models which accurately 
model the epigenetic regulation of normal-sized and FSHD-sized D4Z4 macrosatellite 
repeats. While D4Z4-2.5 mice show strong overlap with the molecular phenotype of 
FSHD, D4Z4-12.5 mice more reflect D4Z4 regulation observed in control individuals. 
These mouse models will facilitate studies focusing on the in vivo regulation of DUX4 
and the consequences of somatic derepression of this germline transcription factor. 




All animal experiments were approved by the local animal experimental committee of 
the Leiden University Medical Center and by the Commission Biotechnology in Animals 
of the Dutch Ministry of Agriculture.
Generation & maintaining Transgenic mice
D4Z4-2.5 mice were generated by microinjection of the λ42 (L42) phage into pronuclei of 
fertilized oocytes of B6CBAF1/J mice (Charles River Laboratories, Wilmington MA, USA). 
The λ42 phage contains a 13.5 kb EcoRI fragment encompassing the partially deleted 
D4Z4 locus of a patient with FSHD50. D4Z4-12.5 mice were generated by co-injection 
of the 226K22 (accession number AF146191) and 202J3 PAC clones into pronuclei of 
fertilized oocytes of B6CBAF1/J mice (Charles River Laboratories). PAC clone 226K22 
was derived from chromosome 4A161 and isolated as described before51. The 202J3 
PAC contained a genomic fragment extending from the D4S2463 into the D4Z4 repeat, 
including the permissive 4A161 poly-adenlyation site, but not including exon 6 and 7, 
and has been isolated from the RPCI-6 library (detailed on Roswell park cancer institute, 
Buffalo NY, USA). The transgenic mice were genotyped by PCR analysis on tail DNA. 
Presence of permissive haplotype containing intact polyA site distal to last D4Z4 units 
has been assessed by PCR followed by Sanger sequencing of the pLAM region (LGTC, 
Leiden, Netherlands). Primers are listed in table S7. The transgenic mice used in these 
experiments were all back-crossed with C57bl6Jico mice for at least 20 generations 
and were bred at the animal facility of the LUMC. Mice were housed in individually 
ventilated cages with 12-h light–dark cycles. Standard mouse chow and water was given 
ad libitum.
COBRA & Fiber FISH
Metaphase spread FISH analysis was done as described before16. COBRA-FISH was 
performed on D4Z4-2.5 and D4Z4-12.5 fibroblasts essentially according to the method 
of Szuhai et al.52. In short, whole chromosomal painting probes (Cytocell, Adderbury, 
Banbury, UK) for COBRA were labeled with diethylaminocoumarin (DEAC)-, Cy3- and 
Cy5-ULS [reagents included in the Universal Linkage System (Kreatech Biotechnology, 
Amsterdam, The Netherlands), used as ratio-fluorochromes], and dGreen-ULS (used 
as binary fluorochrome) and combined with either biotin-16-dUTP labeled D4Z4-
2.5 or 226K22 or digoxigenin-11-dUTP (Dig) labeled 202J3 (Roche Ap¬plied Science, 
Mannheim, Germany) by nick translation. Streptavidin-LaserPro and mouse-anti 
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digoxigenin were applied to detect biotin and digoxigenin labeled probes, respectively. 
Recorded images were further processed and analyzed with an in house developed 
software tool (ColourProc)52.
Fiber-FISH was done on both cultured spleen and fibroblast cells isolated from the 
D4Z4-2.5 and D4Z4-12.5 transgenic mice. The cells were first attached to aminosilane-
coated microscope slides and then lysed to produce linear DNA fibers, which were fixed 
to the slide with methanol-acetic acid (3:1). The PAC clones 226K22 and 202J3 were 
labeled with biotin and digoxigenin respectively. Both were hybridized simultaneously 
to the fiber preparations and immunocytochemically detected using Alexa Fluor 594 
and fluorescein iso¬thiocyanate (FITC), respectively. The hybridizations were analyzed 
using a fluorescence microscope. At least 40 fibers were assessed to obtain the order 
and the number of the red and green signals.
MLPA
Probes were designed against the transgene and wild type alleles (table S7), containing 
all the criteria as described in White et al53. Reagents for the MLPA reaction and 
subsequent PCR amplification were purchased from MRC-Holland (Amsterdam, 
The Netherlands). The MLPA reactions were performed essentially as described in 
Schouten et al. 54. Briefly, 200 ng of genomic DNA (concentration determined using a 
UV spectrophotometer) in a final volume of 5 μl was heated at 98˚C for 5 minutes. After 
cooling to room temperature, 1.5 μl probe mix and 1.5 μl SALSA hybridization buffer 
was added to each sample. Next, the samples were denatured at 95˚C for 1 minute and 
hybridized for 18 hrs at 60˚C. Ligation was performed at 54˚C for 15 minutes by adding 
25 μl water, 3 μl buffer A, 3 μl buffer B and 1 μl ligase. The reaction was stopped by heat 
inactivation at 98˚C for 5 minutes. PCR amplification was carried out for 30–33 cycles 
in a final volume of 25 μl. The MLPA primers were labeled with FAM and added with a 
final concentration of 200nM. From each PCR reaction, 1.5 μl of product was mixed with 
10 μl (Hi Di) formamide and 0.05 ul ROX500 size standard in a 96 well plate. Product 
separation was performed using capillary electrophoresis on the ABI 3700 (Applied 
Biosystems/Life technologies, Bleiswijk, The Netherlands). To obtain a ratio for each 
product, the peak height was divided by the sum of the peak heights of the wild type 
probes.
Isolation single muscle fibers and culturing of the mouse myoblasts
Mice were sacrificed by cervical dislocation and the EDL and soleus muscles were 
carefully dissected from tendon to tendon and digested in 0.2% collagenase (Sigma 
C0130)/DMEM (31966 Gibco/Life technologies) supplemented with 1% penstrep 
(P0781, Sigma, Zwijndrecht, The Netherlands) at 37˚C for 1¾ hrs and 2 hrs respectively. 
The individual myofibres were dissociated by gently passing them through Pasteur 
pipettes with different sized apertures and then abundantly washed, as described in 
detail elsewhere55. To extract and expand the satellite cell pool, muscle fibers were 
cultured on matrigel (354230, BD biosciences, Breda, The Netherlands) coated 6-wells 
plate in DMEM 31966 supplemented with 30% FBS, 10% HS, 1% CEE and 2.5ng/ml FGF, 
1% pen-strep (all Gibco/Life technologies), 150 fibers per well. After 3 days, the fibers 
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were detached and removed. The attached myoblasts were trypsinized, counted and 
plated for further analysis. To induce differentiation into myotubes, serum-rich medium 
was replaced with serum-poor medium (DMEM 31966), supplemented with 2% HS and 
1% pen-strep, 48 hrs after plating. After 48 hours of differentiation cells were either 
fixed for immunofluorescence or lysed to isolate RNA.
Generation MEFs and adult skin fibroblasts
Mouse embryonic fibroblasts were generated from at embryonic stage E13.5. First, 
embryos were dissected out of the uterine horns, rinsed with 70% EtOH and washed 
in PBS (14190-169 Gibco/Life technologies). Next, the embryos were separated from 
the placenta and surrounding membranes. Tails of embryos were cut and used for 
genotyping. Next, the dark red organs were removed and embryos were finely minced 
and suspended in 1.5ml of trypsin-EDTA (25300-096, Gibco/Life technologies) for 15 
minutes at 370C with gentle shaking. Trypsin was inactivated by the addition of 2 ml 
MEF medium: DMEM high glucose (41966-052, Gibco/Life technologies) supplemented 
with 10% FCS, 1% L-glutamine (25030-024, Gibco/Life technologies) and 1% pen/strep. 
Upon centrifugation (5 minutes, 1200 rpm), the minced and trypsinized cell pellet was 
suspended in MEF medium and plated on gelatin coated culture dishes.
Adult skin fibroblasts were generated by dissecting skin tissue from the belly of 5 
months old mice. The skin of each mice was dissociated overnight at RT in 2 ml dispase/
collagenase mix, containing 2 mg dispase (17105-041, Invitrogen/Life Technologies), 
2 mg collagenase (C-9891, sigma), 0.04 ml pen/strep, 0.04 ml glutamine, 0.25 mg 
fungizone and 0.2 mg gentamicine (all Gibco/Life technologies). Next day, cells were 
centrifuged (5 minutes, 1200rpm) and resuspended in 6 ml MEF medium and plated in 
T25 culture flasks.
Immunofluorescence
For co-IF staining of DUX4, myogenin (Myog) and myosin heavy chain, cells were fixed in 
2% paraformaldehyde for 7 minutes at room temperature and then washed twice with 
PBS. Cells were permeabilized with 1% Triton X-100 (Sigma) in PBS for 10 minutes at 
room temperature with gentle rocking. Primary rabbit-DUX4 antibody directed against 
the C-terminal region of DUX4 (E5-5; 1:100)56, Myog (1:100, Dako North America, 
Carpinteria CA, USA) and MF-20 anti myosin heavy chain (1:100, Developmental studies 
hybridoma bank, Univ. of Iowa, Iowa city, IA USA) were diluted in PBS and cells were 
incubated overnight at 4°C with the first antibody. After washing three times in PBS, 
followed an incubation with diluted Alexa 488 conjugated donkey anti-rabbit and 
Alexa 594 conjugated donkey anti-mouse (A21206, A21206, 1:500, Invitrogen/Life 
technologies) for one hour, gently rocking in the dark. Next, cells were washed three 
times with PBS-0.025% TWEEN before they were mounted on microscope slides using 
Aqua Poly/Mount (PolySciences, Warrington PA, U.S.A.) containing 500 ng/ml DAPI. 
Stained cells were analyzed on a Leica DMRA2 microscope (Leica microsystems, Wetzlar, 
Germany).
gDNA, RNA isolation & cDNA synthesis
gDNA isolation from different tissues of both D4Z4-2.5 and D4Z4-12.5 mice was carried 
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out using the Genomic DNA from tissue kit (740952, Machery-Nagel, Düren, Germany) 
following manufacturers instruction. Total RNA was isolated from tissue using miRNeasy 
kit (217004, Qiagen, Venlo, The Netherlands), including a DNase treatment, according 
to the instructions of the manufacturer. For C2C12 expression analysis, RNA was 
isolated using the RNeasy microkit (74004, Qiagen). Both DNA and RNA concentrations 
were determined using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific, 
Wilmington DE, USA). The quality of the RNA was assessed by using a RNA 6000 nanochip 
on an Agilent 2100 BioAnalyzer (Agilent Technologies Netherlands BV, Amstelveen, The 
Netherlands) and RIN scores > 9 were obtained. cDNA was synthesized using 1-3 μg total 
RNA using the Revert Aid H Minus first strand cDNA synthesis kit using oligo-dT primers 
(Fermentas/Thermo scientific, St. Leon-Rot, Germany) according to the manufacturer’s 
instructions. The cDNA was subsequently treated with 0.5 U RNaseH for 20 minutes 
at 37°C and total cDNA was diluted in 50 ul water. For all C2C12 expression studies, 
oligo-dT primed cDNA was synthesized using 300 ng of RNA using the Omniscript RT kit 
(205111, Qiagen) according to manufacturer’s instructions. RT was done at 500C and 
cDNA was diluted to a total volume of 100 μl.
DNA methylation analysis by Southern blotting
Methylation levels of individual CpGs was determined by Southern blot analysis using 
the methylation-sensitive restriction enzymes BsaAI and FspI as described before12. In 
short, 5 μg of genomic DNA was digested with the restriction enzymes EcoRI and BglII 
and either BsaAI (NEB, Ipswich MA, USA) or FspI (NEB). All digestions were performed 
according to the manufacturer’s instructions. After digestion, DNA was separated by 
standard linear gel electrophoresis (0.8%)  followed by Southern blotting of the DNA on 
a hybond-XL membrane (GE Healthcare) and hybridization with the radioactive labeled 
probe p13E-11 (D4F104S1) or D4Z4 to determine the methylation in the proximal 
D4Z4 repeat unit and all internal units respectively. Hybridizations were performed for 
a minimum of 16 hours at 650C in 0.125 M Na2HPO4 (pH 7.2), 0.25 M NaCl, 1 mM 
EDTA, 7% SDS and 100 μg/ml denatured fish sperm DNA (Roche). After hybridization, 
membranes were consecutively washed with 2xSSC/0.1%SDS, 1xSSC/ 0.1%SDS and 
0.3xSSC/0.1%SDS. Finally, the membranes were exposed to a phospho-imager screen 
and signal intensities were quantified with ImageQuant software (Amersham/GE 
healthcare).
Quantitative methylation analysis by bisulphate converted DNA
Bisulphite treatment was performed with the EZ DNA Methylation kit (Zymo Research, 
Irvine CA, USA) and bisulphite primers were designed with MethPrimer software57. 
Primer sequences are listed in table S7. PCR was performed in a final volume of 25 μl 
containing 250 μM dNTPs, 1X Supertaq PCR Buffer (HT Biotechnology Ltd, Cambridge 
UK), 10 pM of each primer and 1 U Silverstar DNA polymerase (Eurogentec, Maastricht, 
The Netherlands). Cycling conditions: 94 °C for 15 min followed by 40 cycles of 94°C for 
40 s, 58°C for 40 s, and 72°C for 40 s, and a final extension step of 15 min at 72°C. PCR 
products were purified directly or by gel extraction using the NucleoSpin Gel and PCR 
Clean-up kit (Machery-Nagel) and subjected to Sanger sequencing (LGTC). Quantitative 
methylation ratios were calculated from sequence traces using the ESME software, 
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including appropriate sequence quality control, normalization of signals, correction for 
incomplete bisulphite conversion, and mapping of positions in the trace file to CpGs in 
reference sequences58.
Histone Chromatin immunoprecipitation 
ChIP experiments were based on the protocol described by Nelson et al. with some 
modifications59. In brief, subconfluent cell cultures were crosslinked in 1% formaldehyde 
for 10 minutes and the reaction was quenched for 5 minutes with glycine at a final 
concentration of 125 mM. Crosslinked cells were lysed and chromatin was sheared in 
a sonicator bath (Bioruptor UCD-20, Diagenode, Liège, Belgium) for 4-6 consecutive 
rounds of 10 minutes at maximum output and 15 seconds on/off cycles. Shearing was 
analyzed by phenol-chloroform extraction of DNA and agarose gel electrophoresis. 
All chromatin samples had a DNA size range between 200 – 2000 bp with a peak 
around 200 bp.  Per reaction 3 μg (DNA content) of chromatin was precleared with 
blocked sepharose A beads (GE healthcare, Diegem, Belgium) and incubated overnight 
at 40 with antibodies: rαH3K9me3 (17-625, Millipore, Billerica MA, USA; 5 μl/rxn) 
rαH3K4me2 (07-030, Millipore; 5 ul/reaction) and total IgG (Millipore; 5 μl/rxn). IP was 
done with 20 μl sepharose A beads/reaction and washing was according to the online 
available Millipore ChIP protocol. DNA was isolated using Chelex resin and diluted 1:1 
for qPCR analysis59. Relative abundance, IgG corrected and input normalized, at D4Z4 
was determined with previously published primers27.
Quantitative PCR
All quantative RT-PCR analysis were performed in duplicate using SYBR green mastermix 
on the MyIQ or CFX96 system (Bio-Rad, Veenendaal, The Netherlands) using 0.5-0.75 
pM of each primer in a final volume of 10-15 μl per reaction. For gene expression 
analysis 2-5 μl of diluted cDNA and for ChIP analysis 5 μl of 1:1 diluted ChIP DNA 
was used per reaction. Cycling conditions: initial denaturation step at 95°C for 3 min, 
followed by 35-40 cycles of 10-15 s at 95°C and 45 s at primer Tm (table S7). Specificity 
of all reactions was monitored by standard gel electrophoresis and/or melting curve 
analysis: initial denaturation step at 95°C, followed by 1 min incubation at 65°C and 
sequential temperature increments of 0.5°C every 10 s up to 95°C. All primer sets were 
designed using Primer3 software and, for cDNA analysis, spanned at least one intron. 
Results were analyzed using iQ5 / Bio-Rad CFX manager version 2.0 (Bio-Rad). For cDNA, 
relative expression was calculated, using Cyclophilin, Hprt or Gapdh as a reference 
gene (indicated) for cDNA input, using the CFX manager software. For ChIP, relative 
quantification was done by background subtraction based on the signal in the normal 
IgG ChIP. Normalization was done using the relative abundance of the product in DNA 
isolated from ChIP input samples.
C2C12 culture, transfection and cell sorting
For C2C12 cultures, plates and dishes were coated with collagen (Purecol, Advanced 
Biomatrix, San Diego CA, USA) 1:30 diluted in MiliQ, for 1 hr at 370C and then dried for 
at least 30 minutes. Before plating the cells, plates and dishes were washed with 1xPBS. 
C2C12 cells were maintained subconfluent in DMEM (11880, Gibco/Life technologies) 
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supplemented with 20% FCS, 1% pen/strep, 1% glucose and 1% glutamax (all Gibco/Life 
technologies). Transfections were performed using lipofectamine reagent, combined 
with plus reagent (both Invitrogen/Life Technologies) according to manufacturer’s 
instructions in 12/6 well plates, 9 or 20 cm dishes with 0.6/1.5, 5 or 12 μg total plasmid 
DNA, respectively. To enrich for DUX4 expressing cells used for gene expression 
analysis, pCS2-DUX45 or the empty pCS2 backbone were equimolarly co-transfected 
with pEGFP-C1 (Life technologies) and then sorted on a FACS aria cell sorter II (BD 
biosciences). In short, the living single cells were first gated based on forward and side 
scatter and then sorted by gating for GFP. Both the GFP enriched and depleted fractions 
were collected in PBS supplemented with 1% FCS, spun down and stored at -800 C.
Expression array analysis 
Global gene expression changes upon DUX4 expression were obtained with illumina 
MouseWG-6 v2.0 expression arrays (Illumina, San Diego CA, USA). RNA from FACS sorted 
C2C12 transfected with pCS2-DUX4 were compared with pCS2 backbone transfected 
cells in triplicate. Labeling of RNA, hybridization of the arrays and primary data analysis 
were carried out by ServiceXS (Leiden, The Netherlands) according to manufacturer’s 
instructions. Probe intensities were corrected and normalized using the lumiExpresso 
function from the lumi Bioconductor package60 with default options. If a probe was not 
present in any of the 6 arrays according to lumi’s “detectionCall” function, we removed 
it from further consideration. Differentially expressed probes were then identified using 
the limma Bioconductor package61 and p-values were adjusted to account for multiple 
testing using Benjamini and Hochberg’s method62.
DUX4 ChIP-seq analysis
Crosslinking, generation of chromatin and ChIP were performed as indicated above. 
In brief, chromatin of wt and DUX4 transfected C2C12s containing 12 μg DNA was 
precleared with IP beads and incubated o/n at 40 C with the rabbit polyclonal MO489 
antibody directed against the C-terminus of DUX45. After washing 6 times in ChIP 
buffer, immunoprecipitated ChIP DNA was isolated and purified with a standard 
phenol extraction. Sequencing and sample preparation were done with the Illumina 
genome analyzer following manufacturer’s instructions. Data analysis was performed 
as previously described5. Briefly, sequences were extracted by GApipeline-0.3.0. Reads 
mapping to the X and Y-chromosomes were excluded from our analysis. Duplicate 
sequences were discarded to minimize effects of PCR amplification and each read was 
extended in the sequencing orientation to a total of 200 bases to infer the coverage 
at each genomic position. Peak calling was performed by an in-house developed 
R package, which models background reads by a negative binomial distribution as 
previously described63. To identify the DUX4 consensus binding sequence, we applied 
an in-house developed Bioconductor package motifRG for discriminative de novo motif 
discovery as previously described64, 65.
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The life threatening immunodeficiency, centromeric instability, and facial anomalies 
syndrome is a genetically heterogeneous autosomal recessive disorder. Twenty percent 
of all patients cannot be explained by mutations in the ICF genes DNA methyltransferase 
3B or zinc finger and BTB domain containing 24. Here we report mutations in the cell 
division cycle associated 7 and the helicase, lymphoid-specific genes in ten unexplained 
ICF cases. Our data highlights the genetic heterogeneity of ICF syndrome and provides 
evidence that all genes act in common or converging pathways leading to the ICF 
phenotype.
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Introduction
ICF syndrome is characterized by recurrent and often fatal respiratory and gastrointestinal 
infections as a consequence of hypo- or a-gammaglobulinemia in the presence of B-cells1, 
2. Nearly all patients also present with distinct facial anomalies, including hypertelorism, 
flat nasal bridge and epicanthus1, 2. Centromeric instability is the cytogenetic hallmark 
of ICF syndrome. It involves the juxtacentromeric heterochromatin repeats on 
chromosomes 1, 9, and 16 and is comparable to what is observed after treatment of 
cells with demethylating agents3, 4. Therefore, CpG hypomethylation of juxtacentromeric 
satellites type II and III is diagnostic for ICF syndrome, with additional hypomethylation 
of centromeric α-satellite repeats in DNMT3B mutation-negative patients5, 6. 
Mutations in the DNA methyltransferase 3B (DNMT3B) gene (OMIM 602900; ICF1) 
account for ~50% of ICF cases while ~30% of cases have mutations in the zinc finger and 
BTB domain containing 24 (ZBTB24) gene (OMIM 614064; ICF2)2, 5. DNMT3B is a de novo 
DNA methyltransferase, primarily acting during early development with a preference 
for CpG dense regions7. ICF1 mutations in the catalytic domain of DNMT3B result in 
largely reduced methyltransferase activity8, 9. The function of ZBTB24 is unknown, 
but it belongs to a family of ZBTB proteins of which many have regulatory roles in 
hematopoietic differentiation10, 11. Despite the successful identification of ICF genes, the 
pathophysiological mechanism underlying the syndrome remains largely unresolved.
Previous studies indicated further genetic heterogeneity in ICF syndrome2. To identify 
the genetic cause in genetically unexplained cases (ICFX), we combined homozygosity 
mapping with whole exome sequencing. By using an autosomal recessive inheritance 
model and prioritizing homozygous variants in consanguineous families, we now identify 
four different homozygous and potentially damaging variants in the cell division cycle 
associated 7 (CDCA7) gene in five ICFX patients (now referred to as ICF3). In an additional 
five ICFX patients we identify compound heterozygous and homozygous variants in the 
helicase, lymphoid-specific (HELLS) gene (ICF4). We show that knock down of both new 
ICF genes leads to hypomethylation of juxtacentromeric heterochromatin repeats in a 
murine cell model. Our results emphasize the genetic heterogeneity of ICF syndrome, 
nonetheless provide evidence that all four ICF genes are involved in at least one 
common pathway.
Results 
Missense mutations in CDCA7 cause ICF syndrome type 3
We selected 13 ICFX patients from 11 families, negative for mutations in DNMT3B 
or ZBTB24, of whom the clinicopathological characteristics are listed in Table S1. 
Hypomethylation of pericentromeric satellite type II (Sat II), common to all ICF patients, 
and centromeric α-satellite DNA repeats, shown to be affected only in ICF2 and ICFX, 
was shown before for a subset of patients2, 5, 6, 12. For an additional set of ICFX patients 
we confirmed Sat II and α-satellite hypomethylation using Southern blot analysis (Fig. 
S1). In five ICFX patients from four families we identified and confirmed homozygous 
missense mutations in CDCA7, all near the first two zinc finger motifs in the conserved 
carboxyterminal 4-CXXC-type zinc finger domain (Fig. 1A-E). Segregation with disease 
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Figure 1: Homozygous missense mutations in CDCA7 in five ICF3 patients.
A) Schematic representation of CDCA7, with the identified homozygous missense mutations in red. 
Sequence outtake: 4-CXXC type zinc finger domain, CXXC motifs are underlined, mutated residues 
in red. B-D) Sanger sequencing confirmation of missense mutations in CDCA7 in families A-C. All 
variants were homozygous, the reference sequence is displayed for comparison. E) Sanger sequencing 
confirmation of the homozygous missense CDCA7 mutation in patients 2.2 (proband) and 2.3 of family 
D. Both parents are heterozygous for the variant, sibling 2.1 is unaffected and homozygous for the wild 
type allele.
was confirmed in family D and all mutations were predicted to be pathogenic and have 
an allele frequency supporting pathogenicity (Fig. 1E, Table S1). CDCA7 is involved in 
neoplastic transformation, MYC-dependent apoptosis, and hematopoietic stem cell 
emergence, however its molecular function is unknown13, 14. All four zinc finger motifs 
are completely conserved in the highly homologous 4-CXXC zinc finger domain of the 
transcriptional repressor CDCA7-Like (CDCA7L) (Fig. S2). The repressive activity of 
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CDCA7L is dependent on its 4-CXXC domain and by homology CDCA7 mutations in ICF3 
may disrupt a similar function15.
Mutations in HELLS cause ICF syndrome type 4
In an additional five ICFX patients from four families we identified mutations in 
HELLS that were predicted to be pathogenic and with allele frequencies supporting 
pathogenicity (Fig. 2A, Table S1, ICF4). In affected members of family E we identified a 
missense mutation in the conserved helicase domain (c.2096A>G; p.Gln699Arg) and an 
intronic mutation leading to destruction of the splice donor site in intron 5 (c.370+2T>A) 
(Fig. 2B). Different allelic origin is supported by analysis of maternal DNA, which carried 
only the splice site mutation (Fig. 2C). To analyse the effect of the lost splice donor site 
on mRNA processing, fibroblasts of both patients were treated with cycloheximide to 
inhibit nonsense mediated decay. Upon treatment, RT-PCR analysis showed increased 
levels of a splice variant with complete skipping of exon 5, leading to a frameshift 
followed by a premature stop codon in exon 6 (Fig. 2C).
The patient in family F carries a homozygous out-of-frame deletion (c.2283_2286delGTCT; 
p.[Ser762Argfs*4]), resulting in a frameshift and introduction of a premature stop 
codon in exon 20. The unaffected siblings 2.1 and 2.3 were found to be heterozygous 
for the deletion or homozygous for the wild type allele, respectively (Fig. 2D). In family 
G we found a deleterious homozygous in-frame deletion in the C-terminal domain of 
HELLS, leading to the deletion of Leucine 801 (c.2400_2402delGTT; p.[Leu801del]) 
(Fig. 2E). The proband of family H carries a nonsense mutation (c.610A>T; p.[Lys204*]) 
and a duplication causing the insertion of a stop codon (c.374_381dup; p.[Lys128*]), 
suggesting that absence of HELLS is compatible with human life, whereas Hells-/- mice 
die perinatally16. Different allelic origin of the mutations was confirmed in parental 
DNA (Fig. 2F). 
ICF genes converge at centromeric DNA methylation regulation
In mouse, HELLS is required for T-cell proliferation and mediates de novo DNA methylation, 
through its interaction with DNMT3B, dependent on its ATPase domain16-19. Genome 
wide loss of CpG methylation, including centromeric repeats, has been observed in 
Hells-/- mice, reminiscent of what has been described in Dnmt3b knockout mice and 
in mouse models for ICF120, 21. We show that transient depletion of HELLS, CDCA7 and 
ZBTB24, but not DNMT3B, resulted in decreased CpG methylation at centromeric 
repeats in wild type (wt) mouse embryonic fibroblasts (MEFs, Fig. 2G, Fig. S2A-B). This 
confirms that DNMT3B acts during establishment of centromeric CpG methylation22. 
Moreover, it supports a role for ZBTB24 and CDCA7 in maintenance of CpG methylation 
at centromeric repeats, and, combined with previously published work, suggests that 
HELLS may be involved in both processes19. 
By identifying two new ICF syndrome genes this study highlights its genetic heterogeneity, 
and the identification of at least one additional disease gene is expected with still a 
few cases remaining genetically unresolved. The complex, but highly overlapping 
pathophysiology suggests that all ICF genes act in common or converging pathways 
involved in immunity, chromatin regulation and development. Convergence is supported 
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by hypomethylation of pericentromeric repeats, common to all ICF subgroups, however 
the result of different defective pathways in the establishment and/or maintenance of 
CpG methylation. 
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Methods
Patients
All samples were obtained in an anonymized fashion and all families gave consent 
for genetic analyses. The study was approved by the Medical Ethical Committee of 
the Leiden University Medical Center, the local ethics committee of Necker-Enfants 
Malades Hospital, Paris, France and the Kyushu University Institutional Review Board 
for Human Genome/Gene Research. The patient from family A (referred to as patient 2 
in Kloeckener-Gruissem et. al., 2005), patients from families B and C (referred to as pC 
and pS, respectively, in Velasco et. al., 2014), patient 2.2 from family D, and the patients 
in family E (referred to as P4 and P8/P9, respectively, in De Greef et. al., 2011), as well 
as the three remaining ICFX cases (referred to as pN and P1 in Velasco et. al., 2014 and 
P4 in Kubota et. al., 2004) all show typical clinical features of ICF syndrome including 
hypo- or agammaglobulinemia in the presence of B cells, combined with the classical 
cytogenetic abnormalities involving chromosomes 1, 9 and 16, and hypomethylation of 
α-satellite DNA in addition to SatII hypomethylation. The critical features of all patients 
are summarized in supplementary table 1, further details can be found in previous 
descriptions of these patients2, 5, 6, 12, 23, 24. 
Gene identification by homozygosity mapping and sequencing
Homozygosity mapping was performed using the Sentrix HumanHap-300 Genotyping 
BeadChips (Illumina). To this end, 750ng genomic DNA was processed with the Infinium 
II Whole-Genome Genotyping Assay (Illumina). After DNA amplification, fragmentation, 
precipitation and resuspension, DNA was applied to the BeadChip and incubated 
overnight, followed by enzymatic base extension, fluorescent staining of the beads, 
and detection of fluorescent intensities by the BeadArray Reader (Illumina). To identify 
regions of homozygosity, B allele frequencies were assessed for all SNPs using BeadStudio 
version 3.2 (Illumina).  For a subset of patients, whole exome sequencing was performed 
in the Neuromics project by deCODE Genetics (Reykjavik – Iceland) and analyzed using 
deCODE Clinical Sequence Miner. Recessive analysis for multiple cases and controls 
and gene variant effect count (with VEP consequences moderate to high) were used 
Figure 2: Mutations in HELLS in five ICF4 patients.
A) Schematic representation of HELLS, with the identified mutations in red. B) Sanger sequencing 
confirmation of HELLS mutations in family E. Only c.370+2T>A was identified in maternal DNA, 
indicating different allelic origin of both mutations, or de novo occurrence of the second mutation. 
C) RT-PCR analysis of HELLS mRNA upon treatment of patient derived fibroblasts with cycloheximide 
(C) revealed that c.370+2T>A leads to complete skipping of exon 5 and disruption of the open reading 
frame. Ethanol treated samples (E) served as controls, alternative splicing was confirmed by Sanger 
sequencing in two independent experiments for both samples. D) Sanger sequencing confirmation of 
a homozygous out-of-frame deletion in HELLS in family F. Both parents, as well as unaffected sibling 2.1 
are heterozygous for the deletion allele, unaffected sibling 2.3 is homozygous for the wildtype allele. E) 
Sanger sequencing confirmation of a homozygous in-frame deletion in HELLS in family G. Both parents 
are heterozygous for the deletion allele. F) Sanger sequencing confirmation of nonsense mutations in 
HELLS in family H. Different allelic origin was confirmed in parental DNA. G) Southern blot analysis of 
minor satellite DNA methylation in wt, Dnmt3b-/- and siRNA-treated wt MEFs after digesting DNA with 
MspI or its methylation sensitive isoschizomer HpaII revealed CpG hypomethylation upon knockdown 
of Zbtb24, Cdca7 and Hells. Molecular weights of the 2-Log DNA size marker are in kilo-basepairs.
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to identify possible recessive mutations. For an additional set of patients, DNA libraries 
for whole exome sequencing were constructed using the SureSelect Human All Exon 
V5 kit (Agilent Technologies) according to the manufacturer’s instructions. Sequencing 
was performed on the Illumina HiSeq2500 platform to generate 100bp paired-end 
reads. Reads were mapped to the reference human genome (UCSC hg19) with the 
Burrows-Wheeler Alignment tool (BWA v0.7.4)25. Duplicate reads were removed by 
Picard (v1.87). We called SNVs and indels using the Genome Analysis Toolkit (GATK v2.5-
2)26. Annotations of variants were made using ANNOVAR27. For confirmation, relevant 
exons and flanking sequences of CDCA7 and HELLS were amplified using standard PCR, 
products were purified and analysed by Sanger sequencing. Sequence tracks were 
analysed and visualized using ContigExpress (Vector NTI, Invitrogen-Life Technologies). 
PCR primers are listed in table S2. 
Cycloheximide treatment and RT-PCR analysis
Early passage (p<6) patient derived primary fibroblast were maintained in DMEM F12 
(31331) supplemented with 20% heat inactivated Fetal Calf Serum, 1% pen-strep, 1% 
sodium pyruvate and 1% HEPES (all Invitrogen-Life Technologies). Cells were treated 
with 250 µg ml^-1 cycloheximide (dissolved in ethanol, 01810, Sigma-Aldrich) for 4 
hours using equal volumes of ethanol as control. After treatment, cells were harvested 
in Qiazol lysis reagent and RNA was isolated using the miRNeasy mini kit (both Qiagen) all 
according to manufacturer’s instructions. 2 µg of total RNA was used for random primed 
cDNA synthesis using the RevertAid first-strand cDNA synthesis kit (Thermo scientific). 
Transcripts were amplified by standard PCR with primers listed in supplementary table 
2, separated by standard gel electrophoresis and sequenced by Sanger sequencing.
Knockdown of gene expression in MEFs
The use of animal work has been reviewed by the Animal Experimentation Ethical 
Committee Buffon (CEEA-40), Paris, France, and approved under the number CEB-06-
2012. Female C57BL/6N pregnant mice, age 3 to 6 months, were sacrificed at 12.5 dpc, 
and individual mouse embryonic fibroblasts (MEF) clones isolated from each embryo 
of the litter. Primary MEFs were cultivated for no more than 2-3 passages in complete 
media (DMEM glutamax supplemented with 10% FBS, 100 U mL^-1 penicillin, 100 
µg mL^-1 streptomycin, all from Life Technologies). Two rounds of transfection with 
synthetic siRNAs at a final concentration of 20 nM were performed using Interferin 
transfection reagent (Polyplus-transfection) following the manufacturer’s instructions: 
a first round on MEFs in suspension and the second when cells were allowed to adhere 
to the plate. Cells were collected after 48 hours for genomic DNA extraction. Sequences 
of siRNAs used in the study are listed in Table S2.
Satellite DNA methylation analysis by Southern blotting
Satellite II and α-satellite methylation in whole blood DNA was analysed by Southern 
blot analysis of 2µg genomic DNA digested with methylation-sensitive restriction 
enzymes HhaI for analysis of Sat-α or BstBI for analysis of SatII repeats. Both enzymes 
were purchased from Fermentas. After overnight digestion, DNA was separated by 
electrophoresis using 0.8% agarose gels. DNA was transferred overnight to Hybond-N+ 
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membranes (GE Healthcare) and hybridized with a radioactive probes recognizing the 
α-satellite and satellite II repeats, respectively. Signals were detected by phosphoimaging 
or by exposure to X ray films. For analysis of murine satellite repeats, genomic DNA was 
extracted and purified from MEFs using the NucleoSpin®Tissue kit (Macherey-Nagel) 
according to manufacturer’s instructions. The DNA pellet was eluted in TE containing 
20 μg mL^-1 RNAse A. Genomic DNA from MEFs  (500 ng) was digested with 20 units of 
MspI or HpaII (New England Biolabs) for 16h to analyze the DNA methylation patterns 
of centromeric minor satellite repeats.  The digested DNA fragments were separated 
by electrophoresis using 1% agarose gels and transferred overnight to Hybond-N+ 
membranes (GE Healthcare) in 20XSSC. After UV-crosslink, the membranes were pre-
hybridized in 6X SSC, 5X Denhardt and 0.1% SDS and then hybridized with 32P-labeled 
minor satellite oligonucleotide probe:
(5’-ACATTCGTTGGAAACGGGATTTGTAGAACAGTGTATATCAATGAGTTACAATGAGAAACAT). 
Pre-hybridization and hybridization were carried out at 42°C for 1h. The membranes were 
washed 3 times in 6X SSC and 0.1%SDS at 37°C and signals detected by phosphorimaging 
using FLA 7000 phosphorimager (Fuji). Uncropped scans of the Southern blots are 
presented in Figs. S4-S5.
Quantification of knockdown efficiency by qRT-PCR 
Total RNA from MEFs was isolated using TRIzol® Reagent (Life Technologies) according 
to manufacturer’s instructions. Contaminant genomic DNA was eliminated with 
TURBO DNA-free kit (Ambion). Reverse transcription was carried out using 1 μg DNA-
free RNA and 50 μM random hexamers, 20U of RNase Out and 100U of RevertAid 
reverse transcriptase (Life Technologies). Complementary DNA reactions were used as 
templates for PCR reactions. Real-time PCR was performed using the light cycler-DNA 
MasterPLUS SYBR Green I mix (Thermo Scientific) supplemented with 0.5 μM of specific 
primer pairs (listed in supplementary table 2). Real-time quantitative PCRs were run on 
a light cycler rapid thermal system (LightCycler®480 2.0 Real time PCR system, Roche) 
with 20 sec of denaturation at 95°C, 20 sec of annealing at 60°C and 20 sec of extension 
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The studies described in this thesis aimed at better understanding the genetic and 
epigenetic contributors to two clinically unrelated, but epigenetically related diseases: 
the muscular dystrophy FSHD and the primary immunodeficiency ICF syndrome. 
Common to both disorders is the epigenetic dysregulation of repetitive DNA. FSHD, 
in most cases an in cis epigenetic disorder, is caused by chromatin relaxation of the 
D4Z4 macrosatellite repeat array in somatic cells and misexpression of the DUX4 
transcription factor in skeletal muscle. In ICF syndrome, an in trans epigenetic disorder, 
the most prominent epigenetic characteristic is the loss of CpG methylation at (peri-)
centromeric satellite repeats. How this causes pathology or contributes to the observed 
immunodeficiency is currently not known.
Repressing D4Z4: balancing repeat size and chromatin modifiers
In the majority of cases, FSHD is caused by contraction of the D4Z4 macrosatellite repeat 
on chromosome 4q35. Upon this contraction, a changed chromatin organization at the 
repeat leads to the derepression of the DUX4 transcription factor in somatic cells. These 
two sentences summarize almost 20 years of scientific publications about the etiology 
of FSHD: from the linkage of FSHD to 4q35 and D4Z4 contraction in the early 1990’s 
until the unifying disease mechanism in 20101-3. In between, key publications described 
the specific association of FSHD with the 4qA haplotype, the involvement of epigenetic 
dysregulation at D4Z4 and the transcriptional activity of the D4Z4 repeat4-11. During this 
process, in absence of the proof for the unifying genetic mechanism of FSHD, alternative 
pathomechanisms were described, mainly involving proximal gene dysregulation12-14. 
Recurring throughout the years, and important to all the proposed disease mechanisms, 
is the epigenetic dysregulation of D4Z4 in FSHD. The partial deletion of the D4Z4 repeat 
(FSHD1), or mutations in chromatin modifiers of D4Z4 (FSHD2), lead to a changed 
chromatin conformation at the repeat in somatic cells, which was proposed to spread 
or loop proximally and affect proximal gene regulation through an in cis mechanism. 
Involvement of the transcriptional activation of FRG1 and FRG2 was often studied, 
however never unequivocally proven to play a role in the FSHD disease mechanism12-18.
The work in this thesis strengthens a role for epigenetic dysregulation at D4Z4 and 
derepression of DUX4 as essential contributors to FSHD pathology. Earlier reports 
showed reduced binding of the H3K9me3-HP1-Cohesin network to the D4Z4 repeat 
in FSHD11. Indeed, in chapter 2 we firmly establish that there is a decreased chromatin 
compaction at D4Z4 (expressed as ChCS) in FSHD, either attributable to increased 
H3K4me2 or decreased H3K9me3 levels. However, our data in chapter 4 could not 
confirm a causal role for H3K9me3 loss in the derepression of DUX4 in a myogenic 
context. In patient derived myotubes, characterized by an increase in DUX4 expression, 
the relative amount of H3K9me3:H3 at D4Z4 was similar to that observed in controls. 
Moreover, depletion of SUV39H1, shown to establish H3K9me3 at D4Z4 in HeLa cells 
and in immortalized human myoblasts11, 19, or Cohesin subunits in control myotubes 
was not sufficient to activate DUX4. With this in mind, we attribute the decreased ChCS 
observed in chapter 2 to an increased level of H3K4me2 in FSHD derived myoblasts, 
rather than a reduction in H3K9me3. This could simply reflect the increased expression 
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or “poised” state of the DUX4 gene in FSHD and therefore the ChCS serves great 
purpose as a biomarker, but is uninformative in deciphering the epigenetic mechanism 
underlying DUX4 derepression. 
Chapter 4 highlights SMCHD1 as the most potent known epigenetic regulator of D4Z4 
to date as its ectopic expression reverses derepression of DUX4 in both FSHD1 and 
FSHD2 derived myotubes. This is in line with genetic analyses showing 1) a causal 
role for SMCHD1 mutations in FSHD2 and 2) a modifier effect of SMCHD1 on disease 
severity in FSHD120-22. Depletion of SMCHD1 in control myotubes mimics FSHD2 with 
DUX4 becoming derepressed. In addition, we show in chapter 4 that SMCHD1 is indeed 
partially lost from D4Z4 upon its ectopic depletion and results in increased levels of PRC2 
components and the PRC2 associated histone marker H3K27me3 at the D4Z4 repeat. 
This is also reflected in FSHD2 patient derived myotubes, but not in FSHD1 derived cells. 
Moreover, chemical inhibition of EZH2, the catalytic subunit of PRC2, leads to increased 
DUX4 expression, but only in FSHD2 cells. These data indicate that, although highly 
similar, there are differences between FSHD1 and FSHD2 in the epigenetic regulation 
of D4Z4. Where in both forms of the disease SMCHD1 is a repressor of the repeat, 
involvement of the PRC2 complex in D4Z4 regulation could only be detected in FSHD2. 
A potential confounder in our ChIP-qPCR-based analyses is the selective involvement 
of the contracted D4Z4 repeat in FSHD1 and the epigenetic dysregulation of all four 
D4Z4 repeat arrays on chromosomes 4 and 10 in FSHD2. Our ChIP approach does not 
allow the selective analysis of the contracted allele in FSHD1 cells and therefore the vast 
majority of signal in ChIP-qPCR data generated in FSHD1 cells originates from the three 
(larger) non-affected alleles. Nonetheless, we are able to detect a decreased ChCS at 
D4Z4 in FSHD1 chromatin, supporting sensitivity of the assay. Moreover, with regard 
to the selective involvement of PRC2 in FSHD2, chemical inhibition of EZH2 should 
have still affected FSHD1 cells if increased levels of PRC2 at D4Z4 in FSHD1 would have 
been missed. The generation of isogenic cell lines in a D4Z4-free background, carrying 
a single 4qA type D4Z4 allele in both control and FSHD1 size range, can be used to 
further address this apparent difference between FSHD1 and FSHD2. To further study 
the SMCHD1-dependent enrichment of PRC2 complexes at D4Z4, the SMCHD1 locus 
in these isogenic cell lines could be genetically engineered, e.g. through CRISPR-Cas9 
genomic editing. 
Alternatively, subtle sequence differences between 10q derived repeats and those 
derived from 4qA or 4qB could be exploited in patients carrying only one 4qA allele. A 
challenging aspect in this approach is the repetitive nature of D4Z4 and the technically 
challenging sequence composition of the distal end of the repeat. This could be 
overcome by a combination of single molecule real time sequencing (SMRT, PacBio) and 
massive parallel sequencing (Illumina HiSeq), provided that efficient D4Z4 enrichment 
strategies can be developed. The exact sequence composition of the four D4Z4 repeat 
arrays in a given sample can be determined through a combination of these approaches 
after which the smaller ChIP derived DNA sequence fragments can be superimposed 
on this. This allows to map the origin (which allele, or even which D4Z4 unit) of the 
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fragments enriched during the ChIP. This approach allows the fine mapping of known 
chromatin regulators and/or histone modifications at D4Z4. 
Recently, CRISPR-Cas9 technology was employed to target both a transcriptional 
activator and repressor to the D4Z4 repeat, leading to increased and decreased DUX4 
expression, respectively23. This approach could be used to uncover proteins involved in 
regulating D4Z4 in a more unbiased (non-candidate driven) way. Upon targeting of an 
inactive Cas9 enzyme to the D4Z4 repeat, immunoprecipitation (IP) of the enzyme allows 
the enrichment of the D4Z4 chromatin template which can be subsequently analysed by 
proteomics and/or transcriptomics techniques. Together, these approaches can yield a 
more comprehensive and complete picture of the proteins and/or histone modifications 
present at D4Z4 and thereby facilitates the identification of new therapeutic targets and 
yet unknown FSHD2 disease genes24.
In chapter 2 we could not find a significant correlation between the derepression of D4Z4 
and the age corrected clinical severity in FSHD patients, although a trend was observed 
in fibroblasts. In contrast, a correlation between CpG methylation levels at D4Z4 and 
clinical severity and/or penetrance has been demonstrated in multiple independent 
studies. In FSHD2 patients, the methylation level attributed to the shortest D4Z4 repeat 
of a single CpG in the proximal unit of D4Z4 (the FseI site) showed a significant correlation 
to disease severity25. In two other reports, CpG methylation levels throughout the 
D4Z4 repeat, measured by bisulfite sequencing of specific domains within D4Z4, were 
shown to be indicative for disease penetrance. Non-affected carriers of an FSHD-sized 
repeat on a 4qA allele showed methylation levels comparable to control individuals, 
but are however more susceptible to ectopic DUX4 derepression than controls26, 27. 
These observations fit with other known genetic and epigenetic characteristics of D4Z4 
in FSHD pathology. Firstly, FSHD1 shows the highest penetrance with residual repeat 
sizes of below 7 units and patients carrying only 1-3 residual repeat units are usually 
the most severely affected ones28-33, although a recent study showed high phenotypic 
variability in this patient group as well34. Secondly, asymptomatic carriers of D4Z4 
repeats between 7 and 10 units have a higher methylation level than expected based on 
repeat size25. Thirdly, the size of the residual D4Z4 repeat positively correlates with the 
CpG methylation levels at single CpGs proximal to the repeat35. Finally, FSHD2 patients 
typically carry D4Z4 repeats in the lower size range of controls. 
Overall, a concept emerges that not the size of the repeat per se, but the ability of 
the muscle cell to maintain repression at D4Z4 determines clinical outcome. The main 
contributors to this repression are the size of the D4Z4 repeat and the activity and/or 
presence of chromatin repressors at D4Z4. FSHD1 is mainly a problem of repeat size, 
with an important contribution of chromatin repressors, whereas the opposite is true 
for FSHD2 (Fig. 1). In this respect it should be noted that the patients in which FSHD1 
and FSHD2 co-exist carry residual D4Z4 repeat arrays of at least 6 units, as was the case 
for the FSHD1 cell lines studied in chapter 4 in which we could rescue DUX4 expression 
by ectopic SMCHD1 expression. Conversely, mutations in these repressor genes are only 
harmful for individuals carrying D4Z4 repeat arrays in the lower control size range (<20 
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units) (Fig. 1). This indicates that the ability of SMCHD1, and/or other yet unknown 
modifiers, to repress the D4Z4 macrosatellite increases with the number of repeat 
units. It also suggests that to rescue the effect of repeat contraction, modifiers require a 
minimal amount of repeat units to exert their effect. The insufficient repression by e.g. 
SMCHD1 with lower repeat numbers could be caused by impaired functionality of the 
protein at shorter repeats or with inefficient binding to short repeats. The latter would 
be consistent with the observed preferential binding of SMCHD1 at longer telomeres 
compared to short telomeres36. Although not experimentally proven, this model for 
penetrance and severity of FSHD must include the assumption that with decreasing 
capacity to repress D4Z4, the frequency of sporadic activation of DUX4 and/or the 
expression levels upon activation increase, and that this leads an earlier onset and more 
progressive phenotype.
Polycomb repression at constitutive heterochromatin: targeted failsafe or 
random reshuffling?
There is a striking similarity between the changed chromatin organization of subtelomeres 
during cellular senescence and that of D4Z4 in FSHD2. In chapter 3 we have shown that 
a decrease in subtelomeric CpG methylation (and H3K9me3) coincides with increased 
levels of H3K27me3. In chapter 4 we report the same exchange of CpG methylation 
and H3K27me3 at D4Z4 in FSHD2 versus control derived cell lines. Moreover, increased 
H3K27me3 at D4Z4 was also observed in control cells upon depletion of SMCHD1. 
These observations are in line with reports where inactivation of Dnmt’s, or the 
chromatin remodeler Hells, in murine model systems leads to a similar anti-correlation 
between CpG methylation and H3K27me337-39. Loss of methylation, through knocking 
out Dnmt1, at already lowly methylated CpG islands in majority leads to decreased levels 
of H3K27me3 at these promoters38. In contrast, CpG poor regions are characterized by 
Figure 1: Schematic overview of the relative contribution of D4Z4 repeat size and chromatin 
modifiers in FSHD1 and FSHD2
Traingles represent D4Z4 repeat units. A D4Z4 repeat arrayn of less than ten units is diagnostic for 
FSHD1, however there is a considerable effect of modifiers on repression of repeats of more than 
six units in length. Conversely, in the higher repeat size range (>20 units), the effect of mutations in 








increased presence of H3K27me337-39. The mechanism behind this is unclear, but most 
likely relies on the affinity of PRC2 for unmethylated CpGs. The redistribution of this 
mark upon global loss of CpG methylation is proposed to be the effect of a random 
dilution though the increased genome wide abundance of unmethylated CpGs38.
Based on the strong negative correlation between CpG methylation and gene expression, 
global disruption of CpG methylation patters could be expected to greatly influence 
gene expression patterns. However, only minor changes in global gene expression 
were observed: upon loss of CpG methylation repressed genes remain repressed 
and transcribed genes remain transcribed37, 38. Mainly genes which already display 
promoter hypomethylation were shown to be upregulated, correlating to decreased 
levels of H3K27me3 at these promoters38. At regions which normally display high levels 
of CpG methylation, the increased levels of H3K27me3 maintains the transcriptionally 
repressed state. In chapter 3 we indeed observed that the exchange of these marks 
did not have an effect on transcriptional activity of the loci under study (no CpG islands 
were included except the TERRA promoters). This supports the model delineated above: 
loss of CpG methylation correlates to the increase of H3K27me3 by which a repressive 
chromatin environment is maintained.
In chapter 4 we observed an increase of H3K27me3 in FSHD2 derived cells at D4Z4 
concomitant with hypomethylation of the repeat. In this case, however, the switch 
coincides with the sporadic derepression of DUX4. At first sight, this result opposes 
the model introduced above in which the loss of CpG methylation (and the associated 
repressive mechanisms) is compensated by increased Polycomb silencing. However, 
with the notion that only few cells escape silencing and show bursts of DUX4 expression, 
the repression of D4Z4 by PRC2 and H3K27me3 still seems rather efficient. Moreover, 
an actual repressive effect of PRC2 at D4Z4 in FSHD2 is supported by chemical inhibition 
of EZH2, the catalytic subunit of PRC2, which led to increased levels of DUX4 expression. 
These results either suggest that, at D4Z4, CpG methylation reflects a more potent 
repressive mechanism than the PRC2 protein complex and its associated histone 
modifications. Alternatively, the proposed mechanism of PRC2 dilution may lead to a 
limited pool of PRC2 complexes which are “available” to repress D4Z4 upon loss of CpG 
methylation at the repeat. Both scenarios would fit with the occasional burst of DUX4 
expression in sporadic myonuclei of patients. However, only the latter would explain the 
discrepancy between FSHD1 and FSHD2 with regard to the involvement of PRC2 and 
H3K27me3 at the repeat. Most likely, changes in the chromatin organization in FSHD1 
cells are confined to the contracted D4Z4 repeat. In contrast, mutations in SMCHD1 
in FSHD2, may have a much broader genome-wide effect on chromatin organization, 
as suggested by the genome-wide transcriptional dysregulation and the failure of 
X-inactivation in mouse Smchd1 knock out cells40-42. Although CpG hypomethylation at 
some other repeats was ruled out in FSHD243, studying the genome wide consequences 
of SMCHD1 loss on CpG methylation and H3K27me3 may reveal an inverse correlation 
as was observed for Dnmt’s and Hells. 
Intriguingly, we could mimic the FSHD2 chromatin environment at D4Z4 by depletion 
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of SMCHD1 in control cells, however it is unclear whether this includes CpG 
hypomethylation at the repeat. By logic we can rule out extensive hypomethylation 
through passive demethylation: our experimental setup (depleting SMCHD1 during in 
vitro myogenic differentiation) strongly limits the number of cell divisions which would 
be needed for passive demethylation. Besides, SMCHD1 has so far not been linked to 
active demethylation through the TET family of demethylases, so overall extensive 
hypomethylation is not expected at D4Z4 upon short term SMCHD1 depletion. 
Nonetheless, in this setup, depleting SMCHD1 does lead to the accumulation of PRC2 
and H3K27me3 at D4Z4. Firstly, this suggests that the hypomethylated state of D4Z4 
upon partial SMCHD1 loss in FSHD2 patients is determined during earlier stages of 
(muscle) development, or by prolonged absence of SMCHD1 from the repeat. Secondly, 
it suggests an order of events in which the absence of CpG methylation most likely 
leads to decreased SMCHD1 which in turn leads to increased PRC2 levels at D4Z4. This 
argues against a direct interaction between (absence of) CpG methylation and PRC2 
recruitment and suggests the requirement of additional factors, including SMCHD1, to 
mediate the switch between CpG methylation and H3K27me3. 
The technology to target CRISPR-Cas9 to the D4Z4 repeat described above offers new 
possibilities to mechanistically study the changes in the chromatin organization at D4Z4 
which underlie DUX4 activation. For example, tethering TET enzymes to D4Z4 through 
fusion with the inactive Cas9 enzyme may lead to local demethylation at the repeat 
and allows mapping of downstream molecular effects of CpG hypomethylation at D4Z4. 
Conversely, the effect of re-establishing CpG methylation at D4Z4 could be studied by 
targeting e.g. DNMT3B to the repeat in FSHD2 muscle cells. Using this approach in the 
mono-allelic 4qA D4Z4 cell lines discussed above would allow investigating whether 
similar mechanisms are active in FSHD1 as now described for FSHD2.
The mechanisms of proximal gene regulation revisited
Over the past decades, numerous studies have reported on potential deregulation of 
genes proximal to D4Z4 upon its contraction. Either deregulation was never unequivocally 
proven (FRG1), contribution to the FSHD pathomechanism was not clear (FRG2), or both 
(FAT1). Few studies have described a potential role for deregulation of DUX4c in the 
pathogenesis of FSHD. DUX4c is encoded by an inverted and incomplete D4Z4 repeat 
unit proximal of FRG2. It was reported to be deregulated in FSHD derived samples and 
to inhibit muscle cell differentiation by interfering with myogenic transcription factors 
like Myf5 and MyoD44, 45. However, in contrast to DUX4, its ectopic expression in Xenopus 
laevis did not reveal any developmental abnormalities46. Moreover, since it is lost on 
4q35 in patients with proximally extended deletions of D4Z4, a major contribution to 
FSHD pathology is  unlikely47. Detailed genetic analyses and the subsequent discovery of 
DUX4 derepression, yet the most likely and best supported disease mechanism, further 
challenged the contribution of proximal genes to FSHD. The reported deregulation of 
both FRG1 and FRG2 was attributed to spreading of the derepression at D4Z4 and/or a 
changed higher order chromatin structure at 4q35. In chapter 5 we have demonstrated 
that this is an unlikely explanation for the observed transcriptional upregulation of 
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FRG2. The combination of transcriptional analysis, ChIP analysis and Luciferase reporter 
assays revealed that FRG2 is in fact a target gene of DUX4 and is as such activated during 
muscle cell differentiation in FSHD derived samples.
More recently, a similar study showed that the same mechanism results in the 
upregulation of FRG1 in FSHD48. The direct binding of DUX4 to the FRG1 locus was again 
shown by ChIP and ectopic modulation of DUX4 levels support its role as transcriptional 
activator of FRG1. Intriguingly, whereas the DUX4 binding site at FRG2 is upstream of 
the transcriptional start site (TSS), the DUX4 responsive peak in FRG1 lies in intron 2 
of the gene. At LTR repeats, but also at non repetitive targets like ZSCAN4, DUX4 has 
been shown to often create a new TSS at its exact binding site, leading to alternative 
transcripts from the adjacent target genes49. Unfortunately the exact transcriptional 
consequences of DUX4 binding at FRG1 and the nature of the DUX4-induced FRG1 
transcripts, as well as protein function, were not studied. Thus, both studies provide 
a central role for the DUX4 protein in the transcriptional activation of FRG1 and FRG2 
in FSHD, however are not conclusive about the potential role for both genes in the 
pathology of FSHD.
So far, it is difficult to predict the possible role for DUX4 in regulating FAT1, the third 
gene upstream of D4Z4 which was implicated in FSHD pathology. A detailed study of 
the interaction between DUX4 and the FAT1 locus will be pivotal to further evaluate an 
“D4Z4-independent” role for FAT1 in the pathogenesis of FSHD. So far, FSHD samples 
were shown to have decreased FAT1 expression levels, which in a mouse model was 
shown to affect muscle development50, 51. Decreased FAT1 expression could be the 
consequence of DUX4 expression, although the data are currently inconclusive. On the 
one hand, DUX4 was shown to decrease FAT1 expression by at least twofold upon its 
overexpression in human myoblasts50, 52. DUX4 ChIP analysis revealed a strong binding 
peak in intron 2 of FAT1, suggesting a direct effect of DUX4 binding on FAT1. Intriguingly, 
if the effect would indeed be direct, repression of FAT1 would be in disagreement with 
the currently known function of DUX4 as transcriptional activator. In contrast, inhibition 
of DUX4 expression through shRNA expression did not affect FAT1 expression levels, 
but resulted in decreased expression levels of well-established DUX4 target genes51. 
This discrepancy may be caused by the relatively easy way to detect activated target 
genes which are normally absent versus the diluted effect of restoring FAT1 expression 
in only a minority of cells. A small number of individuals which do not display D4Z4 
hypomethylation and/or D4Z4 contraction, but do shown an FSHD-like phen`otype 
were reported to carry possibly damaging FAT1 variants53. These variants were often 
polymorphisms which are present in the normal population with low frequency53. 
DUX4 expression independent of D4Z4 contraction and/or hypomethylation should be 
analysed in these patients to exclude that the effect of FAT1 deregulation is secondary 
to DUX4.
Altogether, FSHD specific deregulation of FRG2 is now explained through DUX4 activity, 
while it is not inconceivable that DUX4 also affects FRG1 and FAT1. All this is in support 
for a in trans effect of DUX4, as opposed to an in cis effects of the changed chromatin 
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organization at the D4Z4 repeat in FSHD. Additionally, strong genetic evidence 
supporting the in trans model came from the identification of an FSHD1 patient carrying 
a contracted D4Z4 repeat array on chromosome 10, of which the distal end consists of 
chromosome 4 derived D4Z4 units1. If proximal gene deregulation would be mediated 
through an in cis effect, 10q26 genes would be affected. This was not studied, however if 
true it would argue against a causal role for FAT1 and FRG1 in the pathogenesis of FSHD 
as these genes are not present on 10q26. Although the deregulation of the upstream 
4q35 genes is shown to be secondary to DUX4 activation, a role in the pathology cannot 
be excluded and warrants further study.
Recent studies have shown an effect of telomere length on the regulation of 4q35 
genes through a telomeric position effect (TPE). In mammals TPE is a poorly defined 
mechanism of chromatin spreading: telomeric heterochromatin leads to the silencing 
of genes in close proximity to the telomere and this silencing is lost upon progressive 
telomere shortening54. Expression of DUX4 and FRG2, and more recently SORBS2, was 
shown to be increased with decreasing telomere length in FSHD derived cells55, 56. In 
chapter 5 we have shown that the observed effect on FRG2 is most likely secondary 
to increased DUX4 expression as a result of telomere shortening. SORBS2 is located 
~4.5 Mb upstream of D4Z4, is expressed in skeletal muscle and so far described as a 
signal transduction and/or structural protein in cardiac muscle cells55. The increase of 
SORBS2 expression is mediated through a long range interaction of SORBS2 with FRG1, 
which is lost upon extensive telomere shortening in FSHD cells only55. Interestingly, 
several DUX4 binding peaks were identified near or in SORBS2, however there is no 
other evidence for an in trans effect of DUX4 on SORBS2, as observed for the previously 
described upstream genes. Overall, there may be a contribution of telomere shortening 
on the expression of 4q35 genes, including DUX4 itself, however this effect is small 
in comparison to the effect of either D4Z4 contraction and/or mutations in modifiers 
like SMCHD1. For example, carriers of residual repeats of 1-3 units are often severely 
affected in early childhood where extensive telomere shortening is not yet expected. To 
better establish a role for TPE in FSHD, the results obtained in cellular models in which 
telomere length was ectopically modified should be translated to in vivo studies or large 
patient populations. This may prove difficult because the subtelomeric position of these 
genes may be primate specific and because of the large variation in telomere length in 
the general population.
SORBS2 is one of the four genes reported so far which are deregulated through 
disturbed long range interactions with extensive telomere shortening. This mechanism 
has been described as “TPE over long distances” (TPE-OLD) and differs from the classic 
TPE. In TPE-OLD, the 3D conformation of the genome rather than individual gene 
location determines the transcriptional response to extensive telomere shortening57. 
It remains unclear at this point if DUX4 transcription is affected in a similar mechanism 
or is affected through classic TPE. The independent observations that SMCHD1 
preferentially localizes at longer telomeres and that it is the major repressor of D4Z4 




The final result of telomere shortening is a tumor suppressive mechanism called cellular 
senescence.  Cells exit the cell cycle and over the recent years it has become clear that 
senescent cells undergo genome wide changes in chromatin organization. For example, 
recent reports showed genome wide redistribution of CpG methylation, H3K4me3 and 
H3K27me3 upon senescence58, 59. Moreover, global nuclear organization is changed 
upon the formation of senescence associated heterochromatic foci containing large 
heterochromatic regions normally associated with the nuclear lamina60, 61. Indeed, in 
chapter 3 we observed decreased levels of subtelomeric CpG methylation, H3K9me3 
and H4K16ac with a concomitant increase of H3K27me3 and H3K36me3 upon 
telomere induced senescence. Reading out DUX4 transcript levels was not possible 
as these observations were done in fibroblasts without a 4qA allele. In the system 
used to identify targets of TPE-OLD, senescence signalling was excluded, however the 
changed 3D conformation of the genome upon TPE-OLD raises the possibility that both 
mechanisms are related. A careful overlap between genomic regions affected by TPE-
OLD and cellular senescence can yield more insights into whether or not these are two 
independent mechanisms.
In any case, the possible activation of DUX4 with decreased telomere length and/or 
senescence may form the molecular basis for the progressive nature of FSHD. With age, 
average telomere length declines variably but significantly. Moreover, there is build-
up of senescent cells throughout aging tissues62. Both scenarios may lead to increased 
transcription of DUX4 with age and would thereby contribute to the progressive 
nature and general late onset observed in FSHD. In this view, telomere length could be 
considered as a modifier of disease, but to support this claim larger studies in patient 
cohorts and even in specific tissues are necessary.
FSHD disease models: fighting against evolution
The generation of faithful animal models is currently indispensable for translational 
research. In other words: identifying and developing potential therapeutic interventions 
for FSHD requires the generation of an in vivo model for FSHD. In chapter 6 we described 
the generation of two transgenic mouse models which recapitulate key genetic and 
epigenetic features of FSHD. The D4Z4-2.5 mouse carries an FSHD sized 4qA D4Z4 
allele, which is characterized by relative chromatin derepression in somatic cells, as 
compared to the D4Z4-12.5 mouse line carrying a 4qA D4Z4 allele in the size range of 
control individuals. In agreement with the chromatin derepression, several (muscle) 
tissues and primary muscle cells derived from the D4Z4-2.5 mouse express detectable 
amounts of DUX4, whereas DUX4 remains largely repressed in somatic tissues of the 
D4Z4-12.5 mouse. These data show that the mechanism of repeat length dependent 
D4Z4 repression is conserved between mouse and man even though the D4Z4 repeat is 
not present in the mouse genome.
The conservation of D4Z4 repression in our mouse models has great potential to 
study the epigenetic mechanisms involved in (de)repression of D4Z4. In chapter 6 we 
observed that in somatic cells the D4Z4-2.5 mouse displays decreased levels of DNA 
methylation and a lower ChCS than the D4Z4-12.5 mouse. This is in good agreement 
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with the data we have obtained in human cell cultures in chapters 2 and 4 and the 
published data on D4Z4 hypomethylation in FSHD5, 10, 25, 26, 63. It would be interesting to 
see whether the observed negative correlation between DNA methylation and PRC2/
H3K27me3 enrichment in FSHD2 is present at D4Z4 in the D4Z4-2.5 mouse as compared 
to the D4Z4-12.5 mouse. The absence of additional D4Z4 repeat (-like) sequences in 
both mouse lines eliminates the confounding effect of the additional (unaffected) repeat 
arrays in FSHD cells and may reveal whether the PRC2 enrichment is truly FSHD2 specific 
as shown in chapter 4. The limitations of this approach are that the transgenes in both 
lines have integrated at different sites in the genome and only one founder line of each 
is available. This creates the potential of interpreting data on the chromatin structure 
as an intrinsic property of D4Z4 whereas it actually could partially rely on the local 
chromatin environment at the site of integration. One way to overcome this problem, 
and confirm the intrinsic chromatin regulation of D4Z4, is to ectopically induce repeat 
contraction in the D4Z4-12.5 mouse line, for example by CRISPR-Cas9 technology. With 
this approach, the resulting mouse lines will be isogenic, but discordant for D4Z4 repeat 
length.
The D4Z4-12.5 mouse line carries a D4Z4 repeat in the size range of those observed in 
FSHD2 individuals. Crossbreeding this mouse line with a mouse line carrying mutations 
in Smchd1 essentially generates offspring with an FSHD2 genotype. Moreover, the same 
approach in the D4Z4-2.5 mouse creates a genotype in which the genetic requirements 
of both FSHD1 and FSHD2 are met. In humans this genotype leads to an aggravated 
phenotype and led to the identification of SMCHD1 as a disease modifier in FSHD122. 
The generation of these models would yield more mechanistic insight in the effect of 
SMCHD1 on the D4Z4 repeat, but also offers additional models to study therapeutic 
interventions aiming at SMCHD1. However, it first remains to be determined whether 
these mice display a similar interaction between Smchd1 and D4Z4 as observed in 
humans.
Although genetic, epigenetic and transcriptional features of FSHD are recapitulated 
in our models, the D4Z4-2.5 mouse does not display a clinically relevant muscle 
phenotype. Approximately half of the D4Z4-2.5 mice do develop an abnormal eye 
phenotype of yet unclear etiology. This is in contrast to a published animal model 
relying on ectopic expression of DUX4. Intramuscular delivery of DUX4-expressing 
adeno-associated viruses (AAV) resulted in profound local muscle damage through the 
induction of p53 dependent apoptosis64. Mice developed muscle weakness, but also 
showed quick recovery after these ectopic bursts of DUX4 expression. The expression 
of DUX4 in this model is localized to the site of injection and does not reflect the 
typical pattern of sporadic nuclei expressing DUX4. Moreover, the distinct regulatory 
mechanism including chromatin derepression of a repeat array is not recapitulated in 
this model64. Similar detrimental effects of DUX4 expression, muscle specific or body 
wide, were observed in Danio rerio, highlighting the in vivo toxicity of DUX464, 65. Gross 
developmental muscle abnormalities and the muscle degeneration seen in D. rerio 
and AAV injected mouse muscle are not representing the muscle histology observed 




More recently, a doxycycline inducible transgenic mouse model was generated in 
which the DUX4 transgene was inserted in an euchromatic region of the mouse 
genome, upstream of the ubiquitously expressed Hprt gene on the X chromosome67. 
Unexpectedly, leaky expression in non-doxycycline-treated animals led to early lethality 
in male mice only. Females displayed several non-muscular phenotypes, including 
a striped pattern of scaly skin, possibly as a consequence of random X-inactivation. 
Rarely surviving male carriers displayed runting, delayed muscle development and 
had a homogenous scale skin. DUX4 was detectable in several tissues including testis, 
retina and brain, but was hardly detectable in muscle samples67. In concordance with 
the D4Z4-2.5 mice described in chapter 6, cultured muscle cells showed sporadic bursts 
of DUX4 expression. Strikingly, this mouse model confirms our observation of absence 
of an obvious muscular muscle phenotype upon systemic DUX4 transgenesis. What is 
also in common is the detrimental effect of DUX4 on the eye, which may be related to 
the observed extra-muscular phenotype of FSHD patients. Again, although low levels of 
DUX4 expression can be tolerated in the mouse, the virtually absent muscle phenotype 
suggests different molecular consequences of DUX4 expression between mouse and 
man.
The absence of a muscle phenotype in the two DUX4 transgenic mouse models published 
to date may be a consequence of the evolutionary distance between mouse and man. 
DUX4 has no orthologue in the mouse, however a paralogue, Dux, has been identified 
to be present in a tandem array in the mouse. DUX4 in human cells has the propensity 
to bind repetitive elements, in particular specific subclasses of LTRs, which have 
expanded specifically in the primate genome. This correlates well with the presence of 
DUX4/DUXC in primates while absent in rodents. This suggests co-evolutionary events 
in which DUX4, normally expressed in germline cells, has a specifically evolved set of 
target genes to exert its yet unknown normal function. This selective pressure on DUX4 
binding sites is absent in the mouse. Therefore, the transcriptional consequences of 
DUX4 in mouse cells have, are far less obvious than in human cells, as was reported in 
chapter 6 and elsewhere68. Consequently, the small overlap in transcriptional targets 
of DUX4 between mouse and man is a plausible explanation for the absence of muscle 
phenotypes and the manifestation of abnormalities not seen in FSHD patient.
The recent observation that FRG1 is a DUX4 target gene in human cells, but not in the 
mouse, was suggested to explain the absence of a muscle phenotype in the D4Z4-2.5 
mouse48. Although it may have some relevance, the transcriptional activation of FRG1 in 
response to DUX4 expression in human cells is low compared to the minimum levels of 
FRG1 associated with a muscle phenotype in the previously published transgenic FRG1 
mouse13. Generating the FSHD2 mouse model described above could reveal a possible 
role for the activation of human FRG1 in recapitulating FSHD like muscle symptoms in 
the mouse, as the transgene in the D4Z4-12.5 mouse model includes FRG1. As FRG1 
is only one of the many target genes discordant between mouse and man, and it is 
currently not known which of the pathways deregulated in humans by DUX4 are causal 
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to muscle pathology, it is difficult to predict biological consequence of the DUX4-FRG1 
axis.
This discrepancy between mouse and man does not necessarily mean that the generated 
mouse lines lose their scientific and translational value. The D4Z4-2.5 and D4Z4-12.5 are 
promising tools to study epigenetic contributors to FSHD and, given a good measurable 
outcome, may become very useful to test therapeutic strategies aimed at inhibiting 
DUX4 transcription. The doxycycline inducible transgenic DUX4 mouse, as well as the 
viral delivery of DUX4 in mouse muscle, allows for the induction of high levels of DUX4 
expression and can become valuable considering therapeutic strategies aiming at DUX4 
transcript and/or protein reduction.
Instead of expressing the DUX4 transgene in mouse muscle, Zhang et al. decribed a 
completely different approach by xenografting human control and FSHD patient derived 
muscle biopsies into immunodeficient recipient mice69. This approach is similar to our 
previous work using isogenic muscle cell clones discordant for D4Z4 repeat size70. In 
both models, the human derived muscle cells succeeded to form new myofibers in the 
mouse muscle and specifically FSHD patient derived material was shown to express 
DUX4. Although the evolutionary distance between mouse and man is overcome in 
these models, they have their own limitations. First of all, in these models a contribution 
of the immune system to FSHD pathology cannot be analysed. More importantly, the 
xenografting procedure does not allow high-throughput studies and relies on the 
availability of donor material. Additionally, scoring performance of these animals in 
functional tests is uninformative with only single muscles being affected by the grafting. 
In conclusion, every conceivable disease model relying on DUX4 expression in non-
primate species will suffer from the primate specific evolution of DUX4 and its targets, 
while more humanized models come with their own constraints. With these limitations 
in mind, the scientific community should adjust their demands and expectations 
regarding animal models for FSHD.
ICF syndrome: identifying the point of functional convergence of different 
disease genes
In chapter 7 we have described the identification of two new disease genes underlying 
ICF syndrome. ICF syndrome is characterized by a triad of seemingly non-related 
phenotypes. Firstly, patients suffer from recurring infections of the gastro-intestinal 
and respiratory tracts due to a- or hypogammaglobunemia, in the presence of B-cells. 
Secondly, cultured blood cells from patients display chromosomal instability at the 
centromeres of chromosomes 1, 9 and 16, which is correlated to CpG hypomethylation 
of centromeric repeats. Finally, almost all patients display a distinct but variable set of 
facial dysmorphisms, often including hypertelorism, flat nasal bridge and epicanthus. 
So far, mutations in four different genes - DNMT3B, ZBTB24, CDCA7 and HELLS - have 
been identified to underlie the syndrome. Although the phenotype can vary between 
patients, it cannot be used to classify the patients into one of the genetic subtypes a 
priori71. The overlap between the different patients with regard to the three phenotypic 
features suggests that the four causative genes functionally converge at one or multiple 
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points during (B-cell-) development. Identification of these shared, similar or redundant 
pathways will be a key step to unravel the complex disease mechanism underlying ICF 
syndrome. 
For two of the four genes, DNMT3B and HELLS, a clear functional connection has been 
previously reported. The chromatin remodelling activity of HELLS is required for proper 
functioning of the de novo methyltransferase DNMT3B during early development72. 
Loss of Hells in murine cells mainly leads to defects in CpG methylation at repetitive 
elements, but also affects a significant number of genic CpG sites37, 73-75. These effects 
were reported to rely on the role of HELLS in enabling the proper establishment of CpG 
methylation through interacting with DNMT3A and DNMT3B, however the involvement 
of HELLS in maintaining CpG methylation is unclear yet. Arguing against a role for Hells 
in maintenance of CpG methylation is that the methylation status of episomal DNA can 
be maintained in absence of HELLS76. In contrast, HELLS associates with late replicating 
DNA, interacts with DNMT1 and Hells deficiency was initially reported to affect CpG 
methylation at an imprinted region, all implicating a role for HELLS in maintaining 
CpG methylation patterns77-79. In chapter 7 we provide additional evidence for a role 
of HELLS in maintaining CpG methylation at murine satellite repeats. siRNA mediated 
knockdown of HELLS in mouse embryonic fibroblasts (MEFs), in which the establishment 
of DNA methylation is completed, led to decreased CpG methylation of satellite DNA. 
Considering the molecular function of HELLS, a chromatin remodeler necessary for 
DNMT functioning, it may not be surprising that it promotes both the establishment 
and maintenance of CpG methylation patterns. 
The hypomethylated state of centromeric repeats is a hallmark of the disease and is 
shared by all patients. As for Hells, the data in chapter 7 also revealed a role for Zbtb24 
and Cdca7 in the maintenance of CpG methylation at centromeric minor satellites. It 
remains unclear at this point whether these genes are only involved in maintaining, 
or also plays a role in establishing CpG methylation at centromeric repeats. More 
importantly, the observed effects on minor satellite CpG methylation cannot be linked 
to any other known functional aspect of ZBTB24 or CDCA7, mainly because no clear 
molecular function has been described for both genes. 
By homology, ZBTB24 belongs to a family of BTB-domain transcription factors of which 
some are involved in lymphocyte development80. The presence of 8 tandem zinc 
finger domains suggests that ZBTB24 has DNA binding capacity and can likely act as 
a transcription factor. However, we have recently discovered that ZBTB24 promotes 
the repair of DNA double strand breaks during immunoglobulin class switching in 
B-cells and that this depends on its ZNF domain (unpublished observations). During 
this process, ZBTB24 binds and stabilizes poly (ADP-ribose) chains on the DNA damage 
signaling protein poly (ADP-ribose) polymerase 1 (PARP1) and thereby promotes repair. 
Through identification of the molecular function of ZBTB24 these data for the first time 
mechanistically explain the immunodeficiency in ICF2 syndrome. Given the high overlap 
in the  immunological phenotype of all ICF patients, it can be anticipated that DNMT3B, 
CDCA7 and HELLS converge with ZBTB24 at some point during development of antibody 
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producing B-cells. Although our observations establish a plausible explanation for the 
immunodeficiency in ICF2, it is currently unclear how deficiency in ZBTB24 would lead 
to the two other phenotypic hallmarks of ICF syndrome and how loss of its molecular 
function would result in CpG hypomethylation at (peri-) centromeric repeats. 
So far, no molecular function for CDCA7 has been established, although it has been 
implicated in several processes. CDCA7 has been shown to interact with Myc and 
thereby plays a role in neoplastic transformation81. More recently, Cdca7 was identified 
in a screen for Notch target genes involved in hematopoietic stem cell emergence82. 
CDCA7 contains a 4-CXXC zinc finger domain, which is conserved but only shared with 
its close homologue CDCA7L. It has been shown that CDCA7L acts as a transcriptional 
repressor for monoamine oxidases (MAO) and that this likely depends on the DNA 
binding capacity of the 4-CXXC zinc finger83. Based on the high conservation of this 
domain, a similar function could be expected of CDCA7, however the localization of 
CDCA7L to chromatin depends on its N-terminal p75 binding domain which is not 
present in CDCA784. 
To address the etiology of ICF syndrome it will be of great interest to better characterize 
the molecular functions of ZBTB24 and CDCA7. At the same time, it is pivotal to delineate 
how the absence of these functionalities, and that of DNMT3B and HELLS, leads to all 
phenotypic characteristics of ICF syndrome. One way to address these questions is by 
generating mouse models harboring ICF-like genotypes. Mouse models in which Dnmt3b 
or Hells were knocked out, were proven very useful to characterize the molecular 
function of both proteins, however early lethality in both models greatly impairs 
studying immunological and developmental features characteristic of ICF syndrome85, 
86. Moreover, the immunological phenotype observed in ICF mouse models, based 
on patient derived missense mutations in Dnmt3b, involves impaired T-cell function, 
rather than impaired B-cell function. Based on the genetics observed in ICF patients, 
a “classic” knockout model for Zbtb24 should recapitulate ICF2. By using CRISPr-Cas9 
technology, the identified missense mutations at conserved residues in CDCA7 could 
be introduced into the mouse genome to model ICF3. To overcome (possible) lethality 
in mouse models for ICF syndrome, an alternative would be to isolate fetal liver cells 
from developing embryo’s deficient for one of the four genes and transplant those into 
immune compromised recipient mice to specifically follow the development of the 
immune cell repertoire87.
In conclusion, the identification of four different genes to underlie ICF syndrome offers 
a great opportunity to better study the mechanisms underlying the disease. The shared 
phenotype between all patients calls for the identification of the molecular functions 
and especially the spatio-temporal expression of the disease genes. Only functions and/
or (redundant) pathways shared by all four genes are likely to be disease causing. For 
example, it remains to be determined whether loss of ZBTB24, CDCA7 and HELLS results 
in similar genome wide CpG hypomethylation as observed in ICF1 derived patient 
material88. Overlapping these shared functions, pathways and phenotypes will likely 
result in shared defective pathways leading to disease and filter out effects mediated by 
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only a subset of the four genes which are unlikely to contribute largely to the disease 
mechanism.
FSHD and ICF syndrome: chromatin derepression at D4Z4 causing discordant 
phenotypes
The notion that there is the global defect in CpG methylation patterns in ICF1 
patients, including CpG hypomethylation of the D4Z4 repeat, puts those patients at 
risk for developing FSHD. Indeed, while not extensively studied in ICF2-4 syndrome, 
ICF1 patients show a similar degree of D4Z4 hypomethylation as FSHD patients89. 
Moreover, a recent report describes two families in which heterozygous mutations 
in DNMT3B segregate with D4Z4 hypomethylation and result in the development of 
FSHD2 or aggravation of FSHD1 (van den Boogaard et al., 2016). Although limited in 
the number of patients and families, these data confirm DNMT3B as a modifier of D4Z4 
chromatin structure and, more importantly, as an FSHD2 disease gene, similar to what 
is observed for SMCHD1. Since heterozygous carriers of ICF1-like DNMT3B mutations 
are apparently at higher risk for developing FSHD, ICF patients and related heterozygous 
carriers should be carefully examined for the presence of FSHD associated symptoms, 
which was previously reported not to be the case90. However, given the early onset 
and severity of ICF syndrome, the clinical signs of FSHD, usually with later onset, may 
have been missed. Conversely, it will be important to evaluate potential comorbidities 
in FSHD2 families with DNMT3B mutations, as the CpG hypomethylation may not be 
confined to the D4Z4 repeat array. This was suggested in the study of Van den Boogaard 
et al., as some individuals showed CpG hypomethylation of other repetitive elements 
in the genome. In concordance with a normal immune-phenotype in ICF1 carriers, this 
study did not reveal (subclinical) immunological defects in DNMT3B carriers from these 
FSHD2 families. The effect of mutations in ZBTB24, CDCA7 or HELLS on genome wide, 
and more specifically D4Z4, chromatin organization is currently unclear. With similar 
approaches described in chapter 4, the involvement of these genes in D4Z4 repression 
could be studied to mechanistically support co-occurrence of FSHD and ICF syndrome. 
Concluding remarks
The work described in this thesis highlights the relevance of chromatin organization at 
repetitive elements for human health. FSHD and ICF syndrome, two clinically unrelated 
diseases, are hallmarked by a loss of repression at specific repetitive elements. In FSHD, 
revolving around derepression of the D4Z4 repeat, this is primarily an in cis effect of 
partial deletion of the repeat. In ICF syndrome, (peri-) centromeric satellite repeats are 
derepressed and destabilized through an in trans mechanism mediated by at least four 
different genes. Our work, together with published observations, shows that repression 
of repetitive DNA elements is evolutionary conserved between mouse and man, 
although the phenotypic outcome of improper regulation of these elements can be 
different. Studying the commonalities and discrepancies between the different diseases 
and underlying genetic mutations can reveal common and specialized mechanisms to 
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The repressive chromatin organization of repetitive DNA is pivotal for maintaining cell 
homeostasis. Defects in repeat silencing are a hallmark of the two genetic diseases 
studied in this thesis: FSHD and ICF syndrome. In FSHD, the D4Z4 macrosatellite repeat 
gets derepressed through an in cis or in trans mechanism, leading to sporadic expression 
of the toxic transcription factor DUX4. ICF is a severe immunodeficiency syndrome, 
characterized by derepression of (peri-) centromeric satellite repeats and is genetically 
heterogeneous. Mutations in multiple genes lead to a highly similar phenotype, which 
suggests these genes to act in common or converging pathways. The studies described 
in this thesis aimed at better understanding the genetic and epigenetic mechanisms 
underlying these diseases.
In chapter 2 we have studied a possible correlation between D4Z4 chromatin compaction 
in somatic cells, measured by relative abundance of H3K9me3 over H3K4me2 at the 
D4Z4 repeat, and disease severity. Overall, FSHD derived somatic cells are characterized 
by a reduced chromatin compaction at D4Z4, which is especially pronounced in FSHD2 
cells. Although trending in fibroblasts, we did not find a significant correlation between 
the chromatin compaction of D4Z4 and the age corrected clinical severity. Strikingly, the 
muscle pathology score in the vastus lateralis muscle showed a clear correlation with 
clinical severity score. 
Telomere position effects (TPE) could affect the regulation of the subtelomeric D4Z4 
repeat, but we could not investigate the 4q subtelomere directly due to its repetitive 
nature. Therefore, in chapter 3 we have studied the chromatin regulation at two single 
copy subtelomeres (7q and 11q), as a model for subtelomeres in general, in response to 
telomere shortening and cellular senescence. Subtelomeres are characterized by a loss of 
H3K9me3 and CpG methylation upon telomere shortening and senescence. In contrast, 
we did not detect transcriptional activation of subtelomeric loci at the transcriptional 
and chromatin level. Silencing of the studied subtelomeres is most likely maintained 
through increased levels of markers for facultative heterochromatin, mediated by 
PRC2. Both subtelomeres under study, as well as D4Z4, showed similar regulation, with 
the exception of TERRA promoters. Overall, the 7q TERRA promoter showed similar 
regulation to the more proximal subtelomere, whereas the 11q promoter was distinct 
from its more proximal subtelomere, in concordance with the observed difference in 
TERRA transcription from 7q and 11q.
Having established the generic principles of subtelomeric chromatin structure in human 
cells, in chapter 4 we focused on the chromatin regulation of D4Z4 by SMCHD1 in 
control and FSHD derived myotubes. This study established a pivotal role for SMCHD1 
in both genetic forms of the disease. In FSHD cells, the activation of DUX4 during in 
vitro muscle cell differentiation coincides with a decreased level of SMCHD1 at D4Z4. 
More importantly, moderate overexpression of SMCHD1 resulted in silencing of DUX4 
in both FSHD1 and FSHD2 cells. Ectopic inhibition of SMCHD1 expression in control 
cells leads to the accumulation of PRC2 and the PRC2 mediated H3K27me3 marker for 
facultative heterochromatin at D4Z4. Increased abundance of PRC2 and H3K27me3 at 
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D4Z4, and sensitivity to PRC2 inhibition, was also observed in FSHD2 patient derived 
myotubes, however not in FSHD1 myotubes. In conclusion, although SMCHD1 is able 
to silence DUX4 in both FSHD1 and FSHD2 derived myotubes, the epigenetic regulation 
of the D4Z4 repeat in both forms of the disease seem to be distinguished by aberrant 
Polycomb mediated chromatin regulation, which is only observed in FSHD2.
Over the past decades, the absence of evidence for sporadic DUX4 activation resulted 
in numerous studies focusing on proximal gene dysregulation upon D4Z4 contraction 
as a potential disease mechanism. Models were presented in which D4Z4 could act as 
an insulator element to prevent TPE spreading in proximal direction, or in which the 
chromatin structure of D4Z4 itself could affect the transcriptional regulation of nearby 
genes through spreading or looping mechanisms. In chapter 5 we show that the FSHD 
specific dysregulation of FRG2, the gene closest to the D4Z4 repeat array, is a direct 
consequence of DUX4 protein activity, rather than any of the above proposed models. 
This further strengthens the disease mechanism revolving around DUX4 while at the 
same time giving a molecular explanation for a longstanding enigmatic observation of 
FRG2 activation in FSHD patients.
In chapter 6 we show that the epigenetic regulation of D4Z4 and its derepression upon 
contraction can be recapitulated in the mouse, independent from its subtelomeric 
location. We have generated a transgenic FSHD mouse model, carrying an FSHD1 sized 
D4Z4 repeat array of 2.5 units (D4Z4-2.5), and a transgenic “control” mouse carrying a 
12.5 unit containing D4Z4 repeat (D4Z4-12.5). Our data shows that the D4Z4-2.5 mouse 
model, as compared to the D4Z4-12.5 mouse, recapitulates key aspects of FSHD: robust 
DUX4 expression in the germ line, chromatin derepression of the repeat in somatic cells 
accompanied by sporadic DUX4 activation in skeletal muscle and activation of (mouse 
specific) DUX4 target genes. Intriguingly, the D4Z4-2.5 mouse does not develop an 
overt muscle phenotype, suggesting that the consequences of DUX4 expression are not 
conserved between man and mouse. Nevertheless, our model can serve great purpose 
to assess therapeutic interventions aiming at inhibiting the mis-expression of DUX4 in 
FSHD.
Finally, in chapter 7 we describe the identification of two new ICF syndrome disease 
genes, CDCA7 (ICF3) and HELLS (ICF4). Herewith we identify two novel chromatin 
modifiers of repetitive DNA structures in humans, and therefore potentially important 
factors for the regulation of D4Z4 and DUX4. For both newly identified genes, as well 
as for the ICF2 gene ZBTB24, we show a role in the maintenance of CpG methylation at 
centromeric repeats. The identification of two additional ICF disease genes renders new 
possibilities for mechanistic studies into the disease mechanism behind ICF syndrome, 
and to study the epigenetic regulation of (macrosatellite) repeats in general.
The progress made in understanding the (epi-)genetic mechanisms underlying FSHD 
and ICF syndrome offers new possibilities for translational and mechanistic studies 
focusing on chromatin organization of repetitive DNA. The common feature of repeat 
derepression in both diseases offers potential to study commonalities and differences of 




De repressieve chromatine organisatie van DNA repeats is cruciaal voor het behoud 
van cellulaire homeostase. Defecten in de repressie van repeats zijn een kenmerk van 
de twee genetische ziekten bestudeerd in dit proefschrift: FSHD en ICF-syndroom. In 
FSHD is de repressie van de D4Z4 macrosatelliet repeat onvoldoende als gevolg van 
een in cis of in trans-mechanisme, wat leidt tot sporadische expressie van de toxische 
transcriptiefactor DUX4. ICF is een ernstig immunodeficiëntie syndroom, gekenmerkt 
door onvolledige repressie van (peri)-centromere satelliet repeats en is genetisch 
heterogeen. Mutaties in meerdere genen leiden tot een zeer vergelijkbaar fenotype, 
wat suggereert dat deze genen een rol spelen in gemeenschappelijke of convergerende 
moleculaire mechanismen. De studies beschreven in dit proefschrift hadden als doel 
een beter inzicht te krijgen in de genetische en epigenetische mechanismen die ten 
grondslag liggen aan deze ziekten.
In hoofdstuk 2 hebben we een mogelijke correlatie tussen D4Z4 chromatine organisatie 
in somatische FSHD cellen, gemeten door de verhouding tussen H3K9me3 en H3K4me2 
op de D4Z4 repeat, en de klinische ernst van de ziekte bestudeerd. In het algemeen, 
worden somatische cellen verkregen uit FSHD patiënten gekenmerkt door een 
verminderde chromatine compactheid op D4Z4, voornamelijk in FSHD2 cellen. Hoewel 
er een trend zichtbaar is in fibroblasten, hebben we geen significante correlatie kunnen 
vinden tussen de chromatine compactheid van D4Z4 en de klinische ernst gecorrigeerd 
voor leeftijd. Opvallend is dat de pathologie van de vastus lateralis spier significant 
correleert met de klinische ernst.
Telomere positie effecten (TPE) kunnen invloed hebben op de regulering van de 
subtelomere D4Z4 repeat, maar het repetitieve karakter van het 4q subtelomeer hinderde 
de analyse van dit locus. In hoofdstuk 3 hebben we daarom de chromatine regulatie 
op twee niet repetitieve en unieke subtelomere gebieden (7q en 11q) bestudeerd, als 
model voor subtelomere gebieden in het algemeen, in reactie op telomeerverkorting 
en cellulaire veroudering. Tijdens telomeerverkorting en cellulaire veroudering worden 
subtelomere gebieden gekenmerkt door een verlies van H3K9me3 en CpG methylering. 
Noch op chromatine regulatie als op transcriptioneel niveau, konden we activatie 
detecteren op deze loci. Repressie van de bestudeerde subtelomere gebieden wordt 
waarschijnlijk gehandhaafd door middel van verhoogde niveaus van markers voor 
facultatief heterochromatine, gemedieerd door PRC2. Beide bestudeerde subtelomere 
gebieden, evenals D4Z4, toonde vergelijkbare regulatie, met uitzondering van de TERRA 
promotoren. Over het geheel genomen, vertoonde de 7Q TERRA promotor vergelijkbare 
regulatie met de meer proximale subtelomere loci, terwijl de 11q promotor verschilde 
van de meer proximale subtelomere loci, in overeenstemming met het waargenomen 
verschil in TERRA transcriptie van 7q en 11q.
Na de generieke principes van subtelomere chromatine structuur in menselijke cellen 
te hebben vastgesteld, hebben we ons in hoofdstuk 4 gericht op de regulering van het 
D4Z4 chromatine door SMCHD1, in gedifferentieerde spiercellen van zowel controles 
als FSHD patiënten. Deze studie stelde een centrale rol vast voor SMCHD1 in beide 
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genetische vormen van de ziekte. In FSHD cellen valt de activatie van DUX4 tijdens 
in vitro spierceldifferentiatie samen met een verlaagd niveau van SMCHD1 op D4Z4. 
Nog belangrijker is dat matige overexpressie van SMCHD1 resulteerde in repressie van 
DUX4 in zowel FSHD1 en FSHD2 cellen. Ectopische depletie van SMCHD1 expressie in 
controlecellen leidt tot de accumulatie van PRC2 en H3K27me3, markers voor facultatief 
heterochromatine, op D4Z4. Verhoogde niveaus van PRC2 en H3K27me3 op D4Z4, 
en gevoeligheid voor PRC2 inhibitie, werden ook waargenomen in gedifferentieerde 
spiercellen van FSHD2 patiënten, echter niet in FSHD1 cellen. Dus, hoewel SMCHD1 in 
staat is om expressie van DUX4 te onderdrukken in gedifferentieerde spiercellen van 
zowel FSHD1 en FSHD2 patiënten, is de epigenetische regulatie van de D4Z4 repeat 
tussen beide vormen van de ziekte verschillend door afwijkende Polycomb gemedieerde 
chromatine regulatie, uniek voor FSHD2.
In de afgelopen decennia, resulteerde het gebrek aan bewijs voor sporadische DUX4 
activatie in tal van studies, gericht op ontregeling van proximale genen ten gevolge 
van D4Z4 contractie als een potentieel ziektemechanisme. In deze modellen zou 
D4Z4 fungeren als een buffer, ter voorkoming van proximale spreiding van TPE, of de 
chromatine structuur van D4Z4 zelf zou een rol hebben in de transcriptionele regulatie 
van de nabijgelegen genen door positie effecten of formatie van chromatine loops. In 
hoofdstuk 5 laten we zien dat de FSHD specifieke ontregeling van het FRG2 gen, het 
dichtstbij t.o.v. de D4Z4 repeat, een direct gevolg is van DUX4 eiwitactiviteit, in plaats 
van de hierboven voorgestelde modellen. Dit herbevestigt de centrale rol van DUX4 in 
het FSHD ziektemechanisme en tegelijkertijd geeft het een moleculaire verklaring voor 
de raadselachtige en lang bestaande observatie van FRG2 activatie in FSHD patiënten.
In hoofdstuk 6 laten we zien dat de epigenetische regulatie van D4Z4 en de derepressie na 
contractie kunnen worden gerecapituleerd in de muis, onafhankelijk van de subtelomere 
locatie. We hebben een transgeen FSHD muismodel gegenereerd, deze muis draagt een 
D4Z4 repeat van 2,5 units (FSHD lengte, D4Z4-2,5), en een transgene “controle” muis 
met een D4Z4 repeat van 12,5 units (controle lengte, D4Z4-12, 5). Onze data tonen aan 
dat de D4Z4-2,5 muis, in vergelijking met de D4Z4-12,5 muis, de belangrijkste aspecten 
van FSHD recapituleert: robuuste DUX4 expressie in kiembaancellen, chromatine 
derepressie van de repeat in somatische cellen, sporadische DUX4 activatie in de 
skeletspier en activatie van (muis-specifieke) DUX4  targetgenen. De D4Z4-2,5 muizen 
ontwikkelen opmerkelijk genoeg geen duidelijk spierfenotype, wat suggereert dat 
de gevolgen van DUX4 expressie niet zijn geconserveerd tussen mens en muis. Toch 
kan ons model goed gebruikt worden om therapeutische interventies, gericht op het 
remmen van de mis-expressie van DUX4, in FSHD te testen.
Tenslotte beschrijven we in hoofdstuk 7 de identificatie van twee nieuwe ziektegenen 
voor ICF, CDCA7 (ICF3) en HELLS (ICF4). Hiermee identificeren we twee nieuwe eiwitten 
betrokken bij de chromatine regulatie van repeat DNA in de mens en dus potentieel 
belangrijke factoren voor de regulering van D4Z4 en DUX4. We tonen voor zowel 
deze nieuw geïdentificeerde genen, als voor het ICF2 gen ZBTB24, een rol aan in het 
handhaven van CpG methylering op centromere DNA repeats. De identificatie van twee 
Appendices - Samenvatting
176
extra ziektegenen voor  ICF, creëert nieuwe mogelijkheden voor het doen van studies 
naar het mechanisme onderliggend aan ICF syndroom, en naar de epigenetische 
regulatie van (macrosatelliet) repeats in het algemeen.
De vooruitgang die is geboekt in ons begrip van de (epi) genetische mechanismen die 
ten grondslag liggen aan FSHD en ICF-syndroom biedt nieuwe mogelijkheden voor 
translationeel en mechanistisch onderzoek gericht op chromatine organisatie van 
repetitief DNA. Het gemeenschappelijke kenmerk van repeat-derepressie in beide 
ziekten biedt mogelijkheden om de overeenkomsten en verschillen te bestuderen 




Appendices - Curriculum vitae
Curriculum Vitae
Peter Thijssen was born on December 6th 1983 in Zoetermeer, The Netherlands. 
He successfully completed pre-university education (VWO) at Het Alfrink College 
in Zoetermeer in 2002 with a focus on Science and Technology (natuur en techniek) 
supplemented with biology and economics. In September 2002, he started studying 
Life, Science & Technology at the University of Leiden and the Delft University of 
Technology. To finish his Bachelor’s programme he did an internship at the department 
of Nephrology of the Leiden University Medical Center (LUMC), focusing on the role of 
C1q on the inflammation status of macrophages, under supervision of Dr. Wei Xu and 
Prof. Dr. Cees van Kooten. After graduating in February 2006, he enrolled in the master’s 
programme of the Biomedical Sciences programme at Leiden university. During his 
master’s programme, his first internship focused on the effect of D4Z4 repeat length 
on FRG1 expression and was supervised by Dr. Yvonne Krom and Prof. Dr. Ir. Silvère 
van der Maarel at the department of Human Genetics of the LUMC. His second and 
final internship was conducted at TNO Quality of Life, Leiden, under supervision of 
Ing. Margreet de Vries and Prof. Dr. Paul Quax, and focused on the role of epigenetic 
dysregulation during vascular restenosis. He received his master’s degree with honors 
(cum laude) in August 2008. In september 2008 he started working as a Ph.D. student at 
the departments of Human Genetics and Molecular Epidemiology of the LUMC, under 
supervision of Prof. Dr. Ir. Silvère van der Maarel and Prof. Dr. P. Eline Slagboom. Since 
January 2013 he has been working as a post-doctoral researcher at the department of 
Human Genetics of the LUMC under supervision of Dr. Haico van Attikum and Prof. Dr. 
Ir. Silvère van der Maarel.
178
List of Publications
Discussed in this thesis:
Increased DUX4 expression during muscle differentiation correlates with decreased 
SMCHD1 protein levels at D4Z4.
Balog J#, Thijssen PE#, Shadle S#, Straasheijm KR, Van Der Vliet PJ, Krom YD, Van Den 
Boogaard ML, De Jong A, Lemmers RJ, Tawil R, Tapscott SJ, Van Der Maarel SM. 
Epigenetics. 2015 Dec
Mutations in CDCA7 and HELLS cause immunodeficiency–centromeric instability–
facial anomalies syndrome.
Thijssen PE, Ito Y, Grillo G, Wang J, Velasco G, Nitta H, Unoki M, Yoshihara M, Suyama M, 
Sun Y, Lemmers RJ, de Greef JC, Gennery A, Picco P, Kloeckener-Gruissem B, Güngör T, 
Reisli I, Picard C, Kebaili K, Roquelaure B, Iwai T, Kondo I, Kubota T, van Ostaijen-Ten Dam 
MM, van Tol MJ, Weemaes C, Francastel C, van der Maarel SM, Sasaki H.
Nature Communications 2015 Jul
DUX4 promotes transcription of FRG2 by directly activating its promoter in 
Facioscapulohumeral muscular dystrophy.
Thijssen PE, Balog J, Yao Z, Pham TP, Tawil R, Tapscott SJ,  Van der Maarel SM. 
Skeletal Muscle 2014 Oct
Chromatin remodeling of human subtelomeres and TERRA promoters upon cellular 
senescence: commonalities and differences between chromosomes.
Thijssen PE, Tobi EW, Balog J, Schouten SG, Kremer D, El Bouazzaoui F, Henneman P, 
Putter H, Eline Slagboom P, Heijmans BT, van der Maarel SM.
Epigenetics. 2013 May
Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse 
model for FSHD.
Krom YD#, Thijssen PE#, Young JM, den Hamer B, Balog J, Yao Z, Maves L, Snider L, Knopp 
P, Zammit PS, Rijkers T, van Engelen BG, Padberg GW, Frants RR, Tawil R, Tapscott SJ, van 
der Maarel SM.
PLoS Genet. 2013 Apr
Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 
promoter in FSHD.
Balog J, Thijssen PE, de Greef JC, Shah B, van Engelen BG, Yokomori K, Tapscott SJ, Tawil 
R, van der Maarel SM.
Epigenetics. 2012 Jun 1
#: authors contributed equally
Appendices - List of publications
179
Appendices - List of publications
Publications as co-author:
The de-ubiquitylating enzymes USP26 and USP37 regulate homologous recombination 
by counteracting RAP80.
Typas D, Luijsterburg MS, Wiegant WW, Diakatou M, Helfricht A, Thijssen PE, van de 
Broek B, Mullenders LH, van Attikum H.
Nucleic Acids Res. 2015 Jun
DNA methylation signatures link prenatal famine exposure to growth and metabolism
Tobi EW, Goeman JJ, Monajemi R, Gu H, Putter H, Zhang Y, Slieker RC, Stok AP, Thijssen 
PE, Müller F, van Zwet EW, Bock C, Meissner A, Lumey LH, Eline Slagboom P, Heijmans 
BT. 
Nature Communications 2014 Nov
Leukocyte telomere length associates with prospective mortality independent of 
immune-related parameters and known genetic markers.
Deelen J, Beekman M, Codd V, Trompet S, Broer L, Hägg S, Fischer K, Thijssen PE, 
Suchiman HE, Postmus I, Uitterlinden AG, Hofman A, de Craen AJ, Metspalu A, Pedersen 
NL, van Duijn CM, Jukema JW, Houwing-Duistermaat JJ, Samani NJ, Slagboom PE.
Int J Epidemiol. 2014 Jun
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between 
MuSK and Lrp4.
Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, Thijssen PE, 
Vrolijk H, Plomp JJ, Vogels P, Losen M, Van der Maarel SM, Burden SJ, Verschuuren JJ.
Proc Natl Acad Sci U S A. 2013 Dec
Adipocyte telomere length associates negatively with adipocyte size, whereas adipose 
tissue telomere length associates negatively with the extent of fibrosis in severely 
obese women.
El Bouazzaoui F, Henneman P, Thijssen PE, Visser A, Koning F, Lips MA, Janssen I, Pijl H, 
Willems van Dijk K, van Harmelen V.
Int J Obes (Lond). 2013 Sep.
Remodeling and spacing factor 1 (RSF1) deposits centromere proteins at DNA double-
strand breaks to promote non-homologous end-joining.
Helfricht A, Wiegant WW, Thijssen PE, Vertegaal AC, Luijsterburg MS, van Attikum H.
Cell Cycle. 2013 Sep 
Heterogeneous clinical presentation in ICF syndrome: correlation with underlying 
gene defects.
Weemaes CM, van Tol MJ, Wang J, van Ostaijen-Ten Dam MM, van Eggermond MC, 
Thijssen PE, Aytekin C, Brunetti-Pierri N, van der Burg M, Graham Davies E, Ferster A, 
Furthner D, Gimelli G, Gennery A, Kloeckener-Gruissem B, Meyn S, Powell C, Reisli I, 
Schuetz C, Schulz A, Shugar A, van den Elsen PJ, van der Maarel SM.
Eur J Hum Genet. 2013 Mar
180
Gene set analysis of GWAS data for human longevity highlights the relevance of the 
insulin/IGF-1 signaling and telomere maintenance pathways.
Deelen J, Uh HW, Monajemi R, van Heemst D, Thijssen PE, Böhringer S, van den Akker 
EB, de Craen AJ, Rivadeneira F, Uitterlinden AG, Westendorp RG, Goeman JJ, Slagboom 
PE, Houwing-Duistermaat JJ, Beekman M.
Age (Dordr). 2011 Nov
Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced 
vascular morbidity and mortality: evidence for a new concept from three independent 
prospective studies.
Pons D, Trompet S, de Craen AJ, Thijssen PE, Quax PH, de Vries MR, Wierda RJ, van 
den Elsen PJ, Monraats PS, Ewing MM, Heijmans BT, Slagboom PE, Zwinderman AH, 
Doevendans PA, Tio RA, de Winter RJ, de Maat MP, Iakoubova OA, Sattar N, Shepherd 
J, Westendorp RG, Jukema JW; PROSPER study group; WOSCOPS study group; GENDER 
study group.
Heart. 2011 Jan
SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: 
frequency and relation with survival.
Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz 
PW, Twijnstra A, Smitt PA, van der Maarel SM, Verschuuren JJ.
J Clin Oncol. 2009 Sep
Also see: http://goo.gl/D7gnJj or scan the QR-code below
Appendices - List of publications
181
182
